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Abstract 
 
Ventilator-associated pneumonia (VAP) is the commonest nosocomial infection in 
Intensive Care and is associated with significant morbidity and mortality. Biomarkers 
offer the potential to speed up diagnosis and differentiate pulmonary from non-
pulmonary infection. We postulated that measurement of cell surface receptors in 
addition to soluble proteins, in dual sites (blood and BAL) and calculation of an index 
ratio of BAL / blood would increase the discriminative utility and differentiate 
pulmonary from non-pulmonary infection.  
Our body of work included paired blood and BALF obtained from 91 patients in a 
pilot study: 27 with VAP, 15 ventilated patients with non-pulmonary sepsis, 18 
ventilated patients with no evidence of infection and 31 non-ventilated non-infected 
patients. In each sample, the monocytic and neutrophilic surface proteins TREM-1, 
CD11b and CD62L were assessed using flow cytometry. Soluble proteins (IL-1β, IL-
6, IL-8) were assayed using ELISA in addition to Procalcitonin, CRP and white cell 
count. 
The levels of soluble TREM-1, IL-1β and IL-8 were significantly raised in the BAL of 
patients with VAP. BAL monocytic surface TREM-1 was also significantly higher in 
VAP. The BAL / blood ratio increased the discrimination of patients with VAP from 
non-VAP. Furthermore, the BAL / blood ratio of patients differentiated VAP from  
non-pulmonary infection. Monocytic and neutrophilic TREM-1 were assessed during 
the development and resolution phases of VAP. Monocytic surface TREM-1 and its 
BAL / blood ratio accurately mirrored the changes with infection, indicating them to 
be putative biomarkers of infection. 
Finally, we constructed and validated a biomarker panel to discriminate patients with 
VAP from non-VAP. The panel comprised the BAL / blood ratios of monocytic 
TREM-1 and CD11b, the BAL levels of soluble TREM-1, IL-8 and IL-1β together with 
the blood levels of IL-6 and CRP. It had high utility in identifying patients with VAP.  
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Pneumonias are infective inflammatory conditions of the lower respiratory 
tract, caused by bacterial, fungal or viral organisms. They may be subdivided 
on aetiology into a number of types – Community-acquired pneumonia, 
aspiration pneumonia, pneumonia in the immunocompromised and 
nosocomial pneumonia (Table 1.1). In the large EPIC II study of ICU patient 
infection prevalence (2007), 4503 of 13796 ICU patients were considered to 
have a respiratory tract infection, indicating its high prevalence. [1]  
 
Table 1.1 Types of pneumonia 
Pneumonia type Aetiology 
Community acquired (CAP) Contracted outside of healthcare setting 
Aspiration Aspiration of upper gastrointestinal bacteria 




Pneumonia in immunocompromised 
individuals caused by organisms not normally 
pathogenic 
Nosocomial Contracted in a healthcare setting 
 
Table 1.1. Pneumonias may be broadly divided into community-acquired 
pneumonia (CAP), aspiration, nosocomial and infections in the 
immunocompromised patient. 
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1.2 Community-acquired pneumonia (CAP) 
Pneumonia refers to infection of the lung parenchyma; where this is acquired 
outside of hospital or an allied healthcare facility (eg nursing home) this is 
referred to as CAP. The British Thoracic Society (BTS) has defined CAP on 
the basis of clinical and radiological criteria: symptoms of an acute lower 
respiratory tract illness (cough plus at least one other symptom), new focal 
chest signs on examination, symptoms/signs of systemic illness (fever greater 
than 38°C and/or symptoms of fever, chills, aches and pains), new 
radiographic shadowing, no other explanation for the illness (eg pulmonary 
oedema) and which is treated as CAP with antibiotics. Microbiological 
confirmation consists of sputum culture, blood culture of an appropriate 
organism (eg Streptococcus pneumoniae), urinary Legionella and 
pneumococcal antigen and tests for atypical pathogens (eg mycoplasma 
pneumoniae and Chlamydia psittaci)[2]. The CURB-65 score is used to 
assess mortality risk from pneumonia. It comprises (C) Confusion of new 
onset, (U) Urea of >7 mmol/l, (R) respiratory rate >30 / min, (B) systolic BP < 
90 mmHg or diastolic BP < 60 mmHg and (65) Age > 65 years. The greater 
the number of features present, the higher the mortality risk. Microbial causes 
of CAP are described in Table 1.2. CAP is mainly caused by Streptococcus 
pneumoniae, Haemophilus Influenzae, Staphylococcus and Legionella.  
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Table 1.2 Prevalence of causative organisms for CAP in the ICU 
Organisms responsible for CAP in the ICU Prevalence (mean %, 95% CI) 
Streptococcus pneumoniae (pneumococcus) 21.6 (15.9-28.3) 
Haemophilus influenzae 3.8 (1.5-7.6) 
Legionella spp 17.8 (12.6-24.1) 
Staphylococcus aureus 8.7 (5.0-13.7) 
Moraxella catarrhalis Unknown 
Gram negative enteric bacilli 1.6 (0.3-4.7) 
Mycoplasma pneumoniae 2.7 (0.9-6.2) 
Chlamydia pneumoniae Unknown 
Chlamydia psittaci 2.2 (0.6-5.4) 
Coxiella burnetii 0 (0-2.0) 
All viruses 9.7 (5.9-14.9) 
Influenza A and B 5.4 (2.6-9.7) 
Mixed bacterial 6.0 (3.0-10.4) 
Other bacteria 4.9 (2.3-9.0) 
None 32.4 (25.7-39.7) 
 
Table 1.2. Organisms may be single or mixed, bacterial, viral or others. 
Values are given as the mean percentage with the 95% confidence interval. 
Adapted from the British Thoracic Society Community-acquired pneumonia in 
Adults Group [2]. 
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1.3 Nosocomial / healthcare associated pneumonia 
This occurs in people from the following groups [3] : 
(a) Patients hospitalized in an acute care facility for 2 or more days within 90 
days of the infection 
(b) Residents of a nursing home or long-term care facility 
(c) Patients who received wound care, intravenous antibiotic or chemotherapy 
within the last 30 days of this current infection episode 
(d) Patients in any setting receiving haemodialysis  
 
1.4 Ventilator-associated pneumonia (VAP) 
VAP is the commonest nosocomial infection in Intensive Care, affecting 
between 10-20% of intubated patients. It causes significant morbidity, 
increased length of mechanical ventilation, length of hospital stay, healthcare 
costs and potentially increased mortality [3-6]. It has been defined by the 
National Institute of Health and Clinical Excellence (NICE) as ‘a pneumonia 
that develops 48 hours or more after intubation with an endotracheal or 
tracheostomy tube, and that was not present before intubation.’[7] There 
remains debate as to whether VAP increases mortality, because of the risk of 
confounding; if a patient dies, was it due to the VAP or due to the condition 
requiring intubation and ventilation? In 2009, Melsen and colleagues 
concluded that in trauma and ARDS patients there was no attributable 
mortality to VAP, but that there may be mortality in other patient groups [8]. 
More recently, the same group have analysed original patient data from 
randomised clinical trials involving VAP and concluded that it has a mortality 
rate of approximately 13%, principally due to the increased length of stay in 
ICU [9]. 
1.4.1 Aetiology and pathogenesis of VAP 
The presence of an endotracheal tube (ETT) is central to the pathogenesis of 
VAP. During critical illness, the upper airway (oropharynx) becomes colonised 
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with aerobic gram-negative bacteria. The ETT inhibits coughing and the 
normal protective upper airway reflexes; it also allows pooling of 
oropharyngeal secretions in the upper airway. Such secretions micro-aspirate 
beyond the low-pressure, high volume cuff of the ETT (by very small channels 
that develop between the cuff and the tracheal mucosa); with ventilator 
cycling, the bacteria in the secretions enter the lower respiratory tract; they 
also form a biofilm on the internal surface of the ETT; over time this may lead 
to the development of parenchymal infection (VAP) [10].  
The diagnostic criterion for VAP to occur 48 hours after intubation with an 
endotracheal tube excludes patients with pathogens in the lower respiratory 
tract incubating at the time of onset of mechanical ventilation. VAP may be 
caused by a variety of micro-organisms. Ibrahim et al identified different 
organisms in patients who had early onset VAP (within 96 hours of ICU 
admission) versus late onset VAP (>96 hours of admission) [11]. Overall, in 
the cases of early VAP the oropharynx is colonised with largely sensitive 
organisms; later on, antibiotic-resistant bacteria acquired in hospital 
predominate. 
 
1.4.2 VAP microbiology 
Table 1.3 highlights the difference in microbiology between early and late 
onset of VAP, table 1.4 demonstrates the data for all VAP cases. Causative 
micro-organisms include bacteria, viruses and fungi. The proportion of cases 
of sensitive Staphylococcus Aureus decreases in the late-onset VAP. This is 
associated with an increase in the proportion of MRSA, pseudomonas, 
acinetobacter and stenotrophomonas which are associated with antibiotic 
resistance. 
	   33 
Table 1.3 Causative micro-organisms in nosocomial pneumonia 
Pathogens Early-onset NP (n=235) Late-onset NP (n=185) p Value 
Pseudomonas Aeruginosa 59 (25.1) 71 (38.4) 0.003 
Methicillin Sensitive 
Staphylococcus Aureus 
42 (17.9) 20 (10.8) 0.043 
Methicillin Resistant 
Staphylococcus Aureus 
42 (17.9) 39 (21.1) 0.408 
Enterobacter SPP 24 (10.2) 19 (10.3) 0.985 
No growth 22 (9.4) 7 (3.8) 0.025 
Stenotrophomonas maltophilia 17 (7.2) 21 (11.4) 0.144 
Haemophilus influenza 14 (6.0) 5 (2.7) 0.111 
Klebsiella pneumoniae 13 (5.5) 12 (6.5) 0.681 
Candida spp 12 (5.1) 7 (3.8) 0.517 
Acinetobacter spp 6 (2.6) 10 (5.4) 0.130 
Escherichia coli 6 (2.6) 3 (1.6) 0.513 
Serratia marcescens 6 (2.6) 7 (3.8) 0.470 
Aspergillus spp 5 (2.1) 1 (0.5) 0.174 
Proteus mirabilis 4 (1.7) 5 (2.7) 0.482 
Streptococcus pneumoniae 4 (1.7) 2 (1.1) 0.594 
Citrobacter spp 3 (1.3) 3 (1.6) 0.767 
Moraxella catarrahalis 3 (1.3) 1 (0.5) 0.441 
Cytomegalovirus 3 (1.3) 5 (2.7) 0.288 
Herpes simplex virus 1 (0.4) 4 (2.2) 0.103 
Pneumocystis carinii 1 (0.4) 2 (1.1) 0.428 
Alcaligenes xylosoxidans 4 (1.7) 5 (2.7) 0.482 
Multiple pathogens 49 (20.9) 51 (27.6) 0.109 
 
Table 1.3. The organisms were identified in patients with nosocomial 
pneumonia. Greater than 90% of these patients were ventilated. Values are 
given as numbers and percentages of bacteria, viruses or other. In 20-9-
27.6% of cases, mixed organisms were identified. Spp=species. Adapted from 
Ibrahim et al (2000) [11]. 
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Table 1.4 Organisms isolated from VAP cases 
Pathogen Frequency (%) 
Pseudomonas aeruginosa 24.4 
Acinetobacter spp 7.9 
Stenotrophomonas malophilia 1.7 
Enterobacteriaceae* 14.1 
Haemophilus spp. 9.8 
Staphylococcus aureus** 20.4 
Streptococcus spp. 8.0 
Streptococcus pneumoniae 4.1 
Coagulase negative staphylococci 1.4 
Neisseria spp. 2.6 
Anaerobes 0.9 
Fungi 0.9 
Other (<1% each)*** 3.8 
 
Table 1.4.  24 studies were pooled with 1689 episodes, using BAL culture. 
The majority of species were bacterial, with only a minor proportion of fungal 
organisms. 
* Klebsiella spp., Escherichia coli, Proteus spp., Enterobacter spp., Serratia 
spp., Citrobacter spp., Hafnia alvei. 
** Methicillin-resistant S. aureus 55.7%, Methicillin-sensitive S. aureus 44.3% 
*** Includes Corynebacterium spp., Moraxella spp. and Enterococcus spp. 
Adapted from Hunter et al (2012). 
Other includes rarer bacteria (Table 1.3) and viruses [12]. 
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1.4.2a Viral and fungal VAP 
The role of viruses in contributing to VAP has been relatively under-explored 
due to a greater difficulty in isolation and identification in comparison to 
bacterial pneumonias. Luyt et al (2011) discussed that Herpes Simplex Virus 
(HSV) and possibly Cytomegalovirus (CMV) contributed to viral VAP and 
secondary bacterial infection but that their contribution was probably under-
represented in previous studies. Indeed, the H1N1 influenza outbreak may 
also have been associated with an increased risk for VAP [13]. 
The contribution of fungi to VAP remains uncertain. Candida species are 
frequently isolated in BAL cultures but are clinically felt to be due to 
colonisation rather than infection. Aspergillus species may colonise too but 
may be pathogenic in immunosuppressed patients. In a recent study by 
Conway-Morris [14] patients with BAL containing candida species alone were 
seen to have elevated levels of pulmonary cytokines, consistent with 
activation of inflammation. This may be suggestive of fungal infection rather 
than colonisation and may indicate that the prevalence of such infections are 
wider than clinically thought. 
 
1.4.3 Risk factors for VAP 
In a review by Cook et al (1998) many risk factors for VAP were identified [15] 
– table 1.5. These risk factors may further be subdivided into fixed and 
modifiable. Antacid therapy increases gastric pH and reduces the incidence of 
gastrointestinal bleeding associated with critical illness, but encourages the 
growth of aerobic gram-negative bacilli (AGNB). Reintubation of patients 
increases the risk of aspiration of oropharyngeal secretions. In neurological 
cases of critical illness, upper airway reflexes and coughing are already 
inhibited and therefore the patient is at risk of VAP. With supine positioning, 
there is a gravitational risk of aspiration. With enteral feeding, nasogastric 
tubes increase the risk of sinusitis and colonisation of the upper airway with 
AGNB, but overall the benefits of enteral feeding outweigh these risks. Finally, 
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factors such as increased sedation increase the duration of mechanical 
ventilation and the risks of developing VAP. 
 





Increased illness severity 
Neurosurgery 
Head injury or low GCS 
Age > 60 years 
 
Modifiable 
Antacid therapy (H2 antagonists or proton pump inhibitors) 
Supine positioning 
Prolonged mechanical ventilation 
Reintubation 
Enteral / NG feeding 
Aspiration 
Low cuff pressure <20cm H20 
Sinusitis 
ARDS (Acute respiratory distress syndrome) 
 
Table 1.5. From Cook et al (1998). These are divided into fixed and 
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1.4.4 Diagnosis of VAP 
Given that VAP is the most common nosocomial infection in ICU, it is 
essential to correctly diagnose the condition. Prompt treatment with antibiotics 
is life-saving in infected patients [16]. However, over-treatment of non-infected 
patients increases the risk of Clostridium difficile associated colitis and the 
development of multi-resistant organisms. Timely and accurate diagnosis is 
therefore required. On both these counts there are problems; microbiological 
identification of organisms may take 48-72 hours (if positive), although a 
gram-stain may yield information more quickly. False negative results occur 
due to sampling errors, infection with culture-negative organisms or prior 
antibiotic treatment. False positive results can occur with proximal lower-
respiratory tract colonisation (positive microbiology without evidence of 
infection, e.g. candida). This is a particular risk with tracheal aspirate sampling 
where sampling of distal airways is less likely to occur. 
A major problem with VAP that hampers research is that there is no gold 
standard for its diagnosis. Histopathological specimens which show alveolar 
pus can be considered a gold standard, but this technique is not only 
impractical, but relies on post-mortem verification, biasing towards severe 
cases and underestimating sensitivity [17]. Furthermore, histopathological 
findings demonstrate VAP to be a multifocal disease. Therefore, in addition to 
method of sampling and method of analysis, site of sample acquisition is 
clearly important too [18]. If a pathology sample is taken from an area of 
unaffected lung, false negative results can be reported. Moreover, variability 
in reporting of specimens can occur between pathologists, decreasing the 
diagnostic accuracy [19].  
There is no consensus for the practical gold standard. Clinical assessment 
employs clinical, radiological and microbiological criteria to determine VAP 
probability. Diagnosis may either be refuted, ‘possible’, ‘probable’, or definite. 
Clinical features include cough, dyspnoea, fever, auscultatory changes, raised 
or reduced white cell count, worsening gas exchange, presence of purulent 
secretions, roentgenographic changes and positive cultures. An issue with 
these features are that they may be present in non-pneumonic illness; trauma 
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induced pulmonary contusions, pulmonary oedema, pulmonary embolism can 
mimic all these changes. Using histopathology as a gold standard, single 
clinical signs were assessed for their ability to identify VAP. Fever as 
expected had a sensitivity of 67% and specificity of 65% [20]. Purulent 
secretions had 83% sensitivity but poor specificity (42%) compared with WCC 
increase having 77% sensitivity and 58% specificity. CXR infiltrates had high 
sensitivity (92%) but poor specificity (33%) too, suggesting them to be useful 
as a rule-out test [21].  
The radiological features seen on CXR have been compared with 
histopathological specimens by Wunderink et al (1992). Alveolar infiltrates 
and air bronchograms had the best sensitivity (88% and 83% respectively) but 
poorer specificities (27% and 58% respectively). Compared with multiple air 
bronchograms, single ones were less sensitive (17% versus 67%) but highly 
specific (96% versus 62%). Fissure abutment had poor sensitivity (6%) but 
high specificity (96%) [22].  
The Johanson criteria initially encompassed a number of these features; new 
or developing changes on chest radiography, together with two or more of: 
fever >38°C, high or low white cell count and purulent secretions [23]. The 
Johanson criteria had a sensitivity of 69% and specificity of <75% [21].  
Considering microbiology, the method of sampling and the culture technique 
are important. 
Specimens may be acquired in a variety of ways: 
(i) Tracheobronchial aspirate (TBA) – where secretions are suctioned from an 
in-line suction catheter introduced via the endotracheal tube 
(ii) Non-directed bronchial lavage (NBL) – a suction catheter is lodged via the 
endotracheal tube into a distal airway (likely in the right lung), 20ml of saline is 
instilled and 2-3ml sample aspirated back. 
(iii) Protected specimen brush (PSB) – a catheter with a brush is kept within a 
sheath and this is introduced via the endotracheal tube. The sheath protects 
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the inner catheter from organisms that colonise the upper airways; sample is 
then acquired by means of the brush. 
(iv) Mini-BAL – this is similar to the PSB in that the sheath protects the inner 
catheter, however there is no brush. Saline is instilled and sample aspirated. 
(iv) Bronchoalveolar lavage (BAL) – formal bronchoscopy of a defined airway, 
instillation of saline and aspiration of sample. 
Each of these vary in the ease of sampling, the ability to direct sampling to a 
focused site and the utility in sampling distal airways [18]. Compared with a 
histopathological gold standard, TBA had 69% sensitivity and 92% specificity 
for VAP diagnosis [21]; PSB had 22-36% sensitivity and 50-77% specificity 
[24, 25]. Mini-BAL had up to 56% sensitivity and 89% specificity when used 
for gram stain [26]. The sensitivity and specificity of BAL compared with post-
mortem varies depending on the culture method (≥ 104 cfu/ml or presence of 
intracellular organisms/ BAL neutrophil level) from 11-100% and 45-100% [21, 
24-26]. Overall, BAL offers the ability to target a defined lobe/segment but can 
be associated with temporary reduction in oxygenation of the patient when 
PEEP is lost during the procedure. The role of bronchoscopy and other 
invasive techniques versus non-invasive sampling remains under debate. Two 
meta-analyses showed similar rates of mortality, duration of ventilation and 
ICU length of stay between the groups. However, since then Conway –Morris 
et al (2009) showed that use of BAL rather than non-invasive techniques 
resulted in a 21% reduction in the use of antibiotics [27]. Once the sample has 
been obtained, cultures are performed. This may be assessed by quantitative 
or semi-quantitative means. In the former, growth of >104 cfu/ml is considered 
significant for BAL and mini-BAL, >103 cfu/ml for PSB and >105 cfu/ml for 
TBA. With semi-quantitative culture, growth is given as none, light, moderate 
and heavy. A positive culture is considered to have moderate or heavy 
growth. Overall there is much debate as to the optimal means of diagnosing 
VAP microbiologically. In the recent guidance from the CDC, quantitative (≥ 
104 cfu/ml) and semi-quantitative microbiology were both accepted as equal 
means of diagnosing VAP [28].  
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1.4.5 VAP scoring systems 
Attempts have been made to combine the clinical, radiological and 
microbiological features into a score to predict VAP. Three systems have 
been utilised most in VAP research, all employing subtly different 
combinations of these criteria.  
The Center for Disease Control / National Healthcare Safety Network 
(CDC/NHSN) criteria apply to nosocomial pneumonias, not exclusively VAP 
[29]. The Clinical Pulmonary Infection Score (CPIS) and Hospitals in Europe 
Link for Infection Control though Surveillance (HELICS) criteria apply only to 
VAP [30-32]. In 2013, after completion of our study, the CDC published new 
guidance on VAP detection and definition, to improve surveillance amongst 
ICU’s. Whilst not a scoring system for VAP, it details consensus guidelines for 
VAP diagnosis and is therefore included in this review [28]. 
 
 
1.4.5a Clinical Pulmonary Infection Score (CPIS) 
The CPIS score is relatively easy to calculate (Table 1.6). A score of over 6 
was suggestive of pneumonia. The original sensitivity of 93% and specificity 
of 100% obtained by Pugin was based on 28 patients and a quantitative 
microbiological gold standard [30]. Using a histological gold standard rather 
than a bacteriological one, the sensitivity dropped to 72-77% and specificity to 
42-85% depending on the cutoff of the ROC curve [18]. If compared with a 
gold standard obtained by BAL, the sensitivity was 30-89% and specificity 
(17-80%). As Rea-Nato has pointed out, if the cutoff level of 6 for the CPIS 
score is changed and the gold standard to which it is compared is altered as 
above, the diagnostic performance can change. Furthermore, as with all the 
scoring systems for VAP, there is inter-observer variation in the scores 
determined, reducing overall accuracy. Schurink et al (2004) found a kappa 
score of 0.14-0.18 in their series of 52 patients [33]. 
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Comparing studies assessing the utility of CPIS is difficult as the gold 
standard varies (histopathology or quantitative culture). Moreover, some 
studies recruited all mechanically ventilated patients and others patients with 
suspected VAP. The sensitivities varied from 60-89% and specificities 42-85% 
[21, 26, 33, 34]. Overall, the limitations are not unique to CPIS and it remains 
a useful tool in the research setting. 
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≥36.5 and ≤38.4 
≥38.5 and ≤38.9 





Blood leukocytes (mm3) 
≥4000 and ≤11000 
<4000 and >11000 






Absence of tracheal secretions 
Presence of nonpurulent tracheal secretions 





Oxygenation: PaO2 / FiO2 (mmHg) 
>240 or ARDS 












Progression of pulmonary infiltrate 
No radiographic progression 




Culture of tracheal aspirate 
Pathogenic bacteria cultured in rare or light quantity or no growth 
Pathogenic bacteria cultured in moderate or heavy quantity 
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Table 1.6 
The Clinial Pulmonary Infection Score (CPIS) combines clinical, radiological 
and microbiological criteria to determine whether or not a patient has VAP. 
ARDS = acute respiratory distress syndrome. CHF = congestive heart failure. 
PaO2 / FiO2 = ratio of arterial oxygen pressure to fraction of inspired oxygen. 
Pathogenic bacteria cultured = predominant organism in the culture. Overall: 
CPIS at baseline was assessed on the first five variables. CPIS at 72 hours 
was calculated based on all seven variables. A score over six at baseline or at 
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1.4.5b HELICS criteria for diagnosis of ventilator-associated pneumonia  
The HELICS criteria create 5 categories of VAP depending on the 
microbiological technique used to diagnose the pneumonia (Table 1.7). This 
makes comparing one with another difficult. In one study, using quantitative 
BAL culture rather than endotracheal aspirate resulted in a four-fold reduction 
in the diagnosis of VAP [27]. Therefore comparison of VAP rates between 
hospitals requires knowledge of the culture technique used.  
 
	   45 
Table 1.7 The HELICS criteria for VAP diagnosis 
X-ray Two or more serial chest X-rays or CT scans with a suggestive image of pneumonia for 
patients with underlying cardiac or pulmonary disease. In patients without underlying cardiac 
or pulmonary disease one definitive chest X-ray or CT-scan is sufficient 
Symptoms And at least one of the following 
Fever > 38°C with no other cause 
Leucopaenia (≤4000 WBC/mm3) or leucocytosis (≥12 WBC/mm3) 
And at least 1 of the following (or at least 2 if clinical pneumonia only = PN4 and PN5) 
New onset of purulent sputum or change in character of sputum (colour, odour, quantity, 
consistency),  
Cough or dyspnoea or tachypnoea 
Suggestive auscultation (rales or bronchial breath sounds), rhonchi, wheezing 
Worsening gas exchange  
Microbiology And according to the used diagnostic method 
Bacteriologic diagnostic performed by: 
PN1 Positive quantitative culture from minimally contaminated lower respiratory tract 
specimens  
– BAL ≥ 104 CFU/ml or ≥5% of BAL obtained cells contain intracellular bacteria on 
direct microscopic exam (classified on diagnostic category BAL) 
– Protected brush with a threshold of ≥103 CFU/ml 
– Distal protected aspirate with a threshold of ≥103 CFU/ml 
PN2 Positive quantitative culture from possibly contaminated lower respiratory tract 
specimen - Quantitative culture of lower respiratory tract specimen (e.g. endotracheal 
aspirate) with a threshold of ≥ 106 CFU/ml 
Alternative microbiology methods 
PN3 
– Positive blood culture not related to another source of infection 
– Positive growth in culture of pleural fluid 
– Pleural or pulmonary abscess with positive needle aspiration 
– Histologic pulmonary exam shows evidence of pneumonia 
– Positive exams for pneumonia with virus or particular germs (Legionella, 
Aspergillus, mycobacteria, mycoplasma,Pneumocystis carinii)  
– positive detection of viral antigen or antibody from respiratory secretions (e.g. EIA,   
FAMA, shell viral assay, PCR), positive direct exam or positive culture from 
bronchial secretions or tissue, seroconversion (e.g. influenza viruses, Legionella, 
Chlamydia) and detection of antigens in urine (Legionella) 
Others 
PN4 Positive sputum culture or non-quantitative lower respiratory tract culture 
PN5 No positive microbiology 
Table 1.7. HELICS criteria for VAP diagnosis. Of the 5 methods, PN1 and 
PN2 were validated without previous antimicrobial therapy [32]. 
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1.4.5c CDC / National Healthcare Safety Network (NHSN) definition for 
clinical diagnosis of hospital-acquired pneumonia 
This definition of HAP does not specifically refer to VAP, which is one of its 
limitations. Although straightforward to understand, it does not include any 
form of microbiology (Table 1.8). When compared with BAL in approximately 
300 trauma patients, its sensitivity was 84% and specificity 69% [35]. 
Microbiological culture (≥ 105 cfu/ml) of BAL was used as the gold standard, 
which differs from the conventional use of ≥ 104 cfu/ml in most other studies. 
Table 1.8 CDC / NHSN definition of hospital-acquired pneumonia 
Radiological signs Two serial chest radiographs with at least one of the 
following: 
- New or progressive and persistent infiltrate 
- Consolidation 
- Cavitation 
Clinical signs At least one of the following: 
- Fever (temperature > 38°C) with no other recognised 
cause 
- Leucopaenia (<4.0 x 109 cells/L) or leucocytosis (>12.0 x 
109 cells/L) 
- For adults >70 years of age, altered mental status with no 
other recognised cause 
And ≥  two of the following: 
- New onset of purulent sputum, change in character of 
sputum 
- Increased respiratory secretions, or increased suctioning 
requirements 
- New-onset or worsening cough, or dyspnoea, or 
tachypnoea 
- Rales or bronchial breath sounds 
- Worsening gas exchange, e.g. oxygenation index ratio 
(PaO2/FiO2) ≤ 240, increased oxygen requirement, or 
increased ventilation demand 
Table 1.8. Hospital-acquired pneumonia diagnosed by clinical and 
radiological criteria, in the absence of microbiological confirmation. Of note, it 
does not specifically apply to VAP [29]. 
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1.4.5d The new CDC paradigm for VAP surveillance 
In 2013, the CDC published new definitions for VAP for surveillance purposes. 
Their aim was to reduce variability between ICUs in VAP definition rates due 
to observer bias in diagnosis. Such a change was required because VAP 
rates are now becoming used as a benchmark of quality in healthcare 
institutions with funding penalties for Units that have high rates [28].  
The concept of Ventilator-associated events was created, where mechanical 
ventilation in patients is present and stable or improving but then deteriorates. 
If this deterioration continues for 2 or more days then a ventilator-associated 
condition (VAC) is present. Causes may be pulmonary or non-pulmonary but 
are mainly due to pneumonia, pulmonary oedema, atelectasis and ARDS. Any 
of these potentially setback a patient’s progress and increase length of stay. 
Infection related VACs (IVAC) comprise patients with VAC and an abnormal 
temperature or white-cell count and are given new antibiotics for at least four 
days. Possible and probable pneumonias require the presence of purulent 
respiratory secretions, pathogenic bacteria or both. If either of these is 
present, the pneumonia is ‘possible.’ If the purulent secretions and positive 
cultures are present then the pneumonia is ‘probable.’ Patients with ‘probable’ 
pneumonias can also have positive tests for histopathology, pleural-fluid 
cultures or Legionella. Of interest, positive cultures may be either quantitative 
or semi-quantitative to define a pneumonia and VAC. Table 1.9 summarises 
the diagnostic criteria for the CDC definitions. 
 
Overall, the CPIS and the HELICS criteria are used for ongoing VAP 
research. 
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Table 1.9 CDC Surveillance Criteria for Ventilator-Associated Events 






≥2 calendar days of stable or decreasing daily minimum positive end-
expiratory pressure or daily minimum fraction of inspired oxygen, 
followed by a rise in daily minimum positive end-expiratory pressure of 
≥3 cm of water or a rise in the daily minimum percentage of inspired 








VAC plus a temperature of <36°C or >38°C or a leulocyte count of ≤ 
4000 or ≥ 12000 per cubic millimetre, plus one or more new antibiotics 
continued for at least 4 days within 2 calendar days before or after 






Possible pneumonia IVAC plus Gram’s staining of endotracheal aspirate or bronchoalveolar 
lavage showing ≥ 25 neutrophils and ≤ 10 epithelial cells per low-power 
field, or a positive culture for a potentially pathogenic organism, within 2 
calendar days before or after onset of a VAC, excluding the first 2 days 






Probable pneumonia IVAC plus Gram’s staining of endotracheal aspirate or bronchoalveolar 
lavage showing ≥ 25 neutrophils and ≤ 10 epithelial cells per low-power 
field, plus endotracheal aspirate with ≥ 105 colony-forming units per 
millimetre or broncho-alveolar lavage culture with ≥ 104 colony-forming 
units per millimetre, or endotracheal-aspirate or broncho-alveolar 
lavage semiquantitative equivalent, within 2 calendar days before or 
after onset of a VAC, excluding the first 2 days of mechanical 
ventilation 
 
Table 1.9. The CDC defines ventilator-associated conditions (VAC), infection 
related VAC, as well as those due to possible or probable pneumonia [28]. 
The possible pneumonia has either gram stain or positive microbiology 
whereas the probable pneumonia has both. 
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1.5. The pulmonary Immune Response to Infection 
 
1.5.1 Background 
The distal airways of the lung are protected from external microbial challenges 
by a combination of innate and adaptive responses. The initial innate 
response can be considered first-line. It involves both anatomical and 
physiological mechanisms and interacts with the later adaptive response of 
lymphocytes and antibodies. Each will be considered separately. 
 
1.5.2. Anatomical barriers 
Air is filtered through mucus and hairs in the nose and turbinates. The large 
surface area of the intact lung epithelium acts as a mechanical barrier to the 
ingress of organisms. Mucus secreted by goblet cells effectively traps larger 
organisms, which are then wafted by cilia to the proximal respiratory tract to 
be expectorated or swallowed (the ‘mucociliary escalator’). 
 
1.5.3. Physiological innate immunity 
Innate immunity combines a plethora of soluble proteins and cells that act 
against evolutionarily-conserved microbial components. The soluble proteins 
involved include cytokines, chemokines, antimicrobial peptides, complement 
and the coagulation cascade. Cells include neutrophils, 
monocytes/macrophages, natural killer (NK) cells, eosinophils, basophils/mast 
cells and dendritic cells. 
1.5.4. Pathogen pattern recognition receptors (PPR) 
Danger signals are proteins associated with tissue damage and death and are 
perceived by the immune system as a threat. They include intracellular 
proteins such as heat shock proteins and nucleotides released with cell death, 
altered matrix proteins and nucleic acids from micro-organisms. They 
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constitute ‘Danger Associated Molecular Patterns’ (DAMPs) that are detected 
by the innate response. 
‘Pathogen Associated Molecular Patterns’ (PAMPs) are the microbial 
components that are conserved throughout evolution and essential to 
microbial function. They include microbial envelope proteins as well as nucleic 
acids. They too are recognised by the innate response. Examples include 
bacterial flagellin, lipolysaccharide (LPS), lipotechoic acid (LTA), viral 
envelope glycoproteins and RNA (single and double stranded), fungal 
mannoproteins and beta-glucans as well as parasitic glycolipids. 
Both DAMPs and PAMPs are recognised by the innate response by a set of 
receptors known as the ‘Pathogen Pattern Recognition Receptors’ (PPR). 
These are encoded in the germline. Such receptors are present in large 
amounts across epithelial and innate immunity cells allowing a rapid response 
to external challenges. However, unlike the adaptive response, the innate 
response is amnestic – repeated challenged are not ‘remembered’ by this 
system and do not result in any more rapid or amplified response. 
The innate response can either be activated by the detection of PAMPs, 
DAMPs or by detecting the ‘missing self.’ In the latter, healthy cells 
constitutively express MHC (major histocompatibility complex) Class I 
molecules. NK cells are normally inhibited from lysing cells by their inhibitory 
receptors which recognise Class I molecules and override the NK cell 
activation receptors. With virally infected cells, class I production can be 
attenuated (ie a ‘missing self’ protein), leading to a reduction of NK cell 
inhibition and thus activation and lysis of the infected cell. 
 
1.5.5. Receptors detecting PAMPs and DAMPs 
PAMPs may be detected by Toll-like receptors (TLR), NOD (nucleotide 
oligomerisation domain)-like receptors (NLR), C-type lectin receptors (CLR) 
and RIG (Retinoic acid inducible gene)-1 like receptors (RLR). The NLR may 
also recognise DAMPs. 
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1.5.5a. Toll-like receptors (TLR) 
10 different TLR have been defined; they are transmembrane receptors with a 
leucine rich extracellular domain and a cytoplasmic portion for signalling that 
shares homology with the IL-1 receptor. TLR may be found in two main parts 
of the cell; on the surface of epithelial cells, macrophages and dendritic cells 
(TLR 2,4 and 6) and on the surface of the endoplasmic reticulum, 
phagosomes and endosomes (TLR 3,7 and 9). The former recognise PAMPs 
on the surface of microbes whereas the latter recognise intracellular nucleic 
acids. TLR 4 recognises lipopolysaccharide, TLR 2 lipoteichoic acid and the 
others recognise either other lipoproteins, nucleic acids or flagellin. Ligation of 
the TLR receptors results in pro-inflammatory cytokine secretion, interferon 
and immunoglobulin release as well as dendritic cell maturation. 
 
1.5.5b. NOD-like receptors (NLR) 
There are over 20 different NLR in humans, many of which are poorly 
characterised. NLR 1 and 2 recognise peptidoglycans and activate NF-κB; 
others form part of a multi-protein complex called the inflammasome – this 
recognises metabolites from cell damage and activates pro-inflammatory 
cytokines via caspase-1. The NLR are cytoplasmic receptors containing a 
leucine-rich repeating domain, a NOD domain and a signalling domain (eg. 
CARD – caspase recruitment domain).  
 
1.5.5c. C-type lectin like receptors (CLR) 
These receptors recognise microbial carbohydrates. They then activate pro-
inflammatory immune responses, activate complement or opsonise bacteria. 
Examples include the mannose receptor, mannose binding lectin, pentraxins 
(such as C-reactive protein) and Dectin-1 (binding candidal β-glucan). 
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1.5.5d. RIG-1 like receptors (RLR) 
RLR have a role in the innate response to viral infection. Double stranded 
RNA (not normally found in the cytoplasm) is produced during replication of 
some viruses. Both double and single stranded RNA from viruses are 
recognised by the RLR which then activate antiviral interferon responses by 
binding to the mitochondrial protein IPS -1 (interferon-β promoter stimulator).  
 
1.5.6. Soluble proteins involved in the innate response 
1.5.6a. Complement 
Complement has a diverse set of roles that include the innate response, 
interaction with B-cells to facilitate the antibody response, together with the 
disposal of apoptotic cells and immune complexes.  The topic of Complement 
is too large to be covered in detail in this review. However, here is a précis: 
Complement consists of 25 cell surface and plasma proteins. Normally 
controlled by regulator proteins, complement may be activated by antigen-
antibody complexes (classical activation), microbial products (alternate 
pathway) or by mannan-containing microbes (mannan binding lectin 
pathway). The resultant activation results in the formation of C3b which can 
opsonise microbes. c3a and c5a can be formed which are vasoactive – they 
increase vascular permeability and act as chemoattractants for mast cells and 
neutrophils to migrate into affected tissues. Several complement proteins can 
also assemble via a final common pathway into the membrane attack complex 
which can form pores in microbes and cause target cell lysis. Finally, in a 
similar way to MHC class I, the presence of surface complement can act as 
an inhibitor of cell lysis by NK cells (a variant of the ‘missing self’ hypothesis). 
 
	   53 
1.5.6b. Cytokines 
Cytokines are secreted proteins which can regulate the immune response. 
Each cytokine can be secreted by more than one type of cell and their effector 
targets can be multiple cell types too. They can stimulate growth, 
differentiation and activate / inhibit immune responses. The cytokines 
secreted by the antigen presenting cells (APC) have function in regulating the 
innate response. The APC include monocytes/phagocytes and dendritic cells. 
The cytokines released from these cells include IL-1, IL-6, IL-8, IL-12 and 
TNF-α. Each of these cytokines bind to a surface receptor (which often share 
sequence homology with each other). The cytokine receptors tend to signal 
downstream processes via either the STAT protein (signal transducer and 
activation of transcription) or the Janus kinases (Jak). The former dimerise 
and migrate to the nucleus to bind with transcription factors such as NF-κB).  
 
1.5.6c. IL-1 cytokine family 
The family consists of IL-1α, IL-1β, IL-1 ra (receptor antagonist), IL-18 and IL-
33. IL-1α and IL-1β stimulate leukocyte adherence to the endothelium, an 
effect antagonised by IL-1 ra. IL-1 induces fever, anorexia and sleep as well 
as causing the liver to decrease albumin production and synthesise acute 
phase reactants such as CRP. IL-1 can also activate T cells via an IL-2 effect.  
 
1.5.6d. IL-6 cytokine family 
The cytokine members in this group are IL-6, IL-11, IL-27, ostopontin and 
oncostatin M. The receptor for these proteins are a multi-subunit protein with 
a cytokine-specific binding site and a gp130 common subunit. Like IL-1, IL-6 
induces fever, lethargy and anorexia. It also stimulates acute phase protein 
secretion to a greater extent than other cytokines. It helps CD4 Th17 
regulatory T cell differentiation as well as promoting B cell differentiation into 
plasma cells. IL-6 preferentially signals through STAT-3. 
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1.5.6e. Tumour necrosis factor alpha (TNF-α) 
This is the main mediator of septic shock. It may either exist as a soluble 
protein or a surface receptor. It can bind to two types of receptor: p55 and 
p75. It activates neutrophil function (chemotaxis, activation, degranulation and 
respiratory burst). It also increases vascular permeability and facilitates entry 
of neutrophils into inflamed tissues. 
 
1.5.6f. Interferons 
Type 1 interferons include IFN-α, IFN-β and IFN-ω. They are derived from B 
cells, plasmacytoid dendritic cells and monocytes/macrophages. They have 
antiviral properties, inhibiting viral replication and preventing transmission of 
virus to healthy cells. They promote NK and CD8 T cell activity to enhance the 
antiviral response. Type 3 interferons include IFN-λ, IL-28 and IL-29 also have 
similar anti-viral properties to type 1 interferons.  
 
1.5.6g. Chemokines 
These are 8-12 kDa proteins that are chemoattractants for immune cells. 
They recruit leukocytes and activate them to mount an immune response, 
regulate cell migration (T cells, B cells and dendritic cells), assist in 
angiogenesis and organ development and are markers for CD4 T cell subset 
maturation. Chemokines are subdivided by the positioning of conserved 
cysteine amino acid residues on the N-terminus: C-X-C chemokines have an 
interposing amino acid; C-C chemokines have adjacent cysteine residues. 
The C-X-C chemokines attract neutrophils and either activate or inhibit blood 
vessel formation. C-C chemokines attract T-cells, eosinophils and monocytes. 
IL-8 is a member of the C-X-C family and is chemoattractant to neutrophils 
and activates them to have a respiratory burst. IL-8 is released by cells of the 
innate system that have toll-like receptors. 
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1.5.6h. Antimicrobial peptides 
Numerous small peptides exist that direct against evolutionarily-conserved 
microbial components. These peptides have significant antibiotic capability 
and include cathelicidins (such as LL-37) and defensins.  
 
1.5.6i. Other proteins 
Lactoferrin and ferritin bind iron, which is essential for bacterial replication. 
The coagulation cascade generates factors with antimicrobial properties in 
addition to limiting the spread of infection. 
 
1.5.7. Cellular innate immune response 
1.5.7a. Neutrophils 
Neutrophils contain numerous granules to destroy bacteria and fungi. Once 
activated in the blood, they migrate into inflamed tissues along a 
chemoattractant gradient. They possess receptors such as L-selectin (CD62L) 
to allow migration. They activate a respiratory burst, which releases oxygen 
free radicals to destroy organisms. 
1.5.7b. Monocytes/macrophages 
Monocytes patrol the bloodstream and migrate into the tissues. In the tissues 
such as the lung, they are represented as macrophages. They phagocytose 
organisms, forming an endosome of membrane around them. This then 
merges with a lysosome (granule containing proteolytic enzymes) to digest 
the material. In the lung, alveolar macrophages are abundant. They also have 
a role in antigen presentation to the adaptive immune cells. 
1.5.7c. Dendritic cells (DCs) 
DCs are antigen presenting cells, linking the innate and adaptive immune 
responses. They are activated by microbes and pass to the lymph nodes to 
activate T and B cells. They may be divided into myeloid dendritic cells (mDC) 
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which secrete IL-12 and stimulate T-cells and plasmacytoid dendritic cells 
(pDC), which have the ability to secrete IFN-α.  
1.5.7d. Eosinophils 
Eosinophils have granules that are effective against parasitic infections. 
1.5.7e. Basophils/mast cells 
Mast cells release histamine following stimulation by IgE dependent 
pathways. Histamine causes bronchoconstriction, mucus production and 
mucosal oedema.  
1.5.7f. NK cells 
As previously mentioned, NK cells target virally infected cells and are 
activated by means of the ‘missing-self’ hypothesis. 
 
1.5.8. Adaptive immune response 
In contrast to the innate response, the adaptive response is anamnestic ie. 
there is immunological memory. Following a single challenge, subsequent 
microbial challenges result in an earlier and magnified response that 
complements the innate response. This is the principle of vaccination. The 
adaptive response consists of T-cell and B-cell activity. T-cells include CD4+ 
helper cells (which assist B-cells in production of antibodies), CD8+ cytotoxic 
T-cells involved in response to viral infection, Natural Killer T-cells and 
regulatory T-cells which have a role in immunological self tolerance. CD4+ T-
cells are depleted in HIV and increase the risk of opportunistic infections of 
the lung. Pelekanou and colleagues (2009) commented that the levels of 
CD4+ lymphocytes were reduced in the blood of patients with VAP. 
This thesis concentrates on the cells of the innate response (neutrophils and 
monocytes).  
	   57 
1.6 The TREM family 
1.6.1 History 
Neutrophils and monocytes are stimulated via a range of receptors that 
include CD14, Fc and complement receptors, chemokine receptors and Toll-
like receptors (TLR’s). Other activating receptors are present that belong to 
either the immunoglobulin superfamily (Ig-SF), sharing sequence homology 
with immunoglobulins and involved in cell-adhesion and protein binding, such 
as the leukocyte immunoglobulin-like receptors (LIR) and signal regulatory 
protein β1 (SIRPβ1), or to the C-type lectin superfamily, including the myeloid 
DAP-12-associating lectin-1. These receptors share sequence homology with 
activating NK cell receptors; the transmembrane domain possesses a 
negatively charged amino-acid and a cytoplasmic immunoreceptor tyrosine-
based activation motif (ITAM). The receptors couple with either the gamma-
chain of the Fc receptor or DAP-12 (DNA-X adaptor protein of 12 kDa) and 
activation leads to ITAM phosphorylation. This in turn leads to protein tyrosine 
kinase activation and cell activation [36].  
In 1999, Cantoni et al discovered a new receptor (NKp44) on Natural Killer 
cells that was a member of the immunoglobulin superfamily and associated 
with DAP-12 [37]. In 2000, Bouchon and colleagues [36] postulated that other 
receptors similar to this may exist on other myeloid cells. Utilising a 
complementary DNA database, they identified a series of receptors sharing 
homology to NKp44 but present on myeloid cells. These were termed the 
‘Triggering Receptors Expressed on Myeloid Cells’ (TREM). TREM-1, - 2 and 
-3 were identified, all containing Lysine as the negatively charged 
transmembrane amino acid. TREM-1 and TREM-3 have roles in cell activation 
whereas TREM-2 inhibited cell responses. 
 
1.6.2 TREM-1 
TREM-1 exists in a variety of species (bovine, porcine, murine as well as 
human) demonstrating evolutionary conservation and an importance in 
immune functioning. Abrogation of TREM-1 activity in murine gram-negative 
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endotoxaemia protected from lethality [38-40]. TREM-1 exists as two 
isoforms, surface-TREM-1 and soluble TREM-1 (sTREM-1). Surface TREM-1 
is a monomeric receptor present on the surface of neutrophils and 
monocytes/macrophages, herein described as neutrophilic TREM-1 (nTREM-
1) and monocytic TREM-1 (mTREM-1). Dimerisation may occur [41]. 
Receptor activation signals via DAP-12 leading to increased synthesis of pro-
inflammatory cytokines, including IL-8, monocyte chemotactic protein-1 (MCP-
1) and tumour necrosis factor-α (TNF-α) as well as neutrophil degranulation 
[42]. The ligand for mTREM-1 and nTREM-1 still remains elusive, but may be 
present on platelets [43]. Initial research showed that surface TREM-1 is 
elevated in bacterial and fungal infections (extracellular) but not in viral, 
mycobacterial (intracellular) or other inflammatory conditions [36]. Soluble 
TREM-1 (sTREM-1) on the other hand, is not membrane bound. Two theories 
of its origin exist; the first is that it is synthesised separately from surface 
TREM-1 and secreted from the cell [44]; the second, more accepted 
hypothesis (figure 1.1) is that sTREM-1 is cleaved from the membrane 
(surface TREM-1) of the cell by matrix metalloproteinases [45]. In a human 
model of endotoxaemia created by injection of LPS to healthy volunteers, 
peripheral blood nTREM-1 levels decreased immediately. sTREM-1 levels 
increased over time, as did mTREM-1. This supports the hypothesis that 
sTREM-1 may be derived from surface TREM-1 (particularly nTREM-1) [46]. 
The role of sTREM-1 is thought to be as a decoy receptor for the surface 
TREM-1 ligand; in other receptor systems such as the TNF receptor, the 
soluble form acts as a decoy for the surface receptor.  Ligand binding to the 
soluble form is not available to bind and activate the bound receptor, therefore 
acting as an antagonist. With regards to TREM-1, bacterial activation of the 
surface receptor amplifies immune responses; cleavage of the surface 
receptor to the soluble form then leads to reduced receptor activation and a 
natural form of negative feedback [47, 48]. 
Surface TREM-1 expression is increased with lipopolysaccharide and 
lipoteichoic acid stimulation, indicating a role in gram-negative and gram-
positive infections respectively.  Given the lack of a known TREM-1 ligand, 
research has stemmed from the use of antibodies to cross-link and activate 
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the receptor, or peptides (LP17) to block receptor activity. Studies have been 
conducted in animal models, human cell cultures and in vivo human sampling 
in septic states. Activation of TREM-1 in the presence of LPS results in a 
synergistic increase in pro-inflammatory cytokines indicating that TREM-1 
may amplify immune responses to infection [42]. 
TREM-1 has gained attention in the field of infection diagnosis. The reasons 
for this are twofold: the perceived restriction of the surface receptors to 
neutrophils and monocytes, the two types of cells involved in innate response 
to infection and the amplification of cell responses to bacterial and fungal but 
not viral infections. nTREM-1 and mTREM-1 are measurable by 
immunohistochemistry or by flow cytometry; sTREM-1 by Enzyme-linked 
immunosorbent assay (ELISA). Regardless of technique, TREM-1 may be 
measured in a variety of body fluids. 
 
Figure 1.1 Surface and soluble TREM-1 
 
Figure 1.1. Matrix metalloproteinases -8 and -9 may cleave surface receptor 
from monocytes and neutrophils to give soluble TREM-1. The ligand for 
soluble / surface TREM-1 is currently unknown. 
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1.6.3 TREM-2 
TREM-2 has functions in the immune system but also in bone formation and 
neural development. Patients deficient in TREM-2 develop Nasu-Hakola 
disease, a condition characterised by the formation of bone cysts and central 
nervous system demyelination [49]. Immunologically, it functions to attenuate 
macrophage activation in response to ligands such as LPS [50]. Its function in 
the lung has not been well defined thus far. Hoogerwerf et al (2010) instilled 
LPS into the airways of healthy volunteers and then obtained immune cells 
from BAL. The surface expression of TREM-2 did not alter on alveolar 
macrophages [51]. However, Sun et al (2011) measured TREM-2 in the lung 
in experimental ALI. TREM-2 mRNA was decreased from baseline, in 
comparison to TREM-1 (which increased). The effect was reversed by 
administration of vasoactive intestinal polypeptide [52]. TREM-2 also functions 
as a phagocytic receptor for bacteria [53]. Overall, the putative role of surface 
TREM-2 and its soluble counterpart in pulmonary infection is unclear. 
 
1.6.4 Summary of pulmonary immune response in VAP 
The endotracheal tube bypasses the anatomical barriers of the innate immune 
system. Bacteria (or other micro-organisms) can spread to the lung as micro-
aspiration of aerobic gram-negative bacilli around the cuff of the ETT, through 
the ETT or haematogenously. 
In the lung, there are homeostatic mechanisms preventing inflammation. This 
includes proteins such as CD200 on the surface of macrophages, preventing 
activation [54]. In critical illness, there is dysregulation of T-regulatory cells, 
alveolar macrophages and neutrophils [55] that increases the risk of 
nosocomial infections. Sedation with agents such as benzodiazepines may 
also play a role.  
Bacteria overwhelm the antibacterial peptides (such as cathelicidin) and 
stimulate TLR and other PAMP receptors on the surface of innate cells. 
Complement may be activated and the monocytes / neutrophils are stimulated 
to release pro-inflammatory cytokines. CD14 (on monocytes) and CD11b (a 
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protein involved in monocyte cell activation) interact with Toll-like receptors 
during stimulation with LPS [56]. Proteins such as TREM-1 and TREM-2 
modify the immune response by amplifying / dampening cytokine responses 
and neutrophil degranulation. Soluble TREM-1 acts to regulate the surface 
TREM-1 on monocytes and neutrophils. Further immune cells are recruited 
from the blood and inflammation progresses. These neutrophils and 
monocytes use CD62L (L-selectin) to cross the endothelium into the alveolus. 
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1.7 Diagnostic biomarkers for VAP 
A biomarker has been defined as ‘a characteristic  [substance] that is 
objectively measured and evaluated as an indicator of normal biologic 
processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention’ [57]. In the context of VAP, they have the potential to 
improve the speed and accuracy of diagnosis compared with current 
microbiological techniques, or to allow prompt cessation of antibiotic therapy 
when VAP resolves. 
This review aims to understand the features of an ideal biomarker in VAP, 
appraise the biomarkers currently studied or in clinical practice and direct 
further research. 
 
1.7.1 The ideal biomarker 
Identification of a ‘footprint’ of an infectious agent that may be easily 
quantified and tracked so as to provide diagnostic, monitoring and prognostic 
information is the current focus of VAP biomarker research. However, such a 
biomarker does not yet exist for VAP. Distinguishing between infection and 
non-infective inflammation is difficult, as both processes lead to the same 
pathway of cell damage and release of pro-inflammatory cell contents via 
PAMPs and DAMPs. One approach is to screen levels of putative markers in 
the tissues and organs of those with infection, those without infection and in 
those whom it is suspected. Once identified, the validity of such markers may 
then be subsequently tested in blinded clinical trials of patients with suspected 
infection.  
Morrow and de Lemos suggested three criteria that ought to be fulfilled by a 
putative biomarker: 
(i) Ease of measurement by the clinician (including speed of testing) 
(ii) Addition of new information compared to existing markers / tests (eg 
increased sensitivity / specificity of diagnosis) 
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(iii) Does the biomarker aid clinician decision making eg antibiotic stewardship 
[58].  
Firstly, there needs to be an easily accessible and cost-effective validated 
assay. These issues are not straightforward. When assessing techniques in a 
research setting, analysers may be used that are difficult to employ clinically. 
Furthermore, reagent cost may be high whilst being researched, but reduce 
once in clinical use. Secondly, the test should be simple to perform and be 
rapid (over a few hours to influence clinical management). Once again, 
experimental tests may be slow to currently analyse but become faster over 
time. An accurate biomarker should be both sensitive and specific for the 
condition and provide information superior to that obtained in current practice. 
Ideally levels should follow disease progression, rising early in the disease 
process and falling promptly with resolution. Finally there should also be 
randomised controlled studies showing that biomarker-guided therapy 
improves patient outcomes.  
Thus far, VAP biomarkers have failed in one or more of these hurdles. Most 
studies involve small numbers of VAP patients in a single ICU setting, making 
interpretation difficult and prone to the risk of outlier bias. A gold standard for 
the diagnosis of VAP is required to validate each biomarker against and this 
varies between studies. For the reason previously stated, most markers 
cannot distinguish between sepsis and non-specific inflammation (i.e., 
systemic inflammatory response syndrome, SIRS). This decreases accuracy 
in the complex environment of clinical care, where for example in the settings 
of trauma, surgery and burns, both co-exist.  
Moreover, biomarkers are unlikely to be pathogen-specific given the likely 
different inflammatory profiles (“footprints”) elicited by the many causative 
organisms (bacterial, fungal and viral). Microbiological sampling will inevitably 
be required to tailor antimicrobial therapy but biomarkers can influence 
whether to commence or stop treatment [59]. The sampling site of the marker 
is also relevant. A blood biomarker may not necessarily be site-specific even 
though it is straightforward to measure [60]. For example, a raised serum C-
reactive protein may indicate infection in the lung or elsewhere. Therefore 
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sampling of appropriate body fluid is necessary. Finally, in the respiratory 
tract, analysis of BALF soluble proteins requires correction for dilution. When 
bronchoscopy is performed, saline instillation dilutes the epithelial lining fluid 
and its constituent proteins to a variable and unknown extent. Measurement 
of an inert marker in both recovered BALF and serum and assuming their 
concentrations to be equal can allow soluble biomarker level correction. Urea, 
albumin and total protein levels have all been studied but most VAP studies 
correct using urea, according to Rennard’s method [61]. 
Despite these potential difficulties, research into VAP diagnostic biomarkers 
has accelerated over recent years. Sackett and Haynes (2002) outlined the 
methodological approaches to studying and validating biomarkers [62]: 
(i) Determine whether test results in affected patients differ from those in 
healthy individuals. This can screen for putative biomarkers. 
(ii) Determine whether patients with certain biomarker levels are more likely to 
have the target disorder. 
(iii) Determine whether test results distinguish patients with and without a 
condition in a population of ‘at risk’ patients. This is the group where the test is 
likely to have the greatest impact. 
(iv) Determine whether outcome is influenced; whether patients having a test 
fare better than similar patients who are untested. These studies have hitherto 
been rarely performed in VAP. 
 
In studies based on the first and second phases, patients are selected on the 
basis of presence or absence of VAP, or healthy controls. This allows 
generation of cutoff levels together with summary ROCs, sensitivities, 
specificities, predictive values and likelihood ratios. The Youden index [63] 
allows the calculation of the optimal cutoff to obtain the highest combination of 
sensitivity and specificity for a marker. 
In studies of the third phase, sequential patients ‘at risk’ of VAP are assessed 
to determine if the test (in comparison to a gold standard) predicts or refutes 
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disease correctly. Assessors of the markers are blinded to the final diagnostic 
category. Finally, fourth phase studies use biomarker-led treatment (initiation 
or withholding of antibiotic therapy) in a randomised controlled trial to test 
improvement in patient outcomes (such as reduction in ICU length of stay, 
mortality or reduction in use of antibiotics).  
The following makers have been studied in VAP and will be reviewed against 
the Sackett and Haynes study hierarchy:  
 
1. C-reactive protein 
2. Procalcitonin 
3. Cytokines 
4. Triggering receptor expressed on myeloid cells-1 (TREM-1) 
5. Other 
 
1.7.2 C-reactive protein 
C-reactive protein (CRP) is an acute-phase protein released from the liver in 
response to acute inflammation. Tillett and Francis discovered CRP [64] as a 
protein capable of precipitating part of a pneumococcus (Fraction C). Its half-
life is 19 hours as its serum level is only production dependent [65]. Its role is 
believed to be in complement activation as CRP binds to a variety of 
receptors on necrotic and apoptotic cells (such as phosphocholine) in addition 
to bacteria [66].  
Povoa et al [67] prospectively measured CRP levels in a mixed 
medical/surgical ICU. 112 Patients were classified into those who were 
infection-free and those who had proven infection. A third group of patients 
were excluded from analysis who cultured negative but in whom infection was 
suspected and treated accordingly. For a cutoff CRP level of 87 mg/l, the area 
under the ROC curve was high at 0.93 (sensitivity 93.4%, specificity 86.1%). 
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The positive predictive value (PPV) was 93.4% and the negative predictive 
value (NPV) was 86%. CRP had a sensitivity of 87.5% and specificity of 
86.1% at a cutoff CRP level of >96 g/l for the subset of patients with VAP. 
Assessing pyrexia in addition to CRP improved the specificity but at the 
expense of reduced sensitivity.  
A study by Matson et al showed a serum CRP increase of 25% from the 
previous day was a potential marker of secondary sepsis but was not seen in 
6 of 49 episodes [68]. Considering VAP, Ramirez et al [69] assessed CRP 
levels in patients with suspected infection. Nine of twenty patients (45%) had 
microbiologically proven VAP. A CRP level of ≥ 196.9 mg/l had 56% 
sensitivity and 91% specificity for VAP diagnosis (AUROC curve of 0.714).  
Serum CRP levels may be elevated in non-infective inflammatory conditions 
(such as surgery). Furthermore, levels are not site-specific for infection (for 
example VAP versus abdominal or line sepsis). Linssen et al therefore 
employed a high sensitivity assay to measure CRP (and procalcitonin) in the 
BAL fluid as a marker of tissue levels and compared it with microbiologically 
proven VAP as the gold standard. Despite ease of measurement, neither 
tissue biomarker was sufficiently accurate to differentiate VAP from non-VAP 
in 117 patients [70].  
Overall for CRP, the first two criteria of Sackett and Haynes are met 
adequately. CRP measurement is only likely to be beneficial in facilitating 
VAP diagnosis in patients where other tissue sites of sepsis are unlikely. 
 
1.7.3 Procalcitonin 
Procalcitonin (PCT) is a 116 amino acid polypeptide, which under basal 
conditions in health, is synthesised by thyroidal C-cells. Cleavage there 
releases calcitonin (the active hormone), katacalcin and an N-terminal 
fragment (NProCT). Only minute amounts of the native PCT enters the blood 
(< 0.05 ng/ml), with a half-life of approximately 24 hours. During an episode of  
sepsis however, widespread PCT production occurs from parenchymal and 
differentiated cells. This enters the circulation at much higher levels (up to 
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1000 ng/ml) without cleavage [71]. The function of this PCT is unknown. 
Studies show increased mortality where supra-physiological levels of PCT are 
administered to animals with sepsis. Furthermore, antibodies directed at PCT 
abrogate experimental sepsis, suggesting it to be immunomodulatory [72]. In 
terms of ease of measurement, Procalcitonin assay is straightforward. The 
Brahms PCT Kryptor assay, a commercially available kit, measures PCT at 
levels from 0.02 – 5000 ng/ml in 20 minutes using 50 µL of blood (Brahms, 
Hennigsdorf, Germany). 
Procalcitonin has been studied in critically ill patients. In a systematic review 
of adult post-operative and trauma patients, PCT fared better than CRP in 
differentiating sepsis from SIRS [73]. In a medical ICU, 47 septic patients  (37 
VAP and 10 bacteraemia) were compared with 23 culture negative patients. A 
single PCT cutoff level of 0.44 ng/ml on the day of suspected infection had a 
sensitivity of 65.2%, specificity of 83% and an AUROC of 0.8. Sequential PCT 
levels have been measured in critical care patients. A PCT increase of 0.26 
ng/ml in one day had a positive predictive value of 100%, negative predictive 
value of 68% and an area under ROC curve of 0.89 for infection diagnosis. 
However, in some septic patients PCT was undetectable, a major limitation of 
the biomarker. Furthermore, the patients studied were neither post-surgery 
nor survivors of cardiac arrest [74]. Such conditions (in addition to renal 
failure, trauma, burns and rejection after transplantation) trigger SIRS and 
elevate PCT independently of sepsis [75-81]. Single cutoff levels may seem 
inappropriate for all clinical settings. 
Gibot et al studied 50 critically ill patients and determined that the PCT was 
elevated (>0.15 ng/ml) in 88% of patients with proven nosocomial infection 
(31 VAP and 19 patients with extra-pulmonary infection). Absolute PCT levels 
could not differentiate pulmonary from non-pulmonary infection however [82]. 
Duflo et al measured serum PCT in 96 patients with and without VAP. PCT 
had 41% sensitivity and 100% specificity for VAP at a level of 3.9 ng/ml [83]. 
Pelosi et al measured PCT in patients with traumatic and non-traumatic brain 
injury. In this neurological setting, 25 out of 58 patients developed early VAP 
(within 72-96 hours of admission). At study entry, PCT, but not CRP or serum 
amyloid A protein, was elevated in this early VAP group. Brain injury per se 
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did not lead to an absolute increase of PCT levels. The sensitivity and 
specificity of PCT was 76% and 75% respectively. Moreover, PCT levels 
correlated with pneumonic severity [84]. Luyt et al measured serum PCT in 
patients with suspected VAP. 32 patients had proven VAP and 41 were non-
VAP. Procalcitonin was measured on the day of VAP suspicion in addition to 
another day from the previous 5 days. A PCT level > 0.5 ng/ml on the day of 
suspicion had a sensitivity of 72% but poor specificity of 24% to predict VAP. 
A rise in PCT between the two time points had 41% sensitivity and 85% 
specificity. Several cases of infection would have therefore been falsely 
excluded if these criteria had been used to diagnose VAP [85]. Similarly, 
Ramirez et al found an elevated serum PCT in only 9/20 VAP patients, 
yielding an AUROC of 0.87, sensitivity of 78% and specificity of 97% for VAP 
diagnosis for a PCT cutoff of 2.99 ng/ml [69].  
As a potential predictor of VAP following return of spontaneous circulation 
after cardiac arrest, Oppert et al measured serum PCT levels. In 28 patients, 
12 developed VAP and Procalcitonin levels rose a median of 2 days prior to 
developing clinical VAP. A PCT level above 1 ng/ml had 100% sensitivity and 
75% specificity to predict VAP [78]. In contrast Jung et al studied serum and 
BAL PCT levels during 86 VAP episodes in a medical ICU but found neither to 
accurately diagnose the condition [86]. BAL PCT levels have been performed 
in two other studies. Linssen et al assayed PCT and CRP but concluded that 
neither diagnosed VAP despite correcting for epithelial lining fluid dilution. The 
AUROC for CRP in BAL was 0.477 and the AUROC for PCT in BAL was 
0.448 [70]. Duflo et al determined that alveolar PCT obtained by mini-BAL in 
96 patients with and without VAP was not discriminative; no diagnostic 
performance figures were given but the similarity of alveolar PCT levels 
between the groups suggested an AUROC of approximately 0.5 [83]. Overall, 
PCT is not a useful diagnostic biomarker. One feature of an ideal VAP 
biomarker would be that it has high sensitivity. As has been discussed, PCT 
was undetectable in several microbiologically proven cases of infection. 
However PCT may have better utility in prognosticating and de-escalating 
antibiotic therapy for septic critically ill patients. Procalcitonin measurement 
may form part of a de-escalation protocol for antibiotics in VAP patients. In a 
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multicentre trial, Stolz et al [87] randomised 101 patients to conventional 
antibiotic therapy or to de-escalation guided by serum PCT values. Antibiotic 
use was significantly lower in the PCT group, with the number of antibiotic 
free-days alive 28 days after VAP onset 13 in the PCT group vs. 9.5 in the 
control arm, a 27% reduction. Other indicators (ICU length of stay, time on 
mechanical ventilator, 28-day and hospital mortality) did not differ though. 
One caveat is that such lengths of antibiotic duration are not consistent with 
current practice in many ICUs, where shorter courses are the norm.  
 
1.7.4 Cytokines 
Cytokine cascades in pulmonary and plasma compartments reflect the 
complex balance of pro- and anti-inflammatory immune responses to 
infectious agents. Dehoux et al measured dual compartment cytokine levels in 
healthy subjects and in patients with unilateral community-acquired 
pneumonia. In the CAP group, BAL fluid from the affected lung was compared 
with the normal side as an extra control. IL-1β, IL-6 and TNF-α concentrations 
were elevated in the affected lung of patients when compared with either their 
unaffected lung or healthy volunteers, but such changes were not seen in the 
plasma. Such compartmentalisation affirms the need to sample the respiratory 
tract and may be the key to a successful VAP diagnostic biomarker.  IL-6 but 
not TNF-α or IL-1β was raised in the blood of patients compared with control 
[88].  
Levels of pro-inflammatory cytokines are high in the lung of patients with 
ARDS, who may also develop secondary pneumonia. Kanangat et al 
hypothesised that bacterial intracellular growth may be increased by such 
inflammatory mediators [89]. Considering anti-inflammatory cytokines in 
addition, van der Poll et al administered intranasal IL-10 to a murine model of 
Streptococcal pneumonia and demonstrated it to be deleterious. Pneumonia 
worsened with IL-10 but abrogated by its blockade, suggesting it to have a 
key role [90]. In humans, the serum cytokines IL-1, -6, -8, -10 and TNF-α 
were assayed in 44 ICU patients by Ramirez et al [91]. 20 patients were 
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suspected of having VAP, of which 9 had microbiologically proven VAP. Only 
IL-6 levels were raised in VAP compared with non-VAP. Its sensitivity was 
71% and specificity 89%, at a cut-off level of 620 pg/ml. 
Millo and colleagues investigated the cytokines IL-1α, IL-1β, IL-6, IL-10 and 
TNF-α together with the cytokine inhibitors soluble TNF-α receptor I, IL-1 
receptor antagonist and soluble IL-1 receptor II, in the lung and plasma of 9 
patients with VAP. 19 non-VAP patients served as control. Samples were 
obtained via non-directed bronchial lavage (NBL). In temporal samples taken 
on alternate days, plasma cytokine levels were similar between groups. In the 
pulmonary compartment however, there were statistically significant increases 
in the levels of TNF-α, soluble TNF-α receptor I, IL-1α and IL-1β during VAP. 
Furthermore, the BAL/blood ratios of TNF-α, soluble TNF-α receptor, IL-1α, 
IL-1 receptor antagonist and IL-6 increased over time in patients subsequently 
developing VAP. Although this study was not designed to assess diagnostic 
biomarkers, it is tempting to speculate that measurement of 
compartmentalised cytokines may facilitate VAP diagnosis [92]. 
A prospective, observational study by Conway-Morris et al [14] highlighted the 
potential importance for BAL cytokines to diagnose/refute VAP, this time IL-1β 
and IL-8. In a mixed medical/surgical Scottish ICU, they compared 17 patients 
with microbiologically proven VAP, 55 non-VAP (but initially suspected) and 
21 matched healthy controls. VAP was diagnosed by quantitative 
microbiology (BAL bacterial count above 104 cfu/ml). The non-VAP group 
were stratified into 22 patients with sub-clinical growth (<104 cfu/ml) and the 
remainder 33 with no growth. The serum levels of the cytokines TNF-α, IL-1β, 
Il-6, 8,10, G-CSF and MIP-1α were similar between the ventilated groups. 
However IL-1β, IL-8, G-CSF and MIP-1α (corrected for dilution) were 
significantly higher in the BALF of VAP patients compared with ventilated non-
VAP patients. A cutoff IL-1β level of < 10 pg/ml in BALF had a high negative 
predictive value, providing a post-test probability of VAP of 2.8%. An IL-8 level 
of 2000 pg/ml had a positive likelihood ratio of 5.03. One caveat of this study 
was that the VAP case-mix did not include patients with Pseudomonal or 
Klebsiella infections which are common organisms elsewhere [93]. The 
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approach of using a biomarker panel of two or more cytokines (in this case IL-
1β and IL-8) appears to fulfil the first three studies as described by Sackett 
and Haynes, albeit from a single centre. This research is now the subject of a 
prospective multicentre study 
(http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=12129). 
In sepsis, the inflammatory and coagulation cascades interact, with fibrin 
deposition in the pneumonic lung. During VAP development, pulmonary 
protein C levels fall, thrombin levels rise and fibrinolysis decreases [94, 95]. 
Determann et al measured lung coagulation factors by non-directed lavage in 
patients developing VAP. The levels of PAI-1 (plasminogen activator inhibitor-
1) and sTF (soluble tissue factor) were raised two days prior to overt VAP. 
PAI-1 and sTF had sensitivities of 0.89 and 0.78 and specificities of 0.95 and 
0.74 respectively for detecting VAP [96].  




Surface TREM-1 is predominantly located on monocytes and neutrophils, the 
cells responsible for the innate immune response to infection. TREM-1 has 
therefore been investigated in a number of infectious states including sepsis 
[97], empyema [98] and meningitis [99]. Such studies have proposed surface 
and soluble TREM-1 as putative diagnostic biomarkers for infection. 
Soluble TREM-1 has been measured in blood, BAL fluid, NBL and the 
exhaled ventilator condensate (EVC). Its exact role in diagnosis and 
prognostication of VAP remains debated. In a landmark study in a medical 
ICU setting, Gibot and colleagues measured soluble TREM-1 in 148 patients 
using mini-BAL sampling and immunoblotting. At a cut-off level of 5 pg/ml 
sTREM-1 had an AUROC curve of 0.93 and a positive likelihood ratio of 10.38 
for diagnosing VAP (as assessed by quantitative culture). The overall 
sensitivity was 98% and specificity 90%. Dilutional correction was not 
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performed, unlike in more recent studies [100]. Determann et al studied 
temporal changes of sTREM-1 obtained via NBL. In a small cohort of 
ventilated mixed medical and surgical patients, 9/19 patients had VAP, as 
judged by clinico-microbiological criteria. sTREM-1 was assayed on alternate 
day samples using ELISA. sTREM-1 was higher in VAP than controls, with a 
sensitivity of 75% and specificity 84% at a 200 pg/ml cut-off level. The authors 
commented that monitoring serial TREM-1 levels further enhanced diagnostic 
accuracy. In particular, lung sTREM-1 levels fell with antibiotic treatment and 
disease resolution, an important requirement of an ideal VAP biomarker. 
Once again, sTREM-1 was not corrected for possible dilutional effects. 
Interestingly, plasma levels were not discriminative for VAP. This suggests 




The diagnostic utility of TREM-1 has fared less well in other studies. Song et 
al [102] measured sTREM-1 in addition to PAI-1 in their study using samples 
obtained by NBL. VAP due only to the gram-negative bacterium 
Pseudomonas aeruginosa was diagnosed by quantitative culture in 33 ICU 
patients. sTREM-1 was assessed by ELISA but levels but were non-
discriminative for VAP. Contrary to this, sTREM-1 levels have previously been 
shown to be elevated in gram-negative infections, albeit from the blood [36]. 
In 23 medical ICU patients, Horonenko et al measured sTREM-1 in BAL as 
well as in the exhaled ventilator condensate (EVC). In this case BAL sTREM-
1 was not diagnostic of VAP. sTREM-1 in EVC had higher specificity, 
especially when indexed against the total protein content of the EVC. The 
chosen method of VAP diagnosis, beyond clinicopathological standards is 
clearly important; comparison of positive microbiological culture with negative, 
rather than using the CPIS score, resulted in all differences between groups 
disappearing [103]. Anand measured sTREM-1 using ELISA in a study of 105 
medical ICU patients. sTREM-1 was non-significantly increased in the VAP 
patients. The sensitivity was low at 42.1% and specificity 75.6% for a 
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200pg/ml cut-off level, figures not useful clinically [104]. Oudhuis and 
colleagues also reported a negative result for sTREM-1 to diagnose VAP 
[105]. BAL samples from 240 patients were assayed by ELISA and corrected 
for dilution using urea. In both medical and surgical patients, the AUC for 
sTREM-1 to classify VAP cases was 0.58. VAP was diagnosed 
microbiologically by quantitative means (104cfu/ml) or ≥2% intra-cellular 
organisms present on gram stain (ICO). Gibot speculated that the results 
seen may have been confounded in part due to sample contamination or 
perhaps by repeated freeze/thawing of stored samples [106]. In contrast, Huh 
et al measured sTREM-1 in 80 medical ICU patients with bilateral lung 
infiltrates, a patient group in which there is significant risk of co-infection and 
present a diagnostic dilemma. VAP was determined by quantitative culture of 
NBL samples. sTREM-1 levels (assayed using ELISA) at a cutoff of 184 pg/ml 
had a sensitivity of 86% and specificity of 90% for VAP diagnosis. In particular 
sTREM-1 levels were elevated in patients with bacterial and fungal infections, 
but not viral or intracellular bacteria, a finding that correlated with the initial 
bench research into TREM-1 [36, 42]. The authors speculated that some 
cases of alveolar haemorrhage may have confounded the results [107]. 
In a study by Conway-Morris et al [14] BAL sTREM-1 measurement was not 
discriminative for VAP. They compared 17 patients with VAP with 55 with non-
VAP and 21 matched volunteers (see previously). Palazzo et al studied BALF 
and EVC sTREM-1 levels in patients with clinically suspected VAP [108]. 
Using quantitative cultures (>104 cfu/ml) 19/45 patients had VAP. sTREM-1 
BALF levels had a sensitivity of 79% but low specificity of 23%, using a cutoff 
level of 204 pg/ml. EVC fared worse, with a cutoff level of 10 pg/ml yielding a 
poor sensitivity of 42% and specificity of 50%. In a paediatric study of 33 
patients, 16 with VAP (see below in ‘other’) Srinivasan et al [109] measured 
sTREM-1 levels in BAL but found them non-discriminative. Finally, a Chinese 
study on 32/92 patients with VAP (diagnosed with quantitative culture of 
BALF) demonstrated peripheral blood sTREM-1 to have 75% sensitivity and 
64% specificity for diagnosis, with a cutoff level of 189 pg/ml (AUC 0.732) 
[110]. 
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Overall, there is uncertainty regarding the utility of soluble TREM-1 to 
diagnose VAP and whether BAL, NBL or EVC is the best method of sample 
acquisition. The reasons for this may be manifold; sampling differences, 
differences in VAP diagnostic methodology, assay methods, prior antibiotic 
usage and sample sizes. The utility of surface TREM-1 to diagnose VAP has 
never been determined. Further study is necessary in groups suspected to 
have VAP, with comparison to other putative cytokine biomarkers. Table 1.10 




Number of VAP 
patients / total 
Method of measuring 




Gibot et al 
(2004) 
46 / 148 Immunoblotting . No dilutional 
correction 
Mini-BAL (20ml). Quantitative culture 
with >103cfu/ml 
At 5pg/ml AUC 0.93 
LR 10.38, Sens 98%, Spec 90% 




9 / 28 
Note a 
ELISA. No dilutional correction. 
Kinetic TREM-1 changes in BALF 
Non-directed BAL on alternate days 
(20ml of saline). Quantitative culture 
with >104 cfu/ml.  
Cutoff of 200 pg/ml 
Sens 75%, Spec 84% 
Mean TREM-1 (VAP) = 894 pg / ml 
TREM-1 levels fall with antibiotic therapy 
Only 9 VAP patients 
Song et al 
(2007) 
11 / 33 
Note a-d 
ELISA. No dilutional correction.  
Blind BAL, 20-60ml. Quantitative 
culture with >104 cfu/ml. Pseud. 
Aeruginosa patients 
 
TREM-1 not diagnostic of VAP nor does its level 
prognosticate 
Mean TREM-1 in group with ARDS patients 
(VAP) = 203 pg/ml 




14 / 23 ELISA.  
BAL, 100ml saline and in EVC 
(exhaled ventilator condensate). CPIS 
score, Quantitative culture >103cfu/ml 
EVC corrected for protein 
BAL TREM-1 not diagnostic of VAP 
EVC TREM-1 lower levels than BAL but 
diagnostic when correcting for protein 
Mean TREM-1 level (VAP) = 403 pg/ml (BAL) 
Only 14 VAP patients 
Anand et 
al (2008) 
19 / 105 ELISA. No dilutional correction. 
Quantitative culture >103cfu/ml.  





Sens 42.1%. Spec 75.6% 
Not diagnostic for VAP 




Number of VAP 
patients / total 
Method of measuring 
soluble TREM-1 and diagnosing 
VAP 
Diagnostic performance 
Huh et al 
(2008) 
29 / 80 
Note e 
ELISA. No dilutional correction. 
Non-directed BAL  
Quantitative culture >103cfu/ml 
 
Cutoff of 184 pg/ml. Sens 86%, Spec 90%. 
TREM-1 raised in bacterial/fungal not viral or 
intracellular. TREM-1 does not correlate with 
neutrophil count 




90 / 240 
Note e 
ELISA. Urea correction for dilution 
BALF. Quantitative culture>104cfu/ml 
or ≥2% ICO (intracellular organisms) 
 
AUC for diagnosing VAP = 0.58 
Mean TREM-1 (VAP) = 1849 pg/ml 
Conway-
Morris et al 
(2009) 
17 / 72 ELISA with urea correction. 
BALF. Quantitative culture>104cfu/ml 




16 / 33 CDC / NHSN criteria No rise in VAP 
Palazzo et 
al (2012) 
19 / 45 ELISA. BALF and EVC. Quantitative 
culture>104cfu/ml or PSB >103cfu/ml 
 
BAL – cutoff 204 pg/ml. Sens 79% / spec 23%. 
EVC – cutoff 10 pg/ml. Sens 42% / spec 50% 
Su et al 
(2012) 
32 / 92 ELISA. BALF and EVC. Quantitative 
culture>104cfu/ml 
 
Serum TREM-1 – 75% sens and 64% spec at 
cutoff of 189 pg/ml. AUC for diagnosis 0.732 	  	  
Table 1.10. Summary Table of studies to diagnose VAP. Studies are in chronological order. The number of patients out of the total with VAP are given. The 
methods of diagnosing VAP and measuring TREM-1 are highlighted as well as the diagnostic performance. 
Notes: In addition to medical ICU patients, a= surgical ICU, b=neuro ICU, c=cardiac ICU, d=vascular ICU, e=bilateral lung infiltrates only. Cfu – colony 
forming units. AUC – area under ROC curve. LR – likelihood ratio. Sens – sensitivity. Spec - specificity 
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1.7.6 Other markers 
1.7.6a BAL endotoxin 
Many VAP cases result from infection by gram-negative bacilli, which possess 
lipopolysaccharide in their cell membrane but lack the lipotechoic acid 
components of gram-positive bacteria. This LPS (endotoxin) can be secreted. 
If endotoxin could be reliably detected, it might be useful to diagnose gram-
negative VAP. Its utility would depend on the prevalence of gram-positive and 
non-bacterial infections in a particular ICU (which varies worldwide). In 
ventilated patients with multiple trauma, BAL endotoxin was measured [111]. 
In 40 samples, gram-positive VAP or non-infective disease had low levels of 
endotoxin (<6 EU/ml) while all the patients with gram-negative pneumonia (as 
defined on CPIS) had levels above 6 EU/ml, a promising result. It was also 
suggested that endotoxin levels correlated with the overall gram-negative 
bacterial load in the respiratory tract. In 63 patients Kollef et al calculated that 
a cut-off value of 5 EU/ml rather than 6 EU/ml had a sensitivity of 100% and 
specificity of 75% for VAP diagnosis and also that the endotoxin assay was 
superior to simple gram staining [112]. Similarly, Flanagan et al found that 
BAL endotoxin assay in 64 patients had 81% sensitivity and 87% specificity 
for gram negative VAP. However, only when endotoxin was assayed from 
BAL fluid did it correlate with VAP; non-directed BAL fluid (and also serum 
endotoxin) levels did not have diagnostic accuracy [113]. In a general ICU 
population Nys et al [114] prospectively assayed BAL endotoxin in 93 
patients. At a cut-off level of 4 EU/ml there was 82% sensitivity and 96% 
specificity for gram-negative VAP as assessed by quantitative microbiology.  
In summary, BAL endotoxin measurement could diagnose gram-negative 
VAP, but requires a standardised assay. Its role may be to rapidly rationalise 
antibiotic targeting towards gram-negative bacteria as it cannot identify gram-
positive organisms.  
1.7.6b Elastin fibres 
Elastin fibres form part of the lung interstitial scaffolding, thereby allowing 
expansion and elastic recoil of the lung (review by Starcher [115]). They can 
	   78 
be detected in bronchial secretions by simple microscopy as a marker of non-
specific injury to the lung. Their use as a speedy diagnostic tool for VAP has 
been investigated. El-Ebiary et al looked at microbiologically confirmed VAP in 
non-ARDS patients. Unfortunately, the test sensitivity was only 32% and 
specificity 72%. This improved marginally to 43% sensitivity and 86% 
specificity if gram-positive infections were excluded [116]. Shepherd et al 
studied patients with pneumonia and ARDS but found a specificity of only 
40% [117]. Further recent work highlighted the lack of utility of this marker. 
Boots et al analysed patients who were ventilated for more than 48 hours. Of 
almost 1000 samples taken from patients with either ARDS or VAP, elastin 
fibres were only detectable in 7 samples, a level far too low for diagnostic use 
[118]. Overall therefore, elastin fibres is not a suitable candidate for a VAP 
biomarker. 
1.7.6c Other markers 
Srinivasan et al [109] measured BALF PAI-1 (Plasminogen activation 
inhibitor-1) levels in 33 mechanically ventilated children. They distinguished 
16 VAP cases from colonization using the Centers for Disease and Prevention 
/ National Nosocomial Infections Surveillance criteria on suspected cases in 
addition to gram-staining the endotracheal aspirate. PAI-1 levels of ≥ 2.8 
ng/ml had a sensitivity of 81.3% and specificity of 76.5% for VAP diagnosis.  
Clara cell protein-10 (CC-10) is a low molecular weight immunosuppressive 
protein that is secreted into the alveoli. Vanspauwen and colleagues 
assessed its ability to diagnose VAP. In 79/196 patients with VAP (as defined 
by quantitative microbiology of BALF and/or the presence of intracellular 
organisms) the AUC for VAP diagnosis was 0.586, a poor result [119].  
L-selectin (CD62L) is an adhesion molecule used by leukocytes to migrate 
through the endothelium into the tissues. It has a soluble and a surface form. 
Levels were measured in the blood of patients with VAP by Sasajima et al 
[120] There were changes in the levels of neutrophil L-selectin (surface form) 
in the blood of patients with VAP. In non-infected patients, expression rose, 
peaked on day 2 and then fell. In some patients with VAP, the peak was on a 
later day or the level was biphasic – rising, falling and then rising again.  
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CD11b is a leukocyte activation marker and has not been thus far been 
studied in VAP. Buhling et al measured CD11b on alveolar macrophages in 
patients with CAP [121]. CD11b expression increased in CAP compared with 
the negative disease control groups of COPD and interstitial lung disease. In 
contrast, Glynn et al were unable to distinguish CAP from control with blood 
neutrophil CD11b levels [122]. Of more interest, however, Hoogerwerf et al 
instilled lipolysaccharide (LPS) and lipotechoic acid (LTA) into the airways of 
healthy volunteers and obtained BAL fluid [51]. LPS, but not LTA induced a 
significant increase in neutrophilic CD11b expression. It is possible that the 
discrepant results seen were due to inadequate dosing of LTA. However, the 
authors speculated that the effect seen may reflect differences in the 
pulmonary immune response to gram-positive and gram-negative organisms. 
CD11b may be a putative biomarker in VAP but remains poorly studied.  
Emerging techniques that may offer rapid methods of diagnosing VAP include 
proteomics (studying proteins of interest) and metabolomics (studying 
metabolic products). They are being researched to diagnose MRSA, other 
staphylococci, streptococci, Legionella as well as resistance genes. They 
include the ‘AccuProbe’ (Gen-Probe, San Diego, USA), ‘GeneOhm’ (Becton-
Dickinson, New Jersey, USA) and the MALDI-TOF (matrix assisted laser 
desorption / ionization – time of flight mass spectrometry (Bruker Daltonic, 
Coventry, UK). The Accuprobe uses a chemiluminescent DNA probe targeted 
to a micro-organism nucleic acid. GeneOhm uses real-time PCR to identify 
staphylococci. MALDI-TOF identifies proteins and peptides associated with 
the pathogen of interest in blood [123]. Proteomic profiles of BAL specimens 
were examined in patients with VAP by Lu et al (2008). Their assay 
demonstrated around 200 proteins whose levels differed between VAP and 
non-VAP patients. These included those related to cell-structure, metabolism 
and immunity. The latter included complement proteins and immunoglobulin 
fragments, but not cytokines [124]. 
It is clear that numerous proteins have been investigated to diagnose VAP but 
few have shown promise in the small studies conducted thus far. 
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1.8 Discussion of biomarkers in VAP 
Cardiac troponins are an example of an ideal diagnostic biomarker in clinical 
use today. From a negligible basal level, cardiac injury releases troponins into 
the blood allowing rapid identification. The biomarker also reflects the 
pathophysiological process of myocardial damage. In the analogous state of 
VAP, to search for new biomarkers, ideally the marker of interest would 
highlight part of the pathophysiological process causing VAP such as the 
immune response to pulmonary infection. As has been described, endotoxin 
measurement, cytokine analysis and TREM-1 would fit with this principle. 
Elastin fibres however indicate damage per se, not specifically due to 
infection. CRP and PCT are systemic markers of inflammation/infection and 
are not specific for VAP. Overall, in searching for new biomarkers, a marker 
linked to the pathophysiological process is probably the most fruitful way to 
proceed, although it may not identify all prospective candidates. 
Earlier the Morrow and de Lemos criteria of a clinically relevant biomarker 
were described [58]. First was ease of measurement. It is obvious that blood 
tests are simpler to obtain than BAL. However, this review has shown that 
cytokine levels in the blood appear non-specific due to compartmentalization 
and PCT and CRP are not site-specific. Therefore despite the increased 
difficulty, respiratory tract sampling is needed. The means of acquiring 
respiratory samples is still under debate. Some studies highlight that NBL 
provides discordant results to BAL. VAP is a multi-focal disease and it is 
essential to sample the correct area. The relevant lung segment can be 
targeted accurately with bronchoscopy but is more technically difficult to 
perform than NBL. 
The two other factors Morrow and de Lemos discussed were whether the 
biomarker provided new information and whether management dictated by 
biomarker measurement improved patient outcome. Endotoxin measurement 
may find use in restricting antibiotics targeted at gram-negative organisms. 
For PCT, its may facilitate antibiotic de-escalation. Finally, studies suggest 
inflammatory cytokine profiling in BAL may diagnose or refute VAP [14].  
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In complicated clinical entities such as VAP, standalone diagnostic 
biomarkers may be insufficient. Different organisms may elicit variable 
immune effects in the lung. It may be more appropriate to construct a 
biomarker panel and assess its ability to diagnose the condition. In this 
regard, our institution has recently validated a multiplex immune assay to 
assist in the diagnosis of patients with sarcoidosis and systemic sclerosis 
[125]. A further approach may be to index the ratio of non-specific markers of 
inflammation/infection in the lung to those in the blood (a BAL/blood ratio), to 
reduce inter-patient variability. Compartmentalisation as highlighted with the 
cytokines implies an increase in a marker in the lung and would yield an 
increased BAL/blood ratio. Such a result could also provide site-specificity as 
the BAL/blood ratio may be expected to be lower in patients with non-
pulmonary as opposed to pulmonary infection. Finally, flow cytometric 
methods can measure cell surface proteins in the BAL and blood in order to 
study the immune response to pulmonary infection. This has hitherto been an 
under-researched area in the field of VAP. 
 
1.9 Concluding remarks 
An ideal biomarker could increase diagnostic accuracy in VAP and thereby 
improve patient care. Such a biomarker or panel of markers would represent a 
‘footprint’ of infection and would complement clinical findings. Considerable 
challenges remain in translating laboratory based diagnostic work to the 
bedside. Nevertheless, the pursuit of early markers of infection, and 
subsequent resolution has great clinical importance.  It would be useful to 
investigate further a dual compartment approach (i.e. lung-plasma), with cell 
and soluble marker based analysis as well as temporal changes. Furthermore 
biomarker panels incorporating putative cytokine markers (e.g. IL-1β and IL-8) 
have the potential to assist in the diagnosis of suspected VAP.  
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1.10 Hypothesis 
Detection of soluble and surface TREM-1 (alone, or in combination with other 
inflammatory cytokines and surface proteins) in paired peripheral blood and 
BALF may improve the diagnostic classification of VAP and differentiate 
pulmonary from non-pulmonary infection. 
 
1.11 Aims 
1. To evaluate whether measurement of the standalone markers surface and 
soluble TREM-1 in blood and BAL can discriminate VAP from non-VAP cases. 
2. To derive a BAL/blood ratio for surface and soluble proteins and determine 
whether it increases discrimination between VAP and non-VAP groups. 
3. To evaluate whether an inflammatory biomarker panel derived from surface 
and soluble TREM-1, inflammatory cytokines (IL-1, IL-6 and IL-8), 
procalcitonin and expression of L-selectin and CD11b in peripheral blood and 
bronchoalveolar lavage fluid will accurately discriminate VAP from non-VAP 
patients. 
4. To investigate the temporal changes of mTREM-1 and nTREM-1 during the 
development and resolution of VAP. 
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Chapter 2 
Methodology 
2.1 Study population 
Patients were recruited at the Chelsea and Westminster Hospital Intensive 
Care Unit. The ICU comprises patients with general medical and surgical 
conditions as well as a specialised Burns Unit. The ICU does not include 
patients with trauma, neurosurgery or cardiothoracic disorders. The study was 
approved by the local Hospital Research and Development Department and 
by the National Research Ethics Service (NRES)  
NRES number 08/H0702/61 
Chelsea and Westminster R and D NHS Approval No: ANA09001CN 
Please see the Appendix for 
(i) Approval letter from NRES 
(ii) Research and Development approval for Chelsea and Westminster 
Hospital 
(iii) Consent form (ventilated patient) 
(iv) Consent form (non-ventilated patient) 
 
2.1.1 Inclusion criteria 
Consenting patients / volunteers aged > 18 years. In ICU patients who were 
sedated and ventilated, assent from the family was sought in addition to 
approval from the Intensive Care Consultant in charge of the patient. When 
the patient regained mental capacity, their formal consent was then obtained. 
2.1.2 Exclusion criteria 
Patients were excluded if they had a bleeding diathesis, HIV or other 
immunodeficiency, tuberculosis, pregnancy, pneumothorax or hypoxia 
contraindicating bronchoscopy. 
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2.1.3 Recruitment groups 
Patients were recruited into the following groups: 
(i) ICU patients ventilated (through either a cuffed oral endotracheal or cuffed 
tracheostomy tube) with VAP; this was suspected according to standard 
clinical criteria (new CXR findings and at least one of the findings of pyrexia, 
raised WCC and purulent secretions) and defined as CPIS of 6 or more and 
positive microbiology (see below). Patients were ventilated either for 
respiratory failure or for major surgery. Paired blood and BALF samples were 
taken. Whilst the initial chest X-ray interpretation was that of the study 
investigators and the clinical intensive care team all presumed infiltrates in 
enrolled patients were independently confirmed by a radiologist. 
(ii) ICU patients ventilated with no evidence of VAP but positive for non-chest 
sepsis on clinical, radiological and microbiological grounds (see below for 
microbiology). Paired blood and BALF samples were taken. The rationale for 
inclusion of such a group is that ICU patients may have infections at multiple 
sites and the ability of a biomarker to differentiate sites would be 
advantageous. 
(iii) ICU patients ventilated with no evidence of VAP nor sepsis elsewhere (ie 
ventilated control). Such patients had a CPIS of below 6 and were negative 
for all cultures.  Paired blood and BALF samples were taken. 
(iv) Blood samples from patients admitted to hospital with community acquired 
pneumonia. (CAP) Such patients were defined clinically (productive cough, 
purulent sputum, pyrexia, shortness of breath), radiologically (chest x-ray 
changes of lobar or diffuse shadowing) and microbiology (sputum culture, 
pneumococcal and legionella antigen in urine). For those patients negative for 
microbiology, CAP was included if patients were clinically thought to have 
CAP and showed improvement with antibiotics. Bronchoscopy in the CAP 
patients was not feasible as it was too invasive and not part of their routine 
care. 
(v) Given the need for ventilation is often influenced by the extent of chronic 
lung disease (COPD, interstitial lung disease), blood and BALF samples were 
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obtained from patients with these disorders who needed an outpatient 
bronchoscopy as part of their routine care or for assessment of solitary lung 
nodules. 
(vi) Blood samples from healthy volunteers working in the Immunology 
laboratory. 
In addition, a further analysis was performed where VAP was diagnosed using 
the HELICS PN4 and PN5 criteria. The overall agreement (kappa value) 
between the CPIS and HELICS was 0.95 for this study. Two patients with 
VAP would have been classified as non-VAP using HELICS and one patient 
with non-VAP could possibly have been placed into the VAP cohort. Of the 95 
patients approached for the study, 1 declined. 3 patients had samples 
unsuitable for analysis and the remainder 91 were recruited (a 96% 
recruitment rate). 
2.2 Microbiology 
All samples were processed for culture and sensitivity by the Microbiology 
Laboratory at Imperial College Healthcare NHS trust (Chelsea and 
Westminster Hospital Laboratory) according to pre-defined Standard 
Operating Procedures. For BALF, samples were processed using semi-
quantitative methods, with results stated as ‘none’, ‘mild’, ’moderate’ and 
‘heavy’ growth. Cultures were deemed positive if there was moderate or 
heavy growth but not if it was none / light. Quantitative processing to 
determine the number of colony forming units per ml were not available. In 
ICU patients, multi-site sampling was performed of patients with suspected 
sepsis. This could include blood cultures, urine, drain or other body fluid, 
relevant skin swabs and central venous catheter tips (following removal). In 
addition, urinary Legionella and pneumococcal antigen were assayed when 
deemed appropriate (Community-acquired pneumonia). Viral cultures were 
not routinely sent. Standard tests for tuberculosis (smear and growth) were 
conducted on BAL specimens when clinically indicated.  
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2.3 Data collection 
For ventilated patients, the following data was collected: age, sex, diagnosis, 
smoking and antibiotic history, steroid use, chest x-ray findings, microbiology, 
CPIS, APACHE II score, CRP, white cell count and 28-day mortality. For non-
ventilated (non-ICU) patients the same data was collected except for the 
APACHE II and CPIS. 
 
2.4 Acquisition of samples 
2.4.1 Blood samples 
Peripheral venous blood and bronchoscopic samples were undertaken in 
consenting patients within 48 hours of meeting inclusion criteria. For ICU 
patients, two further blood samples were taken on alternate days to monitor 
temporal changes of the biomarker panel (2nd and 4th day following initial 
sampling). 
Peripheral venous blood (10ml in EDTA) was collected for immediate 
analysis. Blood was centrifuged at 2000 rpm for 10 minutes at 20˚C. 
Supernatant was collected and divided into aliquots for freezing at -70˚C, for 
future ELISA analysis. The remaining cells were washed in phosphate 
buffered saline/1% fetal calf serum (FCS) to remove residual soluble TREM-1. 
100 µl of cells were stained with the appropriate flow cytometry antibody for 
30 minutes, after prior incubation with 10% FCS to block non-specific binding. 
Cells were then washed, red cells lysed and leukocytes fixed using a TQ-prep 
(Beckman Coulter, High Wycombe, UK). A 5 colour flow cytometer was used 
to analyse surface cell staining (Becton Dickinson, Oxford, UK). 
CRP, urea and electrolytes, albumin, protein and white cell count were 
routinely measured as part of normal patient care by NHS Biochemistry and 
Haematology laboratories. 
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2.4.2 BAL samples 
In consenting patients, bronchoscopy was performed once by either Dr. Vimal 
Grover, Dr. Suveer Singh or Dr. Pallav Shah (Consultant Respiratory 
Consultant at Chelsea and Westminster Hospital and The Royal Brompton 
Hospital, London UK). In Intensive Care, either a Pentax bronchoscope 
(Pentax Medical, Slough, UK) or Olympus bronchoscope (Olympus UK, 
Essex, UK) was used. In Bronchoscopy Clinic, Olympus bronchoscopes were 
utilised. Bronchoscopy was performed in an identical fashion. Sample site 
was chosen on clinical and X-ray findings; if CXR shadowing was absent or 
there was bilateral shadowing, the right middle lobe was sampled due to its 
ease of location and structure preventing bronchial collapse with gentle 
suction. 
In ICU: The patients were sedated and ventilated with a FiO2 of 1.0. 
Atracurium 50mg (muscle relaxation) was given as a single bolus to facilitate 
bronchoscopy. 100ml of sterile normal saline 0.9% was instilled in aliquots 
into the chosen lung segment. The initial bronchial sample was discarded in 
accordance with other similar studies. The yield was generally about 30ml 
(range 16-43ml). Half the sample was sent to microbiology for culture and 
sensitivity, the other half were analysed for surface and soluble cytokines. 
Bronchoscopy Clinic: Patients were sedated with midazolam (up to 5mg iv) 
and / or fentanyl (up to 50 micrograms iv). Topical lignocaine (4%) was 
administered to the oropharynx and 2% lignocaine instilled by a technique of 
‘spray as you go’. 100ml of 0.9% normal saline was used. The initial bronchial 
sample was also discarded. The yield was typically 30ml (14-47ml). 
Samples were collected on ice for immediate processing. BALF was filtered 
through sterile gauze to remove sputum. It was then centrifuged at 500g at 
18˚C for 10 minutes. Supernatant was collected in aliquots and frozen for 
subsequent ELISA analysis. Cells were washed in phosphate buffered 
saline/fetal calf serum to remove residual soluble TREM-1. Cells were 
resuspended to 1 x 106/ml prior to staining with the appropriate flow cytometry 
antibody for 30 minutes (see below), again after FCS use to prevent non-
specific stain binding. Cells were washed and fixed as above. 
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2.5 Flow cytometry 
2.5.1 Blood 
Surface TREM-1 was assessed on monocytes and neutrophils using a mouse 
IgG1 anti-human fluorochrome-conjugated TREM-1 antibody (R&D systems, 
Abingdon, UK) compared with an appropriate IgG1 isotype control antibody. 
The following other fluorochrome-conjugated antibodies were used: 
(i) CD14-PC5 IgG2a (Beckman Coulter, High Wycombe, UK) 
(ii) TREM-1-PE (R & D systems) or IgG1 isotype control antibody- PE 
(Pharmingen, Oxford, UK) 
(iii) CD16-FITC IgG1(Beckman Coulter) 
(iv) CD45-ECD IgG1(Beckman Coulter) 
(v) CD11b-PE IgG1 or IgG1-isotype-PE control antibody (both Beckman 
Coulter) 
(vi) CD62L-FITC IgG1 (L-selectin) or IgG1 isotype-FITC control antibody (both 
Beckman Coulter) 
(vii) TREM-2-PE (R & D systems) 
All the data (BAL and blood) for a particular patient were acquired using the 
flow cytometer for a single session. The flow cytometer is used in the Imperial 
College Healthcare NHS Trust Immunology Laboratory. As such, there are 
External Quality Assurance (EQA) procedures in place for quality control.  
Laser alignment occurs with ‘Flow-check’ beads (Beckman Coulter). These 
are fluorospheres of 10 µm that fluoresce with a spectrum wavelength of 525-
700nm when excited by photons at 488nm. Furthermore, Immuno-trol cells 
(Beckman Coulter) are used as a positive control; these mimic whole blood in 
terms of scatter, population distribution of lymphocytes, monocytes and 
granulocytes as well as cell-specific antigen density. Finally, isotype control 
antibodies were used with each test antibody to determine the geometric 
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mean fluorescence intensity. Serial measurements of samples (n=3) 
determined that variability in MFI was 4-7%. 
 
CD45 staining and side-scatter characteristics were initially used to select 
CD14 and CD16 positive cells as markers of monocytes and neutrophils 
respectively.  
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2.5.2 BAL 
Once the supernatant had been removed (as above), an aliquot of cells was 
removed for analysis of the proportion of live and dead cells (see below). The 
remainder were washed with PBS/fetal calf serum 1% as for the peripheral 
blood flow cytometry. Incubation of cells and the order of antibodies was 
identical to that of peripheral blood. 
 
2.5.3 Dead cell stain 
In addition to trypan blue staining to confirm cell integrity, the LiveDead ViVid 
stain (Invitrogen, Paisley, UK) was used. This is an amine reactive dye that 
binds to intracellular free amines, but minimally to intact membranes. We 
used the ViVid-red dye and measured dead cells with the ECD detector on 
the flow cytometer. A peripheral blood sample of several days (containing 
numerous dead cells) was used as a positive control to confirm assay 
function. 5 fresh peripheral blood samples were tested for dead cells; none 
showed any present and therefore ViVid staining was not performed on any 
further patient blood samples. In BAL, cell viability ranged from 90-97%. Live 
cells were gated for further analysis. Therefore it is unlikely that results from 
the flow analysis were due to measurement on dead cells. 
 
2.5.4 Acquisition and analysis 
A minimum of 5000 monocytes were analysed from peripheral venous blood 
and 2000 alveolar macrophages from BAL.  The mean fluorescent intensity of 
test antibody was compared with that of an isotype control antibody and the 
geometric mean calculated as an index of protein concentration expressed by 
a particular blood or BALF cell population. Serial analysis of BAL samples 
showed the variability in MFI (n=3) to be 5-7%. The MFI is the standard 
measure of fluorescence as measured by flow cytometry. 
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2.5.5 Dot plot expressions in blood 
The following plots demonstrate the gating strategies and expression of 
TREM-1, CD11b and L-selectin in blood monocytes and neutrophils. Figure 
2.1 shows the gating of monocytes and neutrophils in the blood. 
Figure 2.1 Monocyte and Neutrophil gating (blood) 
 
 
Figure 2.1. The top left figure demonstrates Forward Scatter (FS) vs. Side Scatter (SS). In the top right picture, FS 
against FS area (Aux) allows gating out of couplets caused by antibody cross-linking. The bottom left picture 
demonstrates the immune cells gated on CD45 (region B). In the lower right diagram, neutrophils are region D (CD14 
low), monocytes are region C (CD14 high). 
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Figure 2.2 demonstrates the expression of CD14 and CD16 on the monocytes 
and neutrophils. 
 
Figure 2.2 CD14 and CD16 expression (blood) 
 
 
Figure 2.2. The top left picture demonstrates the TREM-1 expression on CD14 positive cells (monocytes). The top 
right picture demonstrates the TREM-1 expression of neutrophils (CD16 positive). In the lower picture (above), CD14 
and CD16 expression is highlighted, showing the neutrophils (yellow) as CD14 low CD16 high. Monocytes are CD14 
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Figure 2.3 shows the expression of TREM-1 on monocytes and neutrophils 
(blood) . It firstly shows the MFI for the isotype and then that for the TREM-1 
antibody. The geometric mean is the ratio of the latter to the former. 
 
Figure 2.3 TREM-1 expression on monocytes and neutrophils (blood) 
 MONOCYTES     NEUTROPHILS 
 
Figure 2.3 In the above diagram, the TREM-1 expression of monocytes and neutrophils is demonstrated. On the left, 
the TREM-1 expression of monocytes (lower diagram) is compared with staining from an isotype control antibody 
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Figure 2.4 illustrates the CD11b expression on monocytes and neutrophils in 
blood. The MFI for isotype and CD11b antibodies are shown. 
 
Figure 2.4 CD11b expression on monocytes and neutrophils (blood) 
  MONOCYTES    NEUTROPHILS 
 
Figure 2.4 The diagrams above represent typical histograms of expression of CD11b on monocytes (blue) and 
neutrophils (red). The respective cells are gated via CD45 and CD14 as previously. The monocytes (left) 
demonstrate expression of CD11b (lower diagram) compared with an isotype control antibody (top left). Similarly on 
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Figure 2.5 shows the expression of CD62L (L-selectin) on monocytes and 
neutrophils .Firstly the MFI for isotypes are shown and then that for CD62L. 
 
Figure 2.5 CD62L (L-selectin) expression on monocytes and neutrophils 
(blood) 
 
 MONOCYTES     NEUTROPHILS 
 
Fig 2.5 The diagrams above represent typical histograms of expression of L-selectin on monocytes (blue) and 
neutrophils (red). The respective cells are gated via CD45 and CD14 as previously. The monocytes (left) 
demonstrate expression of L-selectin (lower diagram) compared with an isotype control antibody (top left). Similarly 
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2.5.6 Dot plot expressions in BAL 
The following plots demonstrate the gating strategies and expression of 
Live/Dead cells, TREM-1, CD11b and L-selectin BAL macrophages and 
neutrophils. Figure 2.6 shows the gating of macrophages and neutrophils. 
 

















Figure 2.6. The top left figure demonstrates Forward Scatter (FS) vs. Side Scatter (SS). In the top right picture, FS 
against FS area (Aux) allows gating out of couplets caused by antibody cross-linking. The bottom left picture 
demonstrates the immune cells gated on CD45 (region F). In the lower right diagram, neutrophils are region G (CD14 
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The staining of CD14 and CD16 in BAL are demonstrated in Figure 2.7 
 
Figure 2.7 CD14 and CD16 staining (BAL) 
 
Figure 2.7. The left diagram demonstrates neutrophils (red) as CD14 low and CD16 high. Macrophages are CD14 
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The expression of TREM-1 on BAL macrophages and neutrophils are 
highlighted in Figure 2.8. Firstly the MFI for isotype controls are shown and 
then that for the TREM-1 antibody. 
 
Figure 2.8 TREM-1 expression on macrophages and neutrophils (BAL) 
 
 NEUTROPHILS     MACROPHAGES 
 
Figure 2.8. In the above diagram, the TREM-1 expression of monocytes and neutrophils is demonstrated. On the left, 
the TREM-1 expression of neutrophils (lower diagram) is compared with staining from an isotype control antibody 
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Figure 2.9 demonstrates the expression of CD11b on BAL monocytes and 
neutrophils. The MFI for CD11b is compared with its isotype control antibody. 
Figure 2.9 CD11b expression on macrophages and neutrophils (BAL) 
 
Figure 2.9. The diagrams above represent typical histograms of expression of CD11b on macrophages (blue) and 
neutrophils (red). The respective cells are gated via CD45 and CD14 as previously. The macrophages (left) 
demonstrate expression of CD11b (lower diagram) compared with an isotype control antibody (top left). Similarly on 
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Figure 2.10 shows the expression of CD62L (L-selectin) on BAL macrophages 
and neutrophils. Firstly the MFI for the isotype is given and then that for the 
CD62L antibody. 
 
Figure 2.10 CD62L (L-selectin) expression on macrophages and 
neutrophils (BAL) 
 
Figure 2.10. The diagrams above represent typical histograms of expression of L-selectin on macrophages (blue) 
and neutrophils (red). The respective cells are gated via CD45 and CD14 as previously. The macrophages (left) 
demonstrate expression of L-selectin (lower diagram) compared with an isotype control antibody (top left). Similarly 
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The levels of the live/dead cell stain incorporated into BAL cells are shown in 
figure 2.11.  
 
Figure 2.11. Live/Dead stain of BAL 
 
Figure 2.11. The above dot plot demonstrates cells gated according to the Live/Dead cell stain ViVid. The plot has 
previously been tested with peripheral blood cells with a large proportion of dead cells. The BAL cells to the left of the 
solid live stain negatively for ViVid and are therefore alive. The cells to the right of the solid line stain positively for 
ViVid and are therefore dead. In this case, the proportion of live cells is approximately 95%. 
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2.5.7 Temporal changes of mTREM-1, nTREM-1, mTREM-2 and nTREM-2 
We studied the temporal changes of mTREM-1 and nTREM-1 to understand 
whether serial analysis may be effective in monitoring VAP development and 
resolution.12 patients had sequential bronchoscopy (2-4 per patient) as 
clinical progress allowed; bronchoscopy was performed where VAP 
developed and also during resolution. Each bronchoscopy was performed 
approximately 48 hrs apart ie alternate days. For one patient in the Burns 
setting where bronchoscopy was being performed for therapeutic reasons 
(soot removal), BAL sampling was performed during VAP development and 
resolution. mTREM-1 and nTREM-1 levels in the BAL and blood were 
measured as previously stated. WCC and CRP levels were obtained at the 
same time as phlebotomy for blood markers. Neither sTREM-1 nor other 
soluble markers were measured. In addition, mTREM-2 and nTREM-2 were 
measured in six of the twelve patients in the blood and BAL. 
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2.6 ELISA 
We utilised ELISA kits to measure human soluble TREM-1, IL-1 beta, IL-6, IL-
8, Matrix-metalloproteinase-8 and -9 (MMP-8 and -9) and Tissue Inhibitors of 
Metalloproteinase-1 (TIMP-1) (Quantikine, R&D systems, Abingdon, UK) 
according to manufacturer’s instructions. 
 
2.6.1 Soluble TREM-1 
A sandwich ELISA was used. 96 well plates were pre-coated with an antibody 
specific for soluble TREM-1, together with a blocker to prevent non-specific 
protein binding. Supernatants from peripheral blood samples or BALF were 
assayed in duplicate. Serial dilutions of a known concentration of recombinant 
soluble TREM-1 were measured in duplicate in order to construct a calibration 
curve. 
 
After incubation with sample / standard, wells were washed x4 with PBS / 
Tween (polysorbate detergent). A capture antibody with enzyme conjugate for 
soluble TREM-1 was added and further incubation allowed. After 4 further 
washes with PBS / Tween, substrate solution was added. Conjugated enzyme 
(as a result of captured soluble TREM-1) resulted in a colour change to blue. 
Stop solution was added and the resultant yellow colour was read by a plate 
reader at 450nm. Blank wells were used to correct results. Freezing did not 
have an effect on soluble TREM-1 concentrations. Soluble TREM-1 levels 
were similar in three separate samples assayed after 1 month and 9 months 
(coefficient of variation 7.4%). 
 
2.6.2 IL-1-β, IL-6, IL-8, MMP-8, MMP-9 and TIMP-1 
Similarly, commercially available kits (R and D systems, UK) were used 
according to manufacturer’s instructions. Table 2.1 details the performance of 
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each ELISA assay as detailed by the manufacturer. Dr. Ram Vyakernam had 
previously validated the cytokines in BAL using serial dilution. 
Table 2.1 Performance of the ELISA assay kits 
ELISA Intra-plate coefficient 
of variation (%) 
Inter-plate coefficient 
of variation (%) 




3.6-5.2 5.8-7.4 13.8 
IL-1β 2.8-8.5 4.1-8.4 <1 
IL-6 1.6-4.2 3.3-6.4 <0.7 
IL-8 5.4-6.5 6.1-9.7 3.5 
MMP-8 5.0-5.4 4.2-6.0 156 
MMP-9 1.9-2.9 6.9-7.9 312 
TIMP-1 3.9-5.0 3.9-4.9 156 
 
Table 2.1. The manufacturer’s intra- and inter-plate coefficients of variation and the lower limit 
of detection are provided for soluble TREM-1, IL-1β, IL-6, IL-8, MMP-8, MMP-9 and TIMP-1. 
2.6.3 Correction for dilution using urea 
Rennard’s method was used to correct for dilution of the epithelial lining fluid 
(ELF) by saline in the BALF [61]. Briefly, it is assumed that urea, a small 
molecule, freely diffuses amongst the total body water, including the epithelial 
lining fluid. Its concentration in the ELF ought to be identical to that of the 
plasma. Measurement of the urea concentration in a known volume of BAL 
sample by a highly sensitive assay and comparison with a paired blood 
sample allows determination of the ELF dilution. An estimate of the native 
cytokine concentration may be calculated. 
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We employed a highly sensitive urea assay (Abcam, Cambridge, UK). It had a 
threshold of 10 µM urea. The assay uses urea as a substrate in the presence 
of enzymes to form a compound that reacts with an OxiRed probe to effect a 
colour change that is proportional to the urea concentration. The assay was 
used according to manufacturers instructions. A standard 96-well plate was 
used and a calibration curve created. Samples were assayed in duplicate. 
2.7 Procalcitonin assay 
Procalcitonin (PCT) was quantitatively measured in the paired blood and 
BALF samples in duplicate using a Brahms OCT mini-VIDAS machine 
(Biomerieux, Hampshire, UK) according to manufacturer’s instructions. The 
limits of detection were 0.05 – 200 ng/ml. Procalcitonin has previously been 
measured in BALF (see introduction). 
2.8 16S DNA levels 
16S DNA levels were assessed in 2013 from samples frozen in 2009-2011 
but not previously thawed. An in-house assay had been developed to quantify 
the DNA levels but not identify putative organisms. The levels were then 
corrected for dilution of BAL by urea. The plasma levels were assessed in the 
VAP, VC, VSE and NVC groups as well as healthy volunteers and the BAL 
assay was performed in the VAP, VC, VSE and NVC groups. 
 
2.9 Statistics 
2.9.1 Study design 
Cross sectional cohort study. 
 
2.9.2 Statistical analysis 
A pilot study was performed to assess the ability of soluble and surface 
TREM-1 to discriminate VAP from non-VAP. Following this, a power 
calculation was performed. For a 90% power and a two-sided 5% significance 
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level, 25-30 patients in each previously indicated group were required. 
However, recruitment was significantly slowed by an outbreak of 
Acinetobacter Baumannii in the ICU. This curtailed admissions and meant that 
the final number of patients recruited who were ventilated but free of sepsis 
and those ventilated with non-pulmonary sepsis were 18 and 15 respectively. 
Data was reported as medians and inter-quartile ranges. Differences in non-
parametric variables were assessed firstly using the Kruskal-Wallis test and 
secondly the Mann-Whitney U-test with Dunn’s post-hoc correction if there 
were any statistical differences between the groups. Analysis of Receiver 
operator characteristics (ROC) was performed to assess the ability of 
individual components of the biomarker panel to diagnose bacterial VAP. 
Fisher discriminant function analysis was used to determine a combination of 
inflammatory biomarkers that optimally classified VAP in ventilated patients. 
With regards to Fisher analysis, a variable was entered into the “model” if the 
significance level of its F-value was <0.05 and was removed if the significance 
level was >0.1. A panel of biomarkers was identified and its accuracy to 
classify patients into the correct disease group was determined. Two 
techniques were used to validate the findings; the first (cross-validation) 
aimed to reflect the potential for outliers to bias the results of the sample. The 
phenotype of each case was classified by the functions derived from all cases 
other than that index case (‘leave one out classification’). A second technique 
would have involved applying the biomarker panel to new cohorts of patients 
and determining its accuracy in correctly classifying patients into each group. 
However, as previously described, recruitment was curtailed by the outbreak 
of a multi-resistant bacteria in the ICU. Therefore we validated our panel by 
randomly assigning original cases into a training cohort (60% of original 
cases) to obtain new classification function coefficients for the analytes 
derived from our original model and then applied the new parameters to a test 
cohort of the remaining 40% of cases. This was repeated ten times in total 
and a mean accuracy level determined to confirm the robustness of the panel. 
We analysed the data using SPSS v19.0 software (SPSS Inc., Chicago, 
Illinois, US) and GraphPad Prism (GraphPad Software, California, USA).  
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Chapter 3 
Patient characteristics 
Patients and healthy volunteers were recruited into the following groups: 
(a) Healthy volunteers (blood only) – 10 volunteers 
(b) Non-ventilated Community-acquired pneumonia (blood only) – 10 patients 
(c) Non-ventilated (non-infected) control patients from bronchoscopy clinic – 
31 patients 
(d) Ventilated (non-infected) control patients from ICU – 18 patients 
(e) Ventilated with non-pulmonary sepsis from ICU – 15 patients 
(f) Ventilated with VAP in ICU – 27 patients 
 
The healthy volunteers were consenting members of the Immunology 
Department; seven were male and their median age was 31.5 years. None 
had any intercurrent illness and two had previously smoked (none now). Their 
blood was used for the assays but CRP and WCC were not measured (table 
3.1). 
The patients with CAP were those admitted to the Acute Medical Unit. They 
were not admitted to the ICU and were never invasively ventilated. Their 
median age was 59 years and 40% were male. 3 out of 10 patients were 
current smokers and 3/10 were ex-smokers. They all had CXR changes as 
part of their diagnosis. Microbiology was positive in half of the cases. In the 
other half, the clinical picture and resolution with antibiotic therapy was 
strongly suggestive of CAP. Half of the patients were receiving antibiotics 
(prescribed by their GP) at the time of admission. The median WCC was 12 x 
109/L and the median CRP was 89 mg/L. Only one patient did not survive to 
discharge. 
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Table 3.1 CAP patients and healthy volunteers 
 Healthy volunteers Non-ventilated CAP 
Numbers of patients 10 10 
Age 31.5 (23-45) 59 (27-82) 
Sex (% male) 70 40 
APACHE II N/A N/A 
CPIS N/A N/A 
CURB-65 N/A 2 (1-4) 
Microbiology (% +ve) N/A 50 
Smoking (% current / ex) 0 / 20 30 / 30 
Antibiotics (% receiving) Nil 50 
CXR (% with shadowing) N/A 100 
Steroids (%) Nil 0 
Hospital mortality (%) 0 10 
Surgery (%) Nil 0 
Burns (% of cases) Nil 0 
WCC (x109/L) Not tested 12 (6-21) 
CRP (mg/L) Not tested 89 (22-465) 
 
Table 3.1. For patients with CAP, microbiology was positive in five patients 
(50%). Streptococcus pneumoniae was present in sputum / urinary antigen in 
two patients, Haemophilus influenzae in sputum of one patient, enterobacter 
in one sputum sample and MSSA in the final sputum sample (methicillin 
sensitive staphylococcus aureus). 
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31 patients were recruited from the Bronchoscopy Clinic (Table 3.2). Their 
median age was 59, 61% were male. 35% were current smokers and 13% ex-
smokers. Although microbiology was positive in twelve patients, these were 
likely colonisation as no patients were considered infected by the treating 
clinicians. CXR changes were present in the majority (81%) and 32% were 
receiving prescribed antibiotics at the time of presentation. Two patients were 
receiving steroid therapy (for sarcoidosis). Overall the median WCC was 7 x 
109/L and the median CRP 6 mg/L. In terms of diagnosis, 7 patients had lung 
cancer, 4 sarcoidosis, 9 COPD (3 with no other diagnosis), 1 lung fibrosis and 
6 with benign nodules. 
For the ventilated control patients, there were 18 who were free of infection. 
Their median age was 60 and 50% males. Their median APACHE II score 
was 15 and their median CPIS was 4. 50% were receiving antibiotics, 78% 
had CXR changes. One third of patients were receiving steroids as part of 
their ICU stay. 39% of patients were post-operative and 17% burns patients. 
Microbiology was negative in all patients. Table 2 shows the initial data for 
individual groups. 
15 patients were ventilated with non-pulmonary sepsis (‘sepsis-elsewhere’). 
Their median age was 62, 53% were male. Their median APACHE II score 
was 14 and the CPIS values were low (median 2). 27% had positive 
microbiology but clinical findings consistent with non-pulmonary infection 
(abdominal sepsis, cellulitis, infected burns, central venous catheter infection 
and urinary tract infection). 13% of patients had burns and 40% were post-
operative. 93% of patients were receiving antibiotics as part of their clinical 
treatment. 27% had CXR shadowing. 27% of patients were receiving 
hydrocortisone as management of sepsis. 
There were 27 patients with VAP, median age 68. 70% were male. The 
median APACHE II score was 18 and the median CPIS was 7. 100% of 
patients had positive microbiology. 89% were receiving antibiotics at the time 
of sampling. 96% had CXR shadowing and 30% were receiving low-dose 
steroids. 37% of patients were post-op and 15% were burns patients. 
Therefore the ventilated VAP and control patients were reasonably well-
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matched. Cell counts did not differentiate between the groups that had BAL 
performed. 
If the HELICS PN4 and PN5 definitions of VAP were used to diagnose or 
refute VAP then the classification of patients was highly concordant (kappa 
95% for agreement). 2 patients with CPIS scores of 6 and VAP would be 
considered to be non-VAP. One patient in the ventilated control (non-VAP and 
non-VSE) had negative microbiology but could be considered to have had 
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 Table 3.2 Patient characteristics in the four groups 
 VAP VC VSE NVC 
Number of patients 27 18 15 31 
Age 68 (23-84) 60 (18-80) 62 (29-89) 59 (18-84) 
Sex (% male) 70 50 53 61 
APACHE II 18 (5-45) 15 (2-23) 14 (3-24) N/A 
CPIS 7 (6-9) 4 (0-5) 2 (0-5) N/A 
Microbiology (% +ve) 100 0 27 0 
Smoking (% current / 
ex) 
44/15 28/22 33/20 35/13 
Antibiotics (% 
receiving) 
89 50 93 32 
CXR (% with 
shadowing) 
96 78 27 81 
Steroids (%) 30 33 27 6 
28-day mortality (%) 11 5 20 0 
Surgery (%) 37 39 40 0 
Burns (% of cases) 15 17 13 0 
WCC (x109/l)  15 (4-24) 8 (3-27) 13 (7-24) 7 (3-18) 
CRP (mg/L) 84 (7-320) 88(2-193) 107 (69-341) 6 (1-296) 
Table 3.2. The VC and VSE groups have not been combined. WCC levels 
were higher in VAP and VSE than VC (p=0.004 and p=0.003) and NVC 
(p=0.0001 and p=0.0002). Median CRP levels were significantly higher in 
VAP, VC and VSE than NVC (p<0.0001, p=0.0005 and p<0.0001). The data 
indicates the pre-BAL antibiotics and the microbiology following BAL. Steroids 
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were given according to Surviving Sepsis Campaign guidelines. In the VSE 
patients, positive microbiology was associated with pseudomonas, 
enterococcus, E. coli and MSSA. In the VAP patients, 1 patient had serratia, 4 
Klebsiella spp, 6 pseudomonal infection, 2 MSSA, 2 MRSA, 3 E. coli, 5 
Acinetobacter, 2 Stenotrophomonas, 2 Proteus spp and 4 candida spp. 4 
patients had polymicrobial infection including candida spp. 
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Chapter 4 
Expression of soluble proteins in VAP and disease controls 
4.1. Introduction 
Studies into biomarkers and VAP diagnosis have hitherto focused on soluble 
markers measured in BALF and blood. We wished to measure the levels of 
cytokines and sTREM-1 in these two compartments and derive a BAL/blood 
ratio. We then compared these with existing markers (CRP, WCC and PCT) 
to determine their discriminative utility as standalone markers. Given that 
sTREM-1 is cleaved from the surface of neutrophils and monocytes by matrix 
metalloproteinases, we measured levels of MMP-8, MMP-9 and their 
inhibitors (TIMP) in a subset of patients following conclusion of the main 
study. We also assessed 16S bacterial DNA levels in BAL and blood to 
compare with conventional microbiology. 
 
4.2. Aims 
1. Determine the utility of the blood biomarkers IL-1 beta, IL-8, IL-6 and 
sTREM-1 to discriminate patients with VAP and non-VAP in comparison with 
existing markers of inflammation (CRP, WCC and procalcitonin) 
2. Assess the utility of the BAL biomarkers IL-1 beta, IL-6, IL-8, sTREM-1 and 
PCT to discriminate patients with VAP and non-VAP 
3. Calculate a BAL / blood ratio for inflammatory cytokines and determine its 
utility to discriminate VAP from non-VAP patients. 
4. Measure sTREM-1 and inflammatory cytokine levels in the blood of patients 
with CAP. 
5. Determine the utility of 16S DNA to classify patients with and without VAP 
6. Assess the quantitative levels of MMP-8,MMP-9 and TIMP in the BAL of 
patients with and without VAP. 
	   114 
4.3. Results 
The summary data for the soluble biomarkers in blood, BAL, and the BAL / 
blood ratio in the four patient groups (VAP, ventilated non-infected control, 
ventilated with non-pulmonary infection and non-ventilated, non-infected 
control) are shown in Table 4.1. The BAL levels indicate ELF levels as they 
have been corrected for dilution using urea. 
Table 4.1. Soluble protein levels in VAP, VC, VSE and NVC 
 VAP VC VSE NVC 
Blood     
sTREM-1 
(µg/ml) 
181(92-273)* 83(54-221) 105(61-316) 109(69-175) 
IL-6 
(µg/ml) 
64(30-248) 22(4-84)** 62(18-251)*** 10(7-21)+ 
PCT (ng/ml) 1.3 (0.3-5.3) + 1.7 (0.4-5.5) ++ 4.7 (0.9-13.6)*** N/A 
WCC 
(x109/L) 
15 (9-17)$, * 7.5 (5.8-8.5) 13 (10-16)$$, $$$ 10 (6-15) 
CRP (mg/L) 84 (45-129)+ 88 (31-117) 107 (93-189)*** 5 (4-35) 


























PCT (ng/ml) 16.8 (9.7-51.7) 11.6 (6.2-31.5) 17.3 (8.8-27.2) 9.6 (4.1-18.2) 
ELF/blood 
ratio 
    
sTREM-1 190 (70-337)$ 31 (16-85) 23 (7-65)° 84 (26-228) 
IL-6 77 (20-145) 72 (15-272) 29 (21-104) 134 (30-355) 
PCT 28.9 (3.1-54.7) 5.1 (2.0-35.2) 3.2 (1.3-14.9) N/A 
 
	   115 
Table 4.1. PCT levels in blood for NVC were mainly below the detection limit 
of the assay. Median and IQR levels are shown. Key: * VAP > NVC, p<0.001. 
** VC > NVC, p<0.001. *** VSE > NVC, p<0.0001. + VAP > NVC, p<0.0001. ++ 
VC > NVC, p<0.0001. $ VAP > VC, p<0.01. $$ VSE > VC, p=0.003. $$$ VSE > 
NVC, p<0.001. ° VAP > VSE, p< 0.001. ° VAP > NVC, p<0.001. The data 
shows the levels of soluble protein levels in blood, ELF (corrected for dilution) 
and the BAL/blood ratio. Analysis was performed using Mann-Whitney U-tests 
and the Kruskal-Wallis tests using Dunn’s post-hoc correction. 
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4.3.1. Soluble proteins in blood 
The soluble proteins sTREM-1, IL-1β, IL-6, IL-8 and PCT were measured in 
blood. In addition, CRP and WCC levels were obtained from patients via the 
NHS laboratories. IL-1β and IL-8 levels were below the limit of detection. 
4.3.1a. sTREM-1 levels 
The median levels of sTREM-1 in the NVC group were lower than in VAP 
(p<0.001). Separately, the VC and VSE groups did not differ significantly from 
the NVC. The ventilated groups however did not differ in their levels of 
sTREM-1. The CAP group (non-ventilated) were significantly higher than the 
NVC group (p=0.001) and HV groups (p=0.008). See figure 4.1. 
Figure 4.1. Peripheral blood sTREM-1 levels 
	  
Figure 4.1. The data shows the levels of sTREM-1. The median and inter-
quartile range (IQR) are presented for VAP (ventilator-associated 
pneumonia), VC (ventilated non-infected control), VSE (ventilated with sepsis 
elsewhere, non-pulmonary sepsis), NVC (non-ventilated, non-infected 
control), CAP (community-acquired pneumonia) and HV (healthy volunteers). 
No differences between the groups were seen. Analysis was performed using 
Mann-Whitney U-tests and the Kruskal-Wallis tests using Dunn’s post-hoc 
correction.
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4.3.1b. IL-6 levels 
Median IL-6 levels were higher in VAP than NVC and HV (p<0.0001 for both). 
VC was higher than NVC (p<0.0001) and HV( p=0.001). VSE was higher than 
NVC and HV (p<0.0001 for both). See figure 4.2. In general, levels in CAP 
were higher than HV patients and higher still in ventilated patients. Therefore 
IL-6 levels were a general indicator of the severity of illness.  
 
Figure 4.2. Peripheral blood IL-6 levels 
	  
Figure 4.2. The data shows the levels of IL-6. The median and inter-quartile 
range (IQR) are presented for VAP (ventilator-associated pneumonia), VC 
(ventilated non-infected control), VSE (ventilated with sepsis elsewhere, non-
pulmonary sepsis), NVC (non-ventilated, non-infected control), CAP 
(community-acquired pneumonia) and HV (healthy volunteers). VAP > NVC 
and HC (p<0.0001 for both). VC > NVC (p<0.0001) and VC > HV (p=0.001). 
VSE > NVC and HV (p<0.0001 for both). Analysis was performed using 
Mann-Whitney U-tests and the Kruskal-Wallis tests using Dunn’s post-hoc 
correction.
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4.3.1c. PCT levels 
PCT levels were higher in VAP compared with NVC and HC. PCT levels were 
higher in VC than NVC and HC. They were higher in VSE than NVC and HC. 
Levels in CAP were higher than NVC and HC too (p<0.0001 for all 
comparisons except CAP vs. HC where p=0.0001). PCT did not discriminate 
the ventilated groups however. See figure 4.3. The majority of patients in the 
HC and NVC groups had undetectable levels of PCT.  
 
Figure 4.3. Peripheral blood PCT levels	  
	  
Figure 4.3. The data shows the levels of PCT. The median and inter-quartile 
range (IQR) are presented for VAP (ventilator-associated pneumonia), VC 
(ventilated non-infected control), VSE (ventilated with sepsis elsewhere, non-
pulmonary sepsis), NVC (non-ventilated, non-infected control), CAP 
(community-acquired pneumonia) and HC (healthy controls). VAP, VC and 
VSE > NVC and HC (p<0.0001). CAP > HC (p=0.0001). Analysis was 
performed using Mann-Whitney U-tests and the Kruskal-Wallis tests using 
Dunn’s post-hoc correction. 
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4.3.1d. CRP levels 
Median CRP levels were significantly higher in VAP, VC and VSE than NVC 
(p<0.0001, p=0.0005 and p<0.0001). Levels in the ventilated groups were 
higher than the non-ventilated group indicating that ventilation independently 
may be associated with a rise in CRP. See figure 4.4. 
 
Figure 4.4 Peripheral blood CRP levels	  
	  
Figure 4.4. The data shows the levels of CRP. The median and inter-quartile 
range (IQR) are presented for VAP (ventilator-associated pneumonia), VC 
(ventilated non-infected control), VSE (ventilated with sepsis elsewhere, non-
pulmonary sepsis), NVC (non-ventilated, non-infected control) and CAP 
(community-acquired pneumonia). VAP > NVC (p<0.0001); VC > NVC 
(p=0.0005); VSE > NVC (p<0.0001). Analysis was performed using Mann-
Whitney U-tests and the Kruskal-Wallis tests using Dunn’s post-hoc 
correction. CRP was not measured in healthy volunteers. 
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4.3.2e. WCC levels 
WCC levels were higher in VAP and VSE than VC (p=0.004 and p=0.003) and 
NVC (p=0.0001 and p=0.0002). The levels between NVC and CAP were not 
significantly different (figure 4.5). The NVC levels were higher than expected. 
Some patients were receiving steroid therapy, some had cancer and a small 
number may have had resolving infection.  
 
Figure 4.5 Peripheral blood WCC levels	  
	  
Figure 4.5. The data shows the levels of WCC. The median and inter-quartile 
range (IQR) are presented for VAP (ventilator-associated pneumonia), VC 
(ventilated non-infected control), VSE (ventilated with sepsis elsewhere, non-
pulmonary sepsis), NVC (non-ventilated, non-infected control) and CAP 
(community-acquired pneumonia. VAP > VC (p=0.004) and NVC (p=0.0001); 
VSE > VC (p=0.003) and NVC (p=0.0002). Analysis was performed using 
Mann-Whitney U-tests and the Kruskal-Wallis tests using Dunn’s post-hoc 
correction.WCC was not measured in healthy volunteers. 
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4.3.2. Soluble proteins in BAL 
4.3.2a. Cytokine levels 
Median levels of sTREM-1 were higher in VAP than VC (p=0.001) and VSE 
(p=0.0009). See figure 4.6. BAL IL-1β levels were higher in VAP than VC 
(p=0.002), VSE (p=0.0009) and NVC (p=0.0002). The levels of IL-6 in VAP 
were higher than in NVC (p=0.0015). Levels of IL-8 were elevated in VAP 
compared with VC (p=0.0006) and VSE (p=0.0004 





Figure 4.6.  Urea corrected (a) BAL sTREM-1 levels. (b) BAL IL-1β levels. (c) 
BAL IL-6 levels. (d) BAL IL-8 levels. Medians and IQR are described. Analysis 
was performed using Mann-Whitney U-tests and the Kruskal-Wallis tests 
using Dunn’s post-hoc correction. 
(c) (d) 
(a) (b) 
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4.3.2b. PCT levels 
PCT levels in BAL (corrected by urea to represent ELF) did not differ between 
any of the ventilated and non-ventilated groups. See figure 4.7.  
Figure 4.7. BAL PCT levels 
 
Figure 4.7. The data shows PCT levels. The median and inter-quartile range 
(IQR) are presented for VAP (ventilator-associated pneumonia), VC 
(ventilated non-infected control), VSE (ventilated with sepsis elsewhere, non-
pulmonary sepsis) and NVC (non-ventilated, non-infected control). No 
differences between the groups were seen. Analysis was performed using 
Mann-Whitney U-tests and the Kruskal-Wallis tests using Dunn’s post-hoc 
correction. 
4.3.3. BAL/blood ratio of soluble proteins 
The BAL/blood ratio of sTREM-1 is significantly higher for VAP than VC 
(p=0.001) or VSE (p=0.0008). The ratios are all above 1 due to the fact that 
the levels in the pulmonary compartment are significantly higher than the 
blood. The BAL/blood ratio of IL-6 did not discriminate any of the groups. The 
ratios are again above unity, indicating concentration of the cytokine in the 
BAL. For PCT, the majority of patients in the NVC group had undetectable 
levels of PCT. Therefore the BAL/blood ratio is artificially elevated and is 
meaningless. The BAL / blood ratio of the remaining groups did not 
significantly differ. See figure 4.8.  
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Figure 4.8. (a) sTREM-1 (b) IL-6 (c) PCT. Medians and IQR are described. 
The undetectable levels of PCT in the blood of the NVC group render the 
BAL/blood ratio ineffective. For sTREM-1 VAP > VC (p=0.001) and VC 
(p=0.00008). There was no difference between the levels for PCT or IL-6. 
Analysis was performed using Mann-Whitney U-tests and the Kruskal-Wallis 
tests using Dunn’s post-hoc correction. BAL levels represent the ELF 
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4.3.4 Summary of diagnostic performance of the soluble markers 
In table 4.2, the diagnostic performance of the significant biomarkers has 
been presented with area under ROC curves, positive and negative predictive 
values as well as likelihood ratios. 
The blood markers CRP, WCC, IL-6 and PCT have AUROCs of 0.64, 0.72, 
0.73 and 0.67 respectively. The BAL markers fare better, with AUROCs of 
0.74, 0.78, 0.75 and 0.68 for sTREM-1, IL-1β, IL-8 and IL-6 respectively. The 
BAL/blood ratio of sTREM-1 had an AUC of 0.71. The cutoff levels were 
chosen to optimise the sensitivity and specificity of the marker.  
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Blood CRP 70 mg/L 0.64 
(0.52-
0.75) 
53 63 38 76 1.4 0.7 





69 70 49 84 2.3 0.4 













62 56 37 77 1.4 0.7 





75 70 52 87 2.5 0.4 





73 78 58 87 3.3 0.3 





72 74 54 86 2.8 0.4 













60 63 41 79 1.6 0.6 
BAL/blood 
sTREM-1 ratio 
92 0.71  
(0.59-
0.83) 
69 74 53 85 2.6 0.4 
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Table 4.2. This data includes diagnostic data for individual markers in Blood 
and BALF and the BALF/Blood ratios. The optimal cut-off for the Area under 
Curve (AUC), sensitivity (sens), specificity (spec), positive predictive value 
(PPV), negative predictive value (NPV) positive likelihood ratio (+LR) and 
negative likelihood ratio (- LR) are given for each individual analytes. The 
NPV and PPV are given for the analyte at the given cutoff level. The BAL 
levels represent ELF concentrations following correction for dilution. The 
Youden index was utilised to determine the optimal sensitivity and specificity 
of each analyte. 
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4.3.5. Matrix metalloproteinases 
Matrix metalloproteinases and their inhibitors have been studied in VAP and 
pneumonias. MMPs (likely -8 and -9) shed soluble TREM-1 from the surface 
receptor [45]. Their pulmonary levels are elevated in hospital-acquired 
pneumonias [126] especially those with multi-resistant organisms including 
pseudomonas [127, 128]. Dyregulation of the proteases and their inhibitors 
may contribute to chronic lung diseases such as COPD and ILD [129].  
The data we obtained from flow-cytometric analysis led to the hypothesis that 
MMP levels in VAP could contribute to differences in surface expression of 
mTREM-1 and nTREM-1 in the BAL and blood. We sought to assess the 
levels of MMP-8 and -9 together with their inhibitors in the BAL samples. 
Following the conclusion of the main study, the levels of the matrix 
metalloproteinases MMP-8 and MMP-9 as well as TIMP-1 (tissue inhibitors of 
metalloproteinases) were assayed (2012) in a random selection of BAL 
samples that had been frozen at the time of the initial study (2009-2011) but 
not previously thawed. Their levels were corrected for dilution using the urea 
assay method. We did not measure MMP activity. 
Figure 4.9 shows the levels of MMP-8, MMP-9 and TIMP-1. The levels of 
MMP-8 were not significantly different between the groups. The MMP-9 levels 
were significantly higher in the ventilated groups than the non-ventilated 
control; VAP > NVC (p=0.0002), VC > NVC (p<0.0001) and VSE > NVC 
(p=0.0002). There were no differences between the groups for TIMP levels.  
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Figure 4.9. (a) BAL MMP-8 levels. (b) BAL MMP-9. (c) BAL TIMP-1 levels. 
Urea corrected cytokine levels with median and inter-quartile range 
highlighted. For MMP-9, VAP > NVC (p=0.0002); VC > NVC (p<0.0001) and 
VSE > NVC (p=0.0002). Analysis was performed using Mann-Whitney U-tests 
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4.3.6. 16S DNA levels 
Bacterial (prokaryotic) ribosomes comprise a 30S and 50S subunit. The 30S 
subunit contains ribonucleoproteins and ribosomal RNA, including the 16S 
ribosomal RNA (rRNA). The 16S gene DNA encodes for the rRNA. It has 
elements that are conserved between species, allowing binding of primers for 
PCR analysis. In addition, there are hypervariable regions, which differ 
between species and allow identification of individual bacteria. Measurement 
of 16S DNA has been studied in the BAL of ICU patients. Flanagan et al 
(2007) demonstrated that antibiotic treatment reduced the number of species 
of bacteria present in the airways that was associated with an increase in 
pseudomonal bacterial load [130]. Bousbia et al (2012) studied patients with 
VAP along with CAP, aspiration pneumonia and non-infected controls. They 
showed a large number of bacterial, viral and fungal species present even in 
control groups (non-infected) [131]. Hoedemaekers et al (2006) described a 
case of VAP associated with Dolosigranulum Pigrum. This was an extremely 
rare cause of VAP but was postulated to be pathogenic in this patient [132]. 
Such studies all illustrate a difficulty of using 16S measurements. Species 
identification is over-sensitive and may be prone to contamination. 
Furthermore, it cannot differentiate colonisation from infection. We measured 
total levels of 16S DNA without species identification, to determine whether 
differences existed between our patient groups. Furthermore, we wished to 
study those patients with negative BAL cultures to understand the bacterial 
load in their airways. 
The plasma levels  of a selection of patients were assessed in the VAP, VC, 
VSE and NVC groups as well as healthy volunteers and the BAL assay was 
performed in the VAP, VC, VSE and NVC groups (figure 4.10). There were no 
significant differences between the absolute levels of 16S DNA in the plasma 
between the groups, nor between the groups in the BAL.  
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Figure 4.10. (a) Blood and (b) BAL levels are highlighted with median and 
inter-quartile range. The BAL levels are urea-corrected for dilution occurring 
with bronchoscopy. No differences between the groups were seen. Analysis 
was performed using Mann-Whitney U-tests and the Kruskal-Wallis tests 
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4.4. Discussion 
4.4.1. Community-acquired pneumonia 
Interestingly, the levels of sTREM-1 in the blood of CAP patients were higher 
than either volunteers or the non-ventilated bronchoscopy clinic patients. This 
was in accordance with a study by Porfyridis et al (2010) who compared 
patients with and without bacterial CAP [133]. In the blood of CAP patients, 
they found elevated CRP levels, sTREM-1, mTREM-1 and nTREM-1. sTREM-
1 at a cutoff level of 19 pg/ml had a sensitivity of 82.6% and specificity of 63% 
to diagnose CAP in this setting. We did not measure sTREM-1 levels in 
acutely unwell medical patients without CAP and therefore cannot calculate a 
comparative sensitivity and specificity. Similarly, How et al (2011) assessed 
plasma sTREM-1 levels in patients with typical and atypical CAP. Median 
sTREM-1 levels in the former were 65.2 pg/ml and 25.9 pg/ml in the latter 
[134]. Our numbers of patients did not include patients with atypical CAP and 
therefore a comparison is difficult. Both studies are suggestive that sTREM-1 
and mTREM-1 / nTREM-1 levels may be elevated in CAP. This warrants 
further study. With regards to PCT, we saw elevated levels in CAP compared 
with volunteers and outpatient bronchoscopy patients. PCT may have utility in 
CAP to diagnose it and also to assist in antibiotic cessation in patients with 
treated LRTI’s [135].  
 
4.4.2. Ventilator-associated pneumonia 
The standalone markers have been investigated for their utility in 
discriminating VAP from the other ventilated and non-ventilated groups and 
comments have been made as each marker was discussed. The conventional 
markers CRP and WCC have limited utility in this regard as does PCT. The 
blood markers did not differentiate VAP from the other groups, suggesting 
VAP to involve compartmentalization. In this regard, sTREM-1, IL-1β and IL-8 
are elevated in the BALF. This is in keeping with several studies previously 
discussed. The sTREM-1 data agrees with Gibot et al (2004) and Determann 
et al (2005) but differs from Song et al (2007), Oudhuis et al (2009), Anand et 
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al (2008) and Conway-Morris et al (2009) in being elevated in VAP [14, 100-
102, 104, 105]. Reasons for this include assay differences, patient selection, 
prior freezing/thawing of samples in other studies, VAP definitions and 
method of sample acquisition. BAL PCT was not discriminative. This was in 
accordance with work by Linssen et al (2008) who showed no benefit to BAL 
measurement of PCT in the diagnosis of VAP [70].  
The BAL/blood ratio of sTREM-1 increased the discrimination between the 
VAP and VC/VSE groups as compared with the BAL level. There may be 
variable levels of sTREM-1 between different individuals and the ratio may 
help correct for this. The data on the BAL/blood ratio will be discussed further 
in the main discussion of the thesis. 
Considering the metalloproteinases, the results differ from those seen by 
Wilkinson et al (2012) who saw elevated levels of MMP-8 and MMP-9 in VAP 
[136]. Our sample size was smaller, due to the availability of BAL samples. 
Their samples did not include patients with non-pulmonary sepsis. Our data 
did not differ whether levels were corrected for dilution or not. As the data was 
acquired from relatively few samples (15 VAP, 9 VC, 8 VSE and 8 NVC), the 
data has not been included in the biomarker panel analysis nor the summary 
tables in this chapter. A caveat to the analysis was that the physiological 
activity of the enzymes was not assayed, just the absolute levels. It is possible 
that a qualitative difference may exist between our groups.  
We found the 16S DNA data of interest. Both BAL and blood samples were 
positive for DNA in patients with VAP as well as non-infected non-ventilated 
controls. The assay used to measure DNA levels is in use by our Department 
across a variety of patient groups, including those with HIV. It is unlikely that 
the results are therefore due to assay error. The data likely reflects sensitivity 
of the technique and colonisation of airways. The results are in keeping with 
those presented by Conway-Morris et al (2011, State of the Art Intensive Care 
Society Winter meeting) and Bousbia et al (2012) where bacterial DNA was 
present even in healthy control patients [131]. It is also possible that some 
non-ventilated control patients had resolving infections that were negative for 
traditional culture methods. One caveat to our work is that we did not measure 
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quantitative bacterial levels for formal microbiology. Potentially, the DNA 
levels could have correlated with the quantitative bacterial burden and may 
have allowed the study of those patients with <104 cfu/ml BAL bacteria but 
high DNA levels. Such patients could have had subclinical VAP. Furthermore, 
we did not identify the dominant bacteria from the DNA samples and so could 
not compare with conventional microbiological results. Rapid bacterial 
identification by PCR could complement existing clinical methods. It could 
allow a better understanding of the role of bacteria not routinely grown in the 
laboratory that may be pathogenic.  
 
4.5. Conclusions 
BAL levels of cytokines (sTREM-1, IL-1β and IL-8) can differentiate VAP from 
non-VAP patients. The BAL/blood ratio of sTREM-1 may increase the 
discrimination between the groups. The conventional markers such as CRP, 
WCC and PCT and other blood biomarkers have limited value as standalone 
markers in diagnosing VAP. Further studies could assess the utility of blood 
sTREM-1 to diagnose CAP. Quantitative analysis of matrix metalloproteinases 
and their inhibitors demonstrated no difference between our groups. 16S DNA 
analysis showed significant levels in non-ventilated control patients which may 









	   134 
Chapter 5 
Expression of inflammatory proteins by monocytes and neutrophils in 
VAP and disease controls 
5.1. Introduction 
We have developed assays to measure surface expression of mTREM-1, 
CD11b and CD62L (L-selectin) in the blood and BAL. We sought to determine 
whether expression of such proteins differed in patients with VAP and non-
VAP. Pilot results demonstrated mTREM-1 in the BAL and the BAL/blood ratio 
to be increased in VAP. We therefore studied the changes in the expression 
of these proteins on the surface of monocytes and neutrophils over time, 
during the development and resolution phases of VAP to inform us of their 
potential utilities as biomarkers. Towards the end of the study, we also 
measured TREM-2 levels in selected patients developing VAP following 
reports of changes in its levels in BAL with ALI [52]. 
5.2. Aims 
1. To determine the utility of the blood monocytic and neutrophilic biomarkers 
TREM-1, CD11b and CD62L (L-selectin) to discriminate patients with VAP 
from non-VAP 
2. To determine the utility of the BAL monocytic and neutrophilic biomarkers 
TREM-1, CD11b and CD62L (L-selectin) to discriminate patients with VAP 
from non-VAP 
3. To determine if the BAL/blood ratio of the monocytic and neutrophilic 
biomarkers TREM-1, CD11b and CD62L increases the discrimination of 
patients with VAP from non-VAP 
4. To determine the temporal changes of mTREM-1 and nTREM-1 in the 
blood and BAL of patients developing and resolving VAP in order to assess 
their utility as biomarkers 
5. To assess the temporal changes of mTREM-2 and nTREM-2 in the blood 
and BAL of selected patients developing and resolving VAP. 
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5.3. Expression of surface markers in blood 
In the six patient populations (four for BAL), TREM-1, CD11b and L-selectin 
(CD62L) were measured on the surface of monocytes and neutrophils in 
blood and BAL. Initally, blood levels will be discussed, then BAL levels and 
finally the BAL/blood ratios. The data is summarised in Table 5.1. 
5.3.1. Blood mTREM-1 levels 
Figure 5.1 illustrates the levels of mTREM-1 in blood. The level of mTREM-1 
in the NVC was significantly higher than the healthy volunteers (p=0.002), as 
was the level in CAP (p=0.001). There was a spread in the levels of mTREM-
1 in volunteers, indicating variation in health between individuals.  
Figure 5.1. Blood monocytic TREM-1 
 
Figure 5.1. Levels of blood mTREM-1 in the six groups with median and inter-
quartile range. VAP = ventilator-associated pneumonia; VC = ventilated 
control (non-infected); VSE = ventilated with sepsis elsewhere (non-
pulmonary infection); NVC = non-ventilated control (non-infected); CAP = 
community-acquired pneumonia; HV = healthy volunteer. CAP > HC 
(p=0.001); NVC > HV (p=0.002). NVC and CAP > HV (p=0.002 and p=0.001). 
Analysis was performed using Mann-Whitney U-tests and the Kruskal-Wallis 
tests using Dunn’s post-hoc correction. 
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Table 5.1. Expression of surface markers in the four patient groups 
 VAP VC VSE NVC 
Blood     
mTREM-1 5.1(3.1-8.5) 6.1(4.6-9.6) 4.8(4.0-7.0) 7.4(4.3-11.1) 
nTREM-1 5.4(2.9-7.5) 2.9(2.0-4.6) 5.9(2.7-9.4) 4.7(3.1-8.5) 
mCD11b 47.2(30-5-93.5) 34.0(23.8-51.8) 43.6(34.5-50.4) 36.6(21.6-
50.7) 
nCD11b 42.0(30.7-87.7) 59.8(40.8-107.2) 61.7(56.0-92.5) 48.8(31.0-
77.7) 
mCD62L 9.4(7.3-16.9)* 9.5(5.5-14.4)** 10.1(7.2-13.7) 5.0(3.5-9.3) 
nCD62L 9.6(6.9-17.2) 8.1(6.2-11.8) 9.0(7.1-11.2) 8.7(7.0-11.8) 
BAL     
mTREM-1 3.9 (2.4-6.5) 1.3(0.24-2.18)$ 1.9 (1.40-2.41)$$ 2.0(1.26-2.90)* 
nTREM-1 2.1(1.7-3.3) 1.2(1.0-1.8) 2.0(1.37-3.61) 1.5(1.18-3.10) 
mCD11b 24.0(8.0-82.0) 18.6(12.8-36.2) 18.2(9.0-26.4) 19.7(7.8-46.0) 
nCD11b 47.0(13.8-84.5) 70.3(34.2-168.0) 40.7(28.3-193.0) 53.0(23.1-
136.0) 
mCD62L 1.2(1.0-1.6) 1.2(1.1-1.4) 1.2(1.1-1.7) 1.2(1.1-1.7) 
nCD62L 1.4(1.0-2.2) 1.4(1.0-2.1) 1.2(1.1-1.4) 1.3(1.0-1.8) 
BAL/blood 
ratio 
    
mTREM-1 0.9(0.6-1.1) 0.3(0.1-0.3) 0.4(0.2-0.5) 0.4(0.2-0.4)+ 
nTREM-1 0.6(0.2-0.8) 1.0(0.6-1.6) 0.4(0.2-0.6) 0.4(0.2-0.8) 
mCD11b 1.2(0.4-2.3) 0.5(0.2-0.8)° 0.2(0.1-0.5)°° 0.6(0.2-1.3) 
nCD11b 0.7(0.5-2.0) 0.5(0.2-1.3) 0.5(0.2-0.6) 0.5(0.1-1.4) 
mCD62L 0.2(0.1-0.5) 0.1(0.1-0.2) 0.1(0.1-0.2) 0.2(0.1-0.3) 
nCD62L 0.2(0.1-0.3) 0.2(0.1-0.4) 0.1(0.1-0.2) 0.2(0.1-0.2) 
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Table 5.1. Expression of surface markers in the four patient groups. The 
levels of the markers in the blood (MFI), BAL (MFI) and the BAL/blood ratio 
are described. MFI = mean fluorescent intensity. The median and interquartile 
range for each patient group is reported. Statistically significant differences 
between groups were determined using the Mann-Whitney U and Kruskal-
Wallis tests with post hoc Dunn correction as follows: * VAP > NVC, p<0.001. 
** VC > NVC, p<0.01. $ VAP > VC, p<0.0001. $$ VAP > VC, p=0.0001. + 
VAP > VC, VSE and NVC (p<0.0001 for all). ° VAP > VC, p=0.0085. °° VAP > 
VSE, p=0.0013. 
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5.3.2. Blood nTREM-1 levels 
Figure 5.2 shows the levels of nTREM-1 in the six groups. There were no 
significant differences between patients who were ventilated and the non-
ventilated and healthy controls.  
Figure 5.2. Blood nTREM-1 levels 
 
Figure 5.2. Blood nTREM-1 levels with medians and IQR. There were no 
significant differences between the groups. Analysis was performed using 
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5.3.3. Blood mCD11b and nCD11b levels 
mCD11b levels were measured in the six groups, but did not differ 
significantly between them. The levels in the healthy volunteers were spread 
over a narrow range in comparison with the other groups. This may be 
suggestive of a dimorphic pattern, where some patients have a raised 
mCD11b MFI and others do not. We were unable to discern a clinical 
difference between the groups even in those patients with raised MFI (fig 
5.3a). nCD11b levels were assessed in the six groups and did not differ 
significantly (figure 5.3b). Once again, the levels in the healthy volunteers 
were within a lower range than the patients. Some patients in each group had 
elevated nCD11b levels but the majority had levels similar to healthy 
volunteers. Amongst those with raised levels (dimorphic pattern), no pattern 
emerged to distinguish the groups. 
Figure 5.3. Blood mCD11b and nCD11b levels 
 
 
Figure 5.3. (a) Blood mCD11b levels and (b) nCD11b levels with medians 
and IQR. There were no significant differences between the groups. Analysis 
was performed using Mann-Whitney U-tests and the Kruskal-Wallis tests 
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5.3.4. Blood mCD62L and nCD62L (L-selectin) levels 
The levels of mCD62L were increased in VAP, VC and CAP compared with 
the NVC (p=0.0003, p=0.0054 and p=0.0041). Although the levels of mCD62L 
were increased in CAP compared with healthy volunteers, the difference was 
not significant when corrected for multiple comparisons (figure 5.4a). There 
was no significant difference between the levels of nCD62L between any of 
the groups. Once again, this differs from the monocyte levels and will be 
discussed later (figure 5.4b). 
 
Figure 5.4. Blood mCD62L and nCD62L (L-selectin) levels 
 
	  
Figure 5.4. Blood (a) mCD62L and (b) nCD62L (L-selectin) levels with 
medians and IQR. For mCD62L, VAP, VC and CAP > NVC (p=0.0003, 
p=0.0054 and p=0.0041 respectively). No differences were seen for nCD62L. 
Analysis was performed using Mann-Whitney U-tests and the Kruskal-Wallis 
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5.4. Expression of surface markers in the BAL 
5.4.1. BAL mTREM-1 levels 
The data for the BAL mTREM-1 levels was significantly different (figure 5.5). It 
was higher in the VAP group than the VC (p<0.0001), VSE (p=0.0001) and 
NVC groups (p<0.0001). The data seen amongst the groups in the BAL is 
different to the blood and indicates that the changes in VAP may be 
compartmentalised to the lung. 
 
Figure 5.5. BAL mTREM-1 levels	  
	  
Figure 5.5. BAL mTREM-1 levels in the four groups. Box-whisker plots 
(median and IQR with range) highlighted. Outliers are identified as dots. VAP 
levels were significantly higher than those in the other groups (p<0.001 for 
all). Analysis was performed using Mann-Whitney U-tests and the Kruskal-
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5.4.2. BAL nTREM-1 levels 
nTREM-1 levels in BAL were assessed in the four groups. However, in 
comparison with mTREM-1, there was no significant difference between the 
groups. Once again, this highlights a difference between the results seen with 
the neutrophils and those seen with the macrophages (figure 5.6). 
 
Figure 5.6.  BAL nTREM-1 levels 
	  
Figure 5.6.  BAL nTREM-1 MFI levels in the four groups with medians and 
IQR. No significant differences were seen between the groups. Analysis was 
performed using Mann-Whitney U-tests and the Kruskal-Wallis tests using 
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5.4.3. BAL mCD11b and nCD11b levels 
Figure 5.7a illustrates the levels of mCD11b in the BAL. There were no 
significant differences between the groups. However, visual inspection 
suggests that there is a narrow spectrum of levels of mCD11b in patients with 
VSE and VC and that there are some patients with VAP (more than in the 
NVC) with higher levels, suggestive of a dimorphic picture. BAL levels of 
nCD11b did not differ between the four groups (figure 5.7b). 
Figure 5.7. BAL mCD11b and nCD11b levels 
	  
	  
Figure 5.7. BAL (a) mCD11b and (b) nCD11b levels in the four groups with 
medians and IQR. No significant differences were seen between the groups. 
Analysis was performed using Mann-Whitney U-tests and the Kruskal-Wallis 
tests using Dunn’s post-hoc correction. 
 
(a) (b) 
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5.4.4. BAL mCD62L and nCD62L (L-selectin) levels 
The BAL levels of mCD62L (L-selectin) did not differ between the four groups 
either (figure 5.8a). The BAL levels of nCD62L (L-selectin) were not different 
across the four patient groups (figure 5.8b). 
 
Figure 5.8. BAL mCD62L and nCD62L (L-selectin) levels 
 
	  
Figure 5.8. BAL (a) mCD62L and (b) nCD62L (L-selectin) levels in the four 
groups with medians and IQR. No significant differences were seen between 
the groups. Analysis was performed using Mann-Whitney U-tests and the 
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5.5. BAL / blood ratios for surface markers 
5.5.1. mTREM-1 BAL/blood ratio 
The ratio is higher for VAP than all other groups (p<0.0001 for all). Secondly, 
there is increased discrimination between the VAP and other groups 
compared with measurement of the BAL level alone (figure 5.9). This is in 
accordance with the ratio reducing the inter-patient variation. The BAL/blood 
ratio and the BAL level of mTREM-1 differentiate pulmonary from non-
pulmonary infection, albeit the latter group only having 15 patients.  
Figure 5.9. BAL/blood mTREM-1 ratios	  
	  
Figure 5.9. BAL/blood mTREM-1 ratios. Box-whisker plots (median and IQR 
with ranges) highlighted. Outliers are represented by dots. The ratio for VAP 
is higher than all groups (p<0.0001 for all). Analysis was performed using 
Mann-Whitney U-tests and the Kruskal-Wallis tests using Dunn’s post-hoc 
correction. 
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5.5.2. nTREM-1 BAL / blood ratio 
The BAL / blood ratio of nTREM-1 was compared amongst the 4 groups but 
there was no significant difference between them. This is a further difference 
between the results seen for the macrophages and neutrophils (figure 5.10).  
 
Figure 5.10. BAL/blood nTREM-1 ratios	  
	  
Figure 5.10. BAL/blood nTREM-1 ratios for the four groups with medians and 
IQR. There was no significant differences between the groups. Analysis was 
performed using Mann-Whitney U-tests and the Kruskal-Wallis tests using 
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5.5.3. mCD11b and nCD11b BAL/blood ratios 
The BAL / blood ratio for mCD11b were higher in VAP than VC (p=0.0085) 
and VSE (p=0.0013). There are several patients with ratios above 1.0 
indicative of elevated pulmonary levels. However, large numbers of patients 
have ratios below 1.0 indicative of low pulmonary levels (figure 5.11a). The 
ratios for nCD11b were similar between the four groups (figure 5.11b) in 
comparison with the data for the monocytic CD11b. The majority of the VSE 
patients have ratios below 1. Visual inspection of the other groups is  
suggestive of a dimorphic picture, with ratios above and below 1.0.  
 
Figure 5.11. BAL/blood mCD11b and nCD11b ratios 
 
	  
Figure 5.11. BAL/blood (a) mCD11b and (b) nCD11b ratios with medians and 
IQR. VAP >  VC (p=0.0085) and VSE (p=0.0013). Analysis was performed 
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5.5.4. mCD62L and nCD62L (L-selectin) BAL / blood ratio 
There were no significant differences between the four groups for mCD62L. 
The ratios are mainly below 1.0 (figure 5.12a). Similarly for nCD62L, the ratios 
were not significantly different between the groups and were all below 1.0 as 
well (figure 5.12b). 
 
Figure 5.12. BAL/blood mCD62L and nCD62L (L-selectin) ratios 
	  
	  
Figure 5.12. BAL/blood (a) mCD62L and (b) nCD62L (L-selectin) ratios for 
the four groups with medians and IQR. There were no significant differences 
between the groups. Analysis was performed using Mann-Whitney U-tests 
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5.6 Diagnostic performance of the standalone surface markers 
The summary data for the surface markers with significant differences 
between VAP and the other groups are highlighted in Table 5.2. The AUROCs 
compare favourably with the soluble proteins (Chapter 4). The BAL/blood ratio 
of mTREM-1 has a higher AUROC than the BAL mTREM-1 (0.93 compared 
with 0.85). The NPV of the BAL/blood ratio of mTREM-1 is high at 96% for a 
cutoff level of 0.50, as are the sensitivity and specificity (92% and 85% 
respectively). The BAL/blood ratio of mCD11b, BAL nTREM-1 and Blood 
mCD62L have intermediate AUROCs of between 0.64 and 0.73. 



















84 74 58 92 3.3 0.2 
BAL/blood 
mTREM-1 ratio 
0.50 0.93  
(0.87-
0.98) 
92 85 72 96 6.2 0.1 





56 78 52 81 2.6 0.6 
BAL/blood 
mCD11b ratio 
0.57 0.73  
(0.61-
0.85) 
65 70 47 82 2.1 0.5 
Blood mCD62L MFI 9.5 0.64 
(0.52-
0.76) 
66 48 35 77 1.3 0.7 
 
Table 5.2. Summary of diagnostic data for selected surface proteins. The 
optimal cutoff for each marker is given to diagnose VAP. The sensitivites, 
specificities, area under ROC curve, PPV (positive predictive value), NPV 
(negative predictive value), LR+ (positive likelihood ratio) and LR- (negative 
likelihood ratio) are described. 
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5.7. HELICS analysis 
The study was conducted with patients classified into VAP on the basis of 
CPIS and positive microbiology. However, given that there is no gold standard 
for VAP, we enrolled patients with a strong likelihood for, or the absence of 
VAP. This led to a cohort of 27 patients with VAP and 33 ventilated controls 
(15 VSE and 18 ventilated and non-infected). We re-analysed the groups 
using the HELICS definitions of VAP. We utilised semi-quantitative 
microbiological culture in our study. Therefore the HELICS definitions of VAP 
appropriate to our study are PN4 and PN5 (see introduction). 
Of the 60 ventilated patients, 2 diagnosed with VAP according to CPIS may 
be non-VAP and 1 patient with non-VAP (negative microbiology) could 
possibly be re-classified as a VAP case. There was agreement on at least 57 
cases therefore, a kappa value of 95%. If the 1 patient with non-VAP 
remained non-VAP, this would be 96.7%. Figure 5.13 shows the BAL/blood 
mTREM-1 data if patients were re-classified by HELICS. As can be seen, the 
pattern demonstrated is identical to that for the CPIS definition of VAP. The 
level of the BAL/blood ratio for VAP is significantly higher than that of the VC, 
VSE and NVC groups (p<0.001 for all).  
Overall, for this preliminary study on VAP biomarkers, we are satisfied that 
our diagnostic criteria are valid. 
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Figure 5.13 
 
Figure 5.13. The BAL/blood ratio of mTREM-1 in the four groups 
according to the HELICS definitions of VAP. The BAL/blood ratio is higher 
for VAP compared with VC, VSE and NVC (p<0.001 for all). The graph shows 
a box-(median and inter-quartile range)-whisker (range) with outliers in dots. 
Analysis was performed using Mann-Whitney U-tests and the Kruskal-Wallis 
tests using Dunn’s post-hoc correction. 
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5.8. Temporal changes of mTREM-1 and nTREM-1 with development and 
resolution of VAP 
Characteristics of ideal biomarkers for VAP diagnosis include the ability to rise 
early with infection and fall with disease resolution. We have shown that 
mTREM-1 in BAL and the BAL/blood ratio are increased in VAP. It is 
important to understand whether these markers have utility in tracking 
infection formation and resolution. 
BAL nTREM-1 and its BAL/blood ratio do not show the same pattern. There 
may be several reasons for the latter observations: firstly, nTREM-1 may not 
correlate with VAP. Secondly, nTREM-1 may rise with VAP but to a lesser 
extent than mTREM-1 making the results non-significant. Finally, nTREM-1 
may display different temporal changes to mTREM-1 and sampling at a single 
point in time may have missed its rise. One study suggested that following 
activation of nTREM-1 and mTREM-1, nTREM-1 surface receptor was 
cleaved, leading to increased sTREM-1 and reduced nTREM-1 (whose level 
gradually recovered) and a slow rising mTREM-1 [48]. We therefore sought to 
explore surface TREM-1 changes during development of, and resolution of 
VAP. This would determine whether mTREM-1 in the BAL (or the BAL/blood 
ratio) rose with infection / fell with resolution; it could also determine the role 
of nTREM-1 over the same time period. The existing definitions of VAP used 
in the study were continued with regards to CPIS and microbiology. 
From previous analysis of standalone markers, thresholds were determined 
for VAP diagnosis, albeit with variable sensitivity and specificity. BAL 
mTREM-1 had an MFI threshold of 2.25, BAL/blood mTREM-1 0.5, BAL 
nTREM-1 1.67 and BAL/blood nTREM-1 1.13. The sensitivities and 
specificities respectively at these thresholds were 76% and 81% for BAL 
mTREM-1, 94% and 85% for BAL/blood mTREM-1, 67% and 78% for BAL 
nTREM-1 and 52% and 45% for BAL/blood nTREM-1. For the 12 patients, the 
thresholds will be discussed in the summary. 
The changes in mTREM-1 and nTREM-1 will be divided into four sections: 
firstly changes in the markers prior to the onset of VAP; secondly, changes in 
the markers with resolution of VAP; thirdly changes in the markers with 
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progressive and ongoing VAP; finally one patient with serial bronchoscopies 
showing the development, worsening and resolution of VAP will be used to 
illustrate the sequential changes in these markers. 
 
 
5.8.1. Expression of mTREM-1 and nTREM-1 on monocytes and 
neutrophils prior to the onset of VAP 
VAP was diagnosed at the time of the second or third bronchoscopies in the 
patients PS72, PS81, PS84, PS86 and PS87 and therefore biomarker levels 
are available prior to and during the development of VAP. 
 
As a representative example, 3 bronchoscopies were performed for PS72 
(figure 5.14). VAP was diagnosed at the time of the third bronchoscopy. The 
BAL mTREM-1 initially falls slightly before rising and the BAL/blood ratio 
shows a continual rise. BAL nTREM-1 falls over this period and the BAL/blood 
ratio shows the same pattern too. Both blood mTREM-1 and nTREM-1 initially 
fall, but the nTREM-1 subsequently rises and the mTREM-1 falls. Overall, the 
BAL/blood ratio mTREM-1 provides a better signal for the development of 
VAP than the BAL mTREM-1. The nTREM-1 signal is discordant. The CRP 
initially rises marginally then a larger rise at the time of the third 
bronchoscopy, akin to the changes in BAL mTREM-1. The WCC rises 
minimally during this period however. 
 
Overall, BAL mTREM-1 and the BAL/blood ratio of mTREM-1 show evidence 
of rising prior to the development of clinical (overt) VAP in four out of five 
patients, highlighting potential for their use as diagnostic biomarkers.


















Figure 5.14. (a) BAL and blood mTREM-1 and nTREM-1 for PS72. (b) BAL 
/ blood ratios for mTREM-1 and nTREM-1. (c) CRP and WCC levels. Each 
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5.8.2. Changes in mTREM-1 and nTREM-1 with resolution of VAP 
For six patients (PS45, PS59, PS60, PS66, PS70 and PS75), VAP was 
diagnosed at the time of the first bronchoscopy and showed resolution over 
the course of the temporal analysis. 
For PS45 (a representative patient), 2 bronchoscopies were performed, which 
show BAL mTREM-1 and nTREM-1 falling (figure 5.15). VAP was present at 
the time of the first bronchoscopy. The fall in mTREM-1 is greater than that of 
nTREM-1. There is a fall in the blood mTREM-1 and nTREM-1 too. The 
BAL/blood ratio of mTREM-1 mirrors the BAL mTREM-1 and is of greater 
magnitude than the change in nTREM-1. The CRP falls slowly whereas the 












Figure 5.15. (a) Blood and BAL levels of mTREM-1 and nTREM-1 in PS45. 
BAL / blood ratios of mTREM-1 and nTREM-1. (c) WCC and CRP levels. 
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Overall, both mTREM-1 in the BAL and its BAL / blood ratio show a reduction 
in the resolution of VAP in the majority of patients. 
 
5.8.3 Changes in mTREM-1 and nTREM-1 with worsening VAP 
For PS80, 2 bronchoscopies were performed following (figure 5.16). VAP 
developed at the time of the first bronchoscopy and clinically worsened. The 
CRP and WCC are concordant, rising slowly with development of infection. 
The BAL mTREM-1 rises (as does the BAL/blood ratio). The BAL nTREM-1 
falls however. The blood mTREM-1 and nTREM-1 fall and the latter is at a 
faster rate than the BAL nTREM-1. Therefore the BAL/blood nTREM-1 ratio 
rises but with a shallower gradient than for mTREM-1. Overall, BAL mTREM-1 
and the BAL/blood ratio highlight changes with progressive infection. 















Figure 5.16. (a) BAL and blood mTREM-1 and nTREM-1 for PS80. (b) BAL 
/ blood ratios for mTREM-1 and nTREM-1. (c) CRP and WCC levels. Each 




	   158 
5.8.4 Changes in mTREM-1 and nTREM-1 during VAP development and 
resolution 
The patient PS87 had four bronchoscopies. Clinically, he developed 
staphylococcal VAP but then clinically deteriorated, requiring antibiotic 
escalation (from Vancomycin to Linezolid). The VAP subsequently settled. 
The CRP and to a lesser extent the WCC rose, as previously described 
(figure 5.17). The BAL mTREM-1 mirrors the deterioration before resolution. 
The BAL/blood ratio of mTREM-1 highlights this signal better. The BAL 














Figure 5.17. (a) Blood and BAL levels of mTREM-1 and nTREM-1 in PS87. 
(b) BAL / blood ratios of mTREM-1 and nTREM-1. (c) WCC and CRP 
levels. Each bronchosopy was 48 hours apart; VAP was present at day 2 and 
worsened by day 4 before resolving. 
(c) 
(a) (b) 
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5.9. TREM-2 
TREM-2 levels were studied in 6 patients. One patient (PS87) had VAP that 
developed, worsened and then resolved over the course of 4 bronchoscopies. 
The other five patients had mTREM-2 and nTREM-2 measured prior to the 
onset of VAP. The data for PS72 will be shown as an example, but the data 
for 4 other patients (PS80, PS81, PS84 and PS86) is also shown in table 5.3. 
Figure 5.18 shows the changes in TREM-2 during development and resolution 
of VAP in PS87. Figure 5.19 shows the changes during development of VAP 
for patient PS72. 
During the development of VAP, blood mTREM-2 remains static (PS87) or 
drops marginally (PS72). BAL mTREM-2 rises (PS72) or falls slightly before 
rising (PS87). The BAL / blood ratio rises gradually (PS72) or falls slightly 
then rises higher than baseline (PS87). In the other patients, the BAL/blood 
ratio rises steadily. 
Just as for TREM-1, the neutrophilic changes in TREM-2 are harder to 
understand. In the blood (PS87), nTREM-2 rises then falls; in PS72 the level 
falls then rises. In the BAL, nTREM-2 falls then rises (PS87) or remains 
reasonably static (PS72). The BAL/blood ratio falls then rises as infection 
develops and resolves (PS87) or rises then falls (PS72) when infection 
develops. Overall, there was no clear pattern for the neutrophilic changes. 
 



















Figure 5.18. (a) TREM-2 changes in the blood and BAL in neutrophils 
and monocytes for PS87 during development and resolution of 
infection.  (b) Changes in the BAL/blood ratio of mTREM-2 and nTREM-2. 
(c) CRP and WCC levels. Bronchoscopies were performed 48 hours apart. 
VAP was diagnosed at the time of the second bronchoscopy, worsened at the 
time of the third and was resolving at the time of the fourth bronchoscopy.
(a) (b) 
(c) 



















Figure 5.19. (a) TREM-2 changes for monocytes and neutrophils in the 
blood and BAL (PS72) during development of infection. (b) Changes in 
the BAL/blood ratio for mTREM-2 and nTREM-2. (c) CRP and WCC 
levels. Bronchoscopies were performed 48 hours apart. VAP was diagnosed 
at the time of the third bronchoscopy. 
(a) (b) 
(c) 
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Table 5.3 mTREM-2 and nTREM-2 changes with development of VAP 
 PS72 PS80 PS81 PS84 PS86 
1st bronchoscopy  VAP    
Blood mTREM-2 5.1 1.6 1.6 3.3 2.3 
Blood nTREM-2 3.9 1.3 1.3 3.5 2.8 
BAL mTREM-2 1.3 1.3 1.3 1.4 1.0 
Blood nTREM-2 1.9 1.3 1.3 1.8 1.2 
BAL/blood 
mTREM-2 
0.3 0.9 0.9 0.4 0.4 
BAL/blood 
nTREM-2 
0.5 1.0 1.0 0.5 0.4 
CRP 68 46 97 24 34 
WCC 12.4 8.3 12.4 17.7 16.2 
2nd bronchoscopy   VAP VAP VAP 
Blood mTREM-2 3.7 1.0 1.0 1.0 1.1 
Blood nTREM-2 2.9 1.5 1.5 1.9 2.0 
BAL mTREM-2 1.7 1.1 1.1 1.4 2.0 
Blood nTREM-2 1.8 1.8 1.8 1.6 1.3 
BAL/blood 
mTREM-2 
0.5 1.1 1.1 1.4 1.7 
BAL/blood 
nTREM-2 
0.6 1.2 1.2 0.8 0.7 
CRP 73 64 124 44 69 
WCC 17.3 12.4 10.3 14.6 25.7 
3rd bronchoscopy VAP    N/A 
Blood mTREM-2 5.5 N/A 1.3 1.0 N/A 
Blood nTREM-2 3.7 N/A 2.3 2.1 N/A 
BAL mTREM-2 2.2 N/A 1.5 1.2 N/A 
Blood nTREM-2 1.9 N/A 1.6 1.9 N/A 
BAL/blood 
mTREM-2 
0.4 N/A 1.2 1.2 N/A 
BAL/blood 
nTREM-2 
0.5 N/A 0.7 0.9 N/A 
CRP 107 N/A 136 52 N/A 
WCC 15.9 N/A 9.7 15.3 N/A 
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Table 5.3. mTREM-2 and nTREM-2 changes with development of VAP. For 
PS72, VAP was diagnosed at the time of the 3rd bronchoscopy. For PS80, 
VAP was present at the time of the 1st bronchoscopy. For PS81, PS84 and 
PS86, VAP developed at the time of the 2nd bronchoscopy. Serial changes in 
monocytic and neutrophilic TREM-2 in blood, BAL and the calculated 
BAL/blood ratio are shown together with CRP (mg/L) and peripheral blood 
WCC (x109/L). For PS80 and PS81, only two bronchoscopies were 
performed. Overall, bronchoscopies were performed 48 hours apart. In 
general, the BAL mTREM-2 rose with the development of VAP. 
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5.10. Discussion 
The data for the standalone markers will be discussed first, followed by the 
temporal changes in mTREM-1, nTREM-1 and mTREM-2. 
5.10.1. Standalone markers 
mTREM-1 (blood) was raised in CAP compared with healthy volunteers This 
is in keeping with that measured by Porfyridis et al (2010) in a larger patient 
cohort [133]. The levels of mTREM-1 in the ventilated groups did not 
significantly differ from each other, indicating that perhaps that the changes in 
VAP (see later) are compartmentalised. Figure 5.20 demonstrates the levels 
of mTREM-1 in patients with VAP and CAP compared with healthy volunteers. 
In comparison with the study by Porfyridis et al (2010), our study did not 
include patients with non-CAP acute medical illness (non-ventilated) and 
therefore the utility of blood mTREM-1 as a diagnostic biomarker cannot be 
assessed.  
 
Figure 5.20. Blood mTREM-1 levels in pneumonia 
 
Figure 5.20. The mTREM-1 levels for the pneumonic groups have been 
highlighted with medians and inter-quartile ranges (IQR). The levels in CAP 
are significantly higher than the healthy volunteers. CAP > HV (p=0.001). 
Analysis was performed using Mann-Whitney U-tests and the Kruskal-Wallis 
tests using Dunn’s post-hoc correction. 
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In the CAP study (Porfyridis et al, 2010), there was a significantly higher level 
of nTREM-1 in blood in patients with CAP, compared with acute medical 
patients without pneumonia. Our study did not see any difference from healthy 
volunteers. It is possible that this difference may be due to a lower number of 
patients in our study or that we did not study acutely unwell non-CAP patients.  
Considering BAL, the elevated level of mTREM-1 in VAP is in agreement with 
the nine patients with VAP/CAP (ventilated) in the study by Richeldi et al 
(2004) but with a far greater number of patients and different study groups 
[137]. In addition, some of the patients with sarcoidosis in the NVC group had 
elevated BAL levels of mTREM-1. This has been confirmed in a study 
conducted and published after acquisition of our results which showed 
elevated BAL mTREM-1 in patients with sarcoidosis [138]. The BAL mCD11b 
levels appear dimorphic and warrant further investigation to delineate any 
subsets of the VAP population. 
The BAL/blood ratios give rise to a variety of discussion points. The 
BAL/blood mTREM-1 ratio increased discrimination between the groups as 
compared with the BAL level alone. The blood mTREM-1 levels in health 
varied, suggesting inter-patient variation. The ratio therefore may be a means 
of reducing this variability and potentially improving its diagnostic value. 
Secondly, the ratio differentiated pulmonary and non-pulmonary infection 
(VAP and VSE). In a complex clinical situation that is common in ICU patients, 
where infections at multiple sites are common and difficult to discriminate, this 
may be an advantageous aspect of a biomarker. 
Thirdly, the ratios in each patient group were below 1.0. This means that the 
blood level of mTREM-1 is higher than the BAL level. This appears to be 
contradictory to the predicted biology of TREM-1, where elevated levels of 
surface TREM-1 are seen in infective conditions. However, this pattern is still 
apparent in the data – the levels of mTREM-1 are higher in VAP than the 
other patient groups. A likely explanation is that the surface receptor TREM-1 
exists in conjunction with its soluble counterpart, sTREM-1. Cleavage of the 
surface receptor by matrix metalloproteinases is thought to be the main 
reason for sTREM-1 release from the cell (although direct secretion may also 
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be a source). If surface receptor was cleaved then it would result in a lower 
level of receptor. In our patient groups, the level of BAL mTREM-1 is higher in 
VAP than other groups, consistent with increased expression with infection. 
The BAL / blood ratios lower than 1.0 are suggestive of cleavage occurring in 
the pulmonary compartment. There may be similar levels of cleavage 
amongst the groups, or perhaps a reduced amount in the VAP group to 
explain the higher mTREM-1 level. In the previous chapter, we illustrated the 
levels of the matrix metalloproteinases and their inhibitors, MMP-8, 9 and 
TIMP. The levels did not differ between the groups. This result was at 
variance with data by Wilkinson et al (2012) who showed elevated levels of 
MMP-8 and MMP-9 in VAP [136]. Our data was acquired from only a 
proportion of the patients in our study and it may be that a larger cohort would 
have highlighted a difference. However, regardless of the levels of MMP-8 
and MMP-9, it is likely that cleavage of the mTREM-1 surface receptor in part 
explains the results seen.  
In comparison with mTREM-1, the nTREM-1 BAL/blood ratio did not differ 
between the groups. The majority of the patients showed a ratio below 1, 
indicating levels higher in the blood than BAL, consistent with receptor 
shedding. Considering the mCD11b BAL/blood ratio had ratios above and 
below 1.0. The CD11b molecule is not cleaved from the surface like mTREM-
1 and nTREM-1. Examination of the ratio in the VSE group (figure 5.11) 
suggests that here there is no pulmonary activation of this receptor and it is 
therefore low in comparison to the blood. Extrapolating this to the remainder 
of the patients suggest a dimorphic picture, some in whom mCD11b is 
activated and others where it is not. Perhaps mCD11b is not elevated in all 
cases of VAP. In this regard, Hoogerwerf et al (2008) assessed the levels of 
CD11b on neutrophils in volunteers who had lipopolysaccharide and 
lipoteichoic acid instilled into their lung. They saw a difference in that nCD11b 
was elevated in patients with LPS instilled but not LTA. Perhaps some of the 
differences in the ratios of our patients are due to differences in immune 
responses to gram-positive and gram-negative infection [51]. The mCD62L 
and nCD62L BAL/blood ratios were below 1.0. CD62L is a receptor that 
facilitates migration of macrophages and neutrophils across the alveolar 
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epithelium. In doing so, it is shed from the surface to create soluble CD62L 
(not measured by us). Therefore our data is in accordance with the known 
biology of the molecule and is confirmation of the validity of the assay. 
 
Overall, there are a number of positive aspects to this study that warrant 
further mention. The first is that measurement of surface markers in the blood 
and BAL in VAP and other disease states is feasible and yields diagnostic 
information. The assays allow simultaneous measurement of blood and BAL 
levels as well as calculation of a BAL / blood ratio. We believe that the BAL / 
blood ratio allows the opportunity to correct for variable levels of expression 
that occur naturally between patients and result in a reduction of inter-patient 
variation. This is particularly demonstrated by mTREM-1, where the BAL / 
blood ratio increased the discrimination between the groups compared with 
the BAL level alone.  
The second point to note is that often the blood level alone did not 
differentiate the groups; measurement of the pulmonary compartment was 
required. This has implications for diagnostic biomarkers because it is likely 
that blood biomarkers would be unable to diagnose VAP and that pulmonary 
sampling would be required, which is potentially not as straightforward. An 
advantage of tissue-site sampling though is that it can allow differentiation of 
infective states, by highlighting where the infection lies. In this regard, the BAL 
/ blood ratio of mTREM-1 and the BAL level of mTREM-1 were elevated in 
VAP, but not in the VSE group – a cohort of patients who had non-pulmonary 
infection. Given that the blood compartment is unable to differentiate 
pulmonary from non-pulmonary sepsis, measurement of biomarkers in 
multiple compartments could offer the opportunity to rule-in and rule-out tissue 
sites as areas of potential infection. 
The third issue is the differences seen between neutrophils and monocytes in 
the study. Data has shown significant differences between patient groups for 
the monocytic receptors, but not for the neutrophils. There may be several 
explanations for this. The first is that the number of patients in the study is too 
low to detect a difference. However, visual inspection of the levels for the 
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neutophils does not show a pattern / trend that is failing to achieve 
significance. Therefore this is unlikely to be a major factor. The second is that 
the temporal receptor level changes are different for neutrophils than 
monocytes and that we are missing the changes in neutrophils by sampling at 
a comparatively late time. This is indeed possible and was assessed by 
sampling at multiple time points (see later). A final reason is that there is a 
difference in the biology of the receptors on neutrophils as opposed to 
monocytes. Gibot et al (2005) assessed mTREM-1 and nTREM-1 levels in the 
blood of mice with septic shock. They showed that the level of mTREM-1 rose 
but that it did not with nTREM-1. Such a pattern could explain the discrepant 
results we have seen in our study [139].  
Do the results seen with the surface and soluble receptors fit with the 
pathogenesis of VAP? If we consider the pulmonary compartment (fig 5.21) a 
putative model can be constructed. The monocyte migrates from the blood to 
the lung and in doing so sheds mCD62L. The cell possesses mCD11b, 
mTREM-1 and Toll-like receptors. Activation of the cell by TLR and mTREM-1 
ligation allows increased mTREM-1 expression, increased mTREM-1 
cleavage resulting in sTREM-1 secretion and potentially increased mCD11b 
expression. mTREM-1 activation results in IL-1β and IL-8 release and 
therefore these would be increased in the BAL of patients with VAP. 
Differences may occur depending on whether the infection was gram-positive, 
gram-negative or fungal (or viral). 
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Figure 5.21. Putative model for pulmonary compartment in VAP. The 
monocyte possesses CD11b and TREM-1 surface receptors. In some cases, 
activation occurs, in conjunction with ligation of a toll-like receptor. This may 
lead to increased CD11b expression and increased surface TREM-1 levels. 
Cleavage of the latter releases sTREM-1. Activation of the surface receptors, 
in particular mTREM-1 releases IL-1β and IL-8.  
 
 
5.10.2. Temporal changes in mTREM-1 and nTREM-1 
Patients were sampled prior to the development of VAP, during resolution of 
VAP, during worsening of VAP and a combination of these periods.  A number 
of themes emerge. Firstly, in the majority of cases, BAL mTREM-1 accurately 
follows the clinical progress of infection development and resolution, including 
changes in CRP. This also tends to be true for the BAL/blood mTREM-1 ratio. 
Secondly, BAL nTREM-1 often demonstrates one of two patterns – either 
rising / falling in a similar pattern to mTREM-1 but with a lower magnitude 
than mTREM-1, or it falls as mTREM-1 rises. The latter pattern may be akin to 
the published data showing falling nTREM-1 with rising mTREM-1 [42]. 
Perhaps in each patient both processes occur – nTREM-1 and mTREM-1 rise 
and also monocytes/neutrophils shed their receptors, in a metalloproteinase 
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dependent manner. The degree to which each one develops determines the 
pattern of either a shallow rise or a fall. WCC levels do not seem to correlate 
well with development and resolution of infection on their own. 
Overall, there is compartmentalisation of effect, with the blood patterns in part 
explaining differences between the BAL levels and the BAL/blood ratios. BAL 
mTREM-1 appears to rise with infection and fall with resolution. nTREM-1 can 
either rise or may also fall with infection development. This may explain why 
the results for nTREM-1 are less significant than for mTREM-1. 
Further analysis of the results from these patients can include comparisons 
with the previously derived diagnostic threshold levels. These were derived by 
analysis of ROC curves for each marker. The threshold was chosen as the 
point on the ROC curve with the optimum sensitivity and specificity (Youden 
index [63]). The BAL/blood nTREM-1 ratio has poor sensitivity and specificity. 
This can be seen with the temporal analyses where levels did not correlate 
with VAP. There is broad agreement for the BAL levels of mTREM-1 and 
nTREM-1 to diagnose VAP, as is the case with the BAL/blood mTREM-1 
ratio. 
Of interest, patients had evidence of raised BAL mTREM-1 and nTREM-1 
prior to clinical infection. This suggests activation of these receptors prior to 
VAP diagnosis. There is controversy over VAP diagnosis in that it is 
diagnosed 48 hours or more after intubation. This is to differentiate it from 
infection that is already present/developing prior to intubation. The temporal 
analysis would be consistent with pulmonary immune system activation in the 
development of VAP (subclinical VAP) and prior to clinical manifestations. 
5.10.3. Temporal changes in mTREM-2 and nTREM-2 
Overall, the data was strongest for the BAL/blood ratio of mTREM-2 which 
demonstrated that the levels generally rose and fell with infection 
development and resolution. This is akin to the data from TREM-1 and was 
initially surprising to us given that TREM-2 was initially predicted to be a 
negative regulator of inflammation. The data is however in keeping with rises 
in infection seen by Chen et al (2013), albeit in a murine peritonitis model 
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[140].  To our knowledge, this is the first time TREM-2 and the BAL/blood ratio 
has been measured in VAP. This data warrants further exploration in future 
studies to determine whether it too may perform as a suitable biomarker and 
also to better understand the nature of its interaction with TREM-1 in VAP. 
 
5.10.4. Temporal changes in CRP and WCC 
Although not diagnostic for VAP, CRP and WCC levels broadly rose with VAP 
development and fell with resolution. Povoa et al [67] measured serial CRP 
levels in 47 patients with microbiologically proven VAP in a mixed 
medical/surgical ICU. Temporal measurement of CRP over 4 days 
differentiated four groups, with varying mortalities. Patient survival occurred 
where CRP fell (a fast or slow responder). Patients who died frequently had 
either a persistent CRP level despite antibiotic therapy (indicating perhaps the 
antibiotic choice to be incorrect) or exhibited a biphasic profile of a fall and 
secondary rise. Overall, if the ratio of CRP on day 4 to day 0 (VAP diagnosed) 
was above 0.6, this correlated with non-resolving VAP. A study by Lisboa et al 
was also in agreement with this [141]. A CRP ratio of 0.8 (d4 to d0) rather 
than 0.6, 96 hours after VAP treatment, indicated adequate antibiotic effect 
(area under ROC curve 0.86, sensitivity 77%, specificity 87%). In generalised 
sepsis rather than pure VAP, Yentis et al found that in ICU patients a fall of 
serum CRP by 25% from the previous day was associated with sepsis 
resolution. The sensitivity was 97%, specificity 95% and positive predictive 
value was 97% [142].  
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5.11. Conclusions 
BAL mTREM-1 and its BAL/blood ratio rise with the development of VAP and 
resolve with its clearance.  
BAL nTREM-1 does correlate with BAL mTREM-1 in many cases but 
sometimes the level drops in comparison to mTREM-1. The latter data fits 
with basic science data. The net result of some patients having a rise in 
nTREM-1 and some having a fall in nTREM-1 is that the population levels 
provide lower diagnostic utility than mTREM-1. 
The absolute levels of mTREM-1 and nTREM-1 in the BAL would be 
consistent a VAP process developing over time (ie that VAP can be 
developing prior to 48 hours) even though it is not formally diagnosed until 
after 48 hours following intubation. 
Finally, mTREM-2 may be a biomarker worthy of further study to assess its 
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Chapter 6 
Construction of a biomarker panel to classify patients with and without 
VAP 
6.1. Introduction 
In previous chapters, the utility of standalone biomarkers to differentiate VAP 
and non-VAP has been discussed. In a complex clinical condition such as 
VAP, where patients are ventilated in ICU and infection are caused by a 
variety of micro-organisms, single markers may have limited clinical utility. We 
therefore investigated a combination of the biomarkers to determine the ability 
to differentiate our patient populations. In constructing a panel, markers may 
be added which on their own have limited clinical utility but which identify 
cases correctly that other markers do not. Such markers would not be readily 
identified by examining the diagnostic accuracy of that single analyte. 
Similarly, if two markers differentiate cases strongly, both may not be required 
together in the panel as they associate with each other; measurement of the 
second marker may not add further new diagnostic information compared with 
measurement of just the first. In the chronic lung disease setting, a biomarker 
panel has been constructed by our Department and validated for the 
differentiation of sarcoid from other interstitial lung disease and systemic 
sclerosis, using Fisher discriminant analysis [125]. Overall, a biomarker panel 
should include sufficient markers to allocate patients to the correct disease 
category, whilst minimising the number of analytes to reduce the potential 
cost and complexity associated with measurement of multiple markers. 
6.2. Aims 
1. Construction of a biomarker panel to discriminate patients with VAP from 
those with non-VAP 
2. Validation of the biomarker panel to determine its utility in predicting 
patients with VAP. 
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6.3. Methodology and statistical analysis 
6.3.1. Rationale 
Cases were classified into VAP, ventilated non-VAP (a combination of 
patients with no infection and those with non-pulmonary sepsis) and non-
ventilated controls. The reason for combining the two patient groups into a 
non-VAP group was to create three patient groups of similar size; if the VC 
and VSE groups were not combined, the patient numbers would be 
insufficient for analysis. The rationale for including the NVC (non-ventilated 
controls) in the analysis was to determine whether the biomarker panel could 
distinguish ventilated from non-ventilated patients and also to include patients 
with chronic lung conditions (COPD) who comprise a significant proportion of 
the intensive care population. 
In order to combine the VC and VSE groups, it is essential that the enlarged 
group of patients do not differ. We compared the data for VAP, VC, VSE and 
NVC with that from the three groups (VAP, ventilated non-VAP and NVC). 
There was no significant difference between the data. The BAL (figure 6.1) 
once again showed a similar pattern (VAP > non-VAP, p<0.0001 and VAP > 
NVC, p<0.0001).  
The BAL/blood ratio (figure 6.2) showed a similar pattern to that of the four 
groups. 
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Figure 6.1. BAL mTREM-1 levels with combined ventilated control 
groups 
	  
Figure 6.1. BAL mTREM-1 levels where the two ventilated control groups 
(non-infected and non-pulmonary sepsis) have been combined. Box-whisker 
plots (median and IQR with range) highlighted and outliers marked with dots. 
VAP > non-VAP and NVC (p<0.001). Analysis was performed using Mann-
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Figure 6.2. BAL/blood mTREM-1 ratios (ventilated controls combined)	  
	  
Figure 6.2. BAL/blood mTREM-1 ratios with the two ventilated control groups 
combined (ventilated non-infected and ventilated with sepsis-elsewhere 
i.e.both groups do not have pulmonary sepsis). VAP > non-VAP and NVC 
(p<0.001). Analysis was performed using Mann-Whitney U-tests and the 
Kruskal-Wallis tests using Dunn’s post-hoc correction. 
 
The pooled data for the surface markers in the 3 groups has been 
summarised in table 6.1. Again, this shows no significant changes from the 
four groups. Table 6.2 shows the patient characteristics of the three groups. 
Combining these two groups into a ventilated control group without VAP, 
there were 33 patients. Their median age was 62 years. 52% were male. The 
median APACHE II score was 15 and the median CPIS 3. Microbiology was 
positive in 12% of patients. 70% were receiving antibiotics at the time of 
sampling. None of the patients had VAP. CXR shadowing was present in 55% 
and 30% of patients were receiving steroids (low-dose). 39% were post-op 
and 15% were burns patients. 
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Table 6.1. Expression of cell surface proteins in patients with VAP, non-
VAP and NVC 
 VAP Non-VAP NVC 
Blood    
mTREM-1 5.1 (3.2-8.6) 4.6 (3.1-6.1) 6.5 (4.3-10.9) 
nTREM-1 4.7 (2.6-7.3) 3.8 (2.3-6.1) 4.5 (3.1-7.4) 
mCD11b 47.2 (30.0-70.0) 43.3 (27.6-52.3) 39.2( 21.7-51.8) 
nCD11b 44.0 (33.4-91.9) 59.8 (43.4-82.9) 49.0 (38.0-81.0) 
mCD62L 9.4 (7.3-15.1) 9.5 (7.4-13.2) 5.4 (3.9-9.4) *  
nCD62L 9.6 (6.0-17.0) 8.3 (6.0-10.5) 8.6 (6.8-10.5) 
BALF 
 
   
mTREM-1 3.9 (2.5-5.4) 1.6 (1.1-2.3) 1.8 (1.2-2.9) § 
nTREM-1 2.0 (1.7-3.3) 1.5 (1.2-2.2) ** 1.7 (1.3-3.0) 
mCD11b 25.2 (9.0-81.2) 18.6 (13.7-31.2) 21.0 (6.9-47.3) 
nCD11b 47.0 (15.1-86.0) 32.9 (20.3-62.5) 24.0 (6.0-73.5) 
mCD62L 1.2 (1.0-1.5) 1.1 (1.0-1.3) 1.2 (1.0-1.4) 




   
mTREM-1 0.8(0.5-1.0) 0.4(0.2-0.5) 0.3(0.2-0.4)§ 
nTREM-1 0.6(0.2-0.8) 0.4(0.3-0.8) 0.4(0.2-1.1) 
mCD11b 0.53(0.4-2.3) 0.4(0.2-0.7)§§ 0.5(0.2-1.3) 
nCD11b 0.7(0.5-2.0) 0.5(0.2-0.9) 0.5(0.1-1.4) 
mCD62L 0.2(0.1-0.5) 0.1(0.1-0.2) 0.2(0.1-0.3) 
nCD62L 0.2(0.1-0.3) 0.2(0.1-0.2) 0.2(0.1-0.2) 
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Table 6.1.  
The median and interquartile range for each patient group is reported. 
Statistically significant differences between groups were determined using the 
Mann-Whitney U and post hoc Dunn correction as follows:  VAP and non-VAP 
versus NVC (p<0.001)*, VAP versus NVC (p<0.001)† and non-VAP versus 
NVC (p<0.05)‡, VAP versus non-VAP and NVC (p<0.001)§, VAP versus non-
VAP (p<0.01)**, VAP versus non-VAP (p<0.001)††, VAP versus NVC 
(p<0.01)‡‡, VAP versus non-VAP (p<0.001)§§ and NVC > non-VAP (p<0.01)ll. 
Thus there were no significant differences when the VSE and VC groups were 
combined into the single ventilated non-VAP group. Analysis was performed 
using Mann-Whitney U-tests and the Kruskal-Wallis tests using Dunn’s post-
hoc correction. The BAL levels represent ELF levels following dilutional 
correction.  
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Table 6.2 Characteristics of patients recruited to the study 
 VAP Non-VAP NVC 
Number of patients 27 33 31 
Age 
 
68 (23-84) 62 (18-89) 59 (18-84) 
Sex (% male) 70 52 61 
APACHE II 18 (5-45) 15 (2-24) N/A 
CPIS 7 (6-9) 3 (0-5) N/A 
Microbiology (% +ve) 100 12 0 
Smoking (% current / ex) 44/15 30/21 35/13 
Antibiotics (% receiving) 89 70 32 
CXR (% with shadowing) 96 55 81 
Steroids (%) 30 30 6 
28-day mortality (%) 11 12 0 
Surgery (%) 37 39 0 
Burns (% of cases) 15 15 0 
WCC (x109/L)  15 (4-24) 9 (3-27) 7 (3-18)* 
CRP (mg/L) 84 (7-320) 102(2-341)† 6 (1-296)* 
 
Table 6.2. The median and range (lowest-highest) is shown for each group, 
with the VC and VSE groups combined into a single non-VAP group. 
APACHE II and CPIS are only applicable to the ventilated patients. 
Statistically significant differences between the groups were determined using 
the Mann-Whitney U test and Kruskal-Wallis tests with post-hoc Dunn 
correction and are indicated as follows:  VAP versus NVC (p < 0.001)* and 
non-VAP versus NVC (p < 0.001)†. 
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6.3.2. Methodology 
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(xix) mCD11b 
(xx) nCD11b 
(xxi) mCD62L (L-selectin) 
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For the biomarkers IL-1β and IL-8, blood levels were below the limit of 
detection. Therefore neither the blood nor the BAL/blood ratios were 
available. Similarly, WCC and CRP were measured in the blood only and 
therefore BAL and BAL/blood ratios are unavailable. The matrix 
metalloproteases and the 16S RNA levels were measured in separate assays 
after the biomarker panel had been constructed. Their analysis was only 
performed on a subset of patients. They are therefore not included in the 
biomarker panel. 
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6.3.3. Statistical analysis 
6.3.3a. Construction of biomarker panel 
We constructed the panel using Fisher discriminant analysis (FDA). This 
statistical technique allows construction of a linear set of functions derived 
from the markers that accurately classifies patients into a categorical label, 
in this case patient group. This differentiates it from regression analysis where 
the classification dependent variable is numerical. Discriminant analysis 
classifies patients into two or more groups using quantitative variables. Fisher 
analysis is utilised where classification into more than 2 patient groups is 
required. It was first described nearly 80 years ago [143]. It is also normally 
conducted where the markers are normally distributed. We believed that 
combining the 31 analytes would result in a population resembling a normal 
distribution and our department has the greatest familiarity with this technique. 
Fisher analysis attempts to maximize the discrimination between the groups, 
whilst keeping differences in variance to a minimum. If samples are described 
by two variables on x and y axes, FDA aims to create a vector that the 
variables are mapped to. The vector should increase the scatter between the 
groups (class separation), but minimize scatter inside each group (variance). 
This is then repeated for multiple variables to determine the optimal 
combination of ‘vectors’ between them [144].  
Furthermore, stepwise forward linear regression analysis was conducted by 
Dr. Pantelidis (Imperial College Healthcare NHS Trust) in conjunction with 
Professor Athol Wells (Royal Brompton Hospital). In this technique, linear 
functions are created that describe the probability of being in the VAP group, 
as opposed to Fisher analysis which aims to separate three or more groups 
groups maximally. A number of functions are combined to create a panel that 
can optimally predict VAP. In stepwise forward analysis, the panel is built up 
by choosing the marker that best predicts VAP, then adding further markers 
sequentially until there is no improvement in diagnostic accuracy. Rapid 
computational methods are used to test each new function in combination 
with the prior sequence of functions. The analysis completes when either 
there is no improvement in accuracy or there are no further markers to add. 
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‘Forward’ stepwise analysis starts with no markers whereas ‘backwards’ 
stepwise analysis starts with all the markers and removes one or more to 
determine the optimal combination. We used ‘forward’ analysis as we wished 
to create a panel with the minimal combination of markers. The results agreed 
with the data from Fisher analysis. 
 
6.3.3b. Validation 
Once a panel has been constructed, it ought to be applied to data acquired 
from new patients to determine whether the patient group can be accurately 
predicted from the model. However, given the finite time and resources 
associated with the project, recruitment of new patients was not feasible and 
remains a limitation of the study. However, we conducted two further types of 
internal validity analysis. 
The first analysis included the ‘leave one out’ classification (cross-validation). 
In this, the effect of outliers are determined and excluded. Each one of the 91 
patients was excluded from the analysis in turn and the Fisher analysis re-
conducted. If there was a strong effect from outliers, then the data would 
demonstrate high variability. 
The second analysis involved cross-validation by splitting the data into a 
training and validation cohort with a 60:40 split. This technique has previously 
been used to validate a biomarker panel [125]. Randomly, 60% of patients are 
chosen to construct the panel. In effect, for the biomarker panel, new 
classification function coefficients were generated for each analyte [145-147]. 
The data is then applied to the 40% of patients not previously used, as a test 
cohort (as if the patients were new ones that were recruited). This analysis is 
repeated ten times and the summary utility of the panel is determined. This 
has the advantage of testing the panel on ‘new data’ but the disadvantage is 
that the panel is contructed with a smaller subset of patients and therefore 
may be exposed to greater variability. 
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6.3.3c. Fisher discriminant analysis 
Fisher’s analysis was used with the SPSS v19 software package (SPSS, 
Chicago, IL, USA) to determine the optimal biomarker combination to 
discriminate VAP and non-VAP groups. The biomarker variable was entered 
into the “model” if the significance level of its F-value was <0.05 (95% 
confidence level) and removed on subsequent analysis if it rose above 0.1. 




A seven marker bioscore comprising the BAL/blood ratio of mTREM-1 and 
mCD11b, BAL levels of sTREM-1, IL-8 and IL-1β, together with blood levels of 
CRP and IL-6 was generated by the analysis as being optimal in 
discriminating VAP and non-VAP patients (table 6.3). It correctly classified 
100% of the non-VAP patients and 88.9% of the VAP patients (figure 6.3). 
The non-ventilated control patients were defined as non-VAP in 90.3% of 
cases. The ‘leave one out’ validity analysis produced the same results for the 
VAP and non-VAP groups. In the cross-validation model, the average 
predictive accuracies for patients in the test cohort were 98.5% for non-VAP 
and 71% for VAP. 
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Table 6.3. A seven marker panel was generated using Fisher Discriminant 
analysis, with mTREM-1 and mCD11b (BAL/blood ratio), CRP and IL-6 blood 
and sTREM-1, IL-1β and IL-8 in BAL. The analyte level is multiplied by the 
function and then summated to determine patient group classification.  
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Figure 6.3 Utility of a seven-marker panel to discriminate patient groups 
	  
Figure 6.3. Patients in group 1 are VAP, group 2 are ventilated non-VAP and 
‘ungrouped’ patients are non-ventilated control. 24/27 patients (88.9%) with 
VAP are correctly predicted to be in the VAP group. 100% of ventilated non-
VAP patients are predicted to be in the non-VAP group. 28/31 (90.3%) of non-
ventilated controls are predicted to have non-VAP. Fisher Discriminant 
Analysis was used.  
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We compared the utility of the panel by removing one marker and re-
analysing the accuracy. The marker adding the least ‘extra information’ was 
IL-8 in BAL. Removal of this reduced the accuracy of classifying ventilated 
non-VAP patients from 100% to 97% with cross-validation (figure 6.4).  
 










Figure 6.4. BAL IL-8 was excluded from the 7-marker panel. Group 1 is VAP, 
Group 2 is ventilated non-VAP and ungrouped cases are the non-ventilated 
controls. Although there is a slight increase in the correct classification of the 
non-ventilated controls, there is a drop in the utility of the panel to correctly 
classify the ventilated non-VAP from 100% to 97% following cross-validation. 
Fisher Discriminant Analysis was used.  
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Removal of a further marker reduced accuracy further. The least disruptive 
removal was IL-1β. This reduced the VAP diagnostic accuracy to 85.2% 
(figure 6.5).  
 












Figure 6.5. IL-8 (BAL) and IL-1β (BAL) were omitted. Group 1 is VAP, Group 
2 is ventilated non-VAP and the ungrouped cases are the non-ventilated 
control patients. The accuracy of the panel to identify VAP cases drops to 
85.2% and the ventilated non-VAP to 97.0%. The non-ventilated controls are 
correctly classified 93.5% of times. Fisher Discriminant Analysis was used. 
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ROC curves were constructed to demonstrate the utility of the biomarker 
panel to classify patients into VAP, ventilated non-VAP and non-ventilated 
control (Figure 6.6). The AUROCs were high, 0.98 (0.96-1.00) for VAP, 0.95 
(0.91-0.99) for ventilated non-VAP and 0.94 (0.89-0.99) for non-ventilated 
control. Table 6.4 shows the other data for the diagnostic performance of the 
panel. The sensitivity and specificity of the panel to classify patients with VAP 
was 95% and 93%, with a positive likelihood ratio of 12.9. This demonstrates 
the enhanced utility of a panel compared with standalone markers. 
 
Figure 6.6 ROC curves for the biomarker panel 
 
Figure 6.6. The AUROCs for VAP were 0.98, ventilated non-VAP 0.95 and 
non-ventilated control (NVC) 0.94.  
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Table 6.4 Diagnostic performance of the biomarker panel 
 
 VAP Non-VAP NVC 
Area under ROC 
curve (AUC) and 
95% CI 
0.98 (0.96-1.00) 0.95 (0.91-0.99) 0.94 (0.89-0.99) 
Sensitivity (%) 95 97 84 
Specificity (%) 93 84 97 
Likelihood ratio 12.9 6.3 25.2 
 
Table 6.4. The AUROCs are high for the biomarker panel, as are the 
sensitivities, specificities and the positive likelihood ratios. The data was 
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The analysis was redone using stepwise forward linear regression. The 
functions identified were based on the following markers: CRP (blood), IL-6 
(blood), sTREM-1 (BAL), IL-1β (BAL), IL-8 (BAL), mTREM-1 (BAL/blood ratio) 
and mCD11b (BAL/blood ratio). This was an identical to the 7-marker panel 
generated using Fisher analysis, confirming its validity. 
The data for this analysis is shown in Table 6.5. The model was built up one 
marker at a time. The optimal first marker was mTREM-1 (BAL/blood). 
Additions to this (in order) were IL-8 (BAL), mCD11b (BAL/blood), sTREM-1 
(BAL), IL-6 (blood), IL-1β (BAL) and CRP (blood). After the seventh analyte 
was added, no further improvement in the model occurred (data not shown). 
Addition of each additional marker up to the seventh did improve the accuracy 
of the model however.  
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Table 6.5. Summary data for stepwise forward linear regression analysis 
















df1 df2 Sig F 
change 
1 0.527a 0.277 0.265 0.430 0.277 22.276 1 58 0.000 
2 0.697b 0.485 0.467 0.366 0.208 23.028 1 57 0.000 
3 0.750c 0.562 0.539 0.341 0.077 9.836 1 56 0.003 
4 0.795d 0.631 0.605 0.315 0.069 10.330 1 55 0.002 
5 0.819e 0.671 0.640 0.301 0.039 6.445 1 54 0.014 
6 0.838f 0.702 0.668 0.289 0.031 5.524 1 53 0.023 
7 0.853g 0.727 0.690 0.279 0.025 4.811 1 52 0.033 
 
Table 6.5. Differentiation of VAP from non-VAP. The functions used in the 
analysis are: (a) mTREM-1 (BAL/blood); (b) As (a) plus IL-8 (BAL); (c) as (b) 
plus mCD11b (BAL/blood); (d) as (c) plus sTREM-1 (BAL); (e) as (d) plus IL-6 
(blood); (f) as (e) plus IL-1β (BAL); (g) as (f) plus CRP (blood). R2 denotes the 
coefficient of determination and determines how well the data fits a straight 
line. The adjusted R2 has the same meaning but is independent of the number 
of data points. R2 change shows the difference of R2 from the preceding 
model to the next. F change shows whether the addition of a function 
improved the accuracy of the model (the higher the better). The df1 and df2 
represent degrees of freedom. ‘Sig F change’ demonstrates whether the 
improvement in accuracy by addition of a function is significant or not. 
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By comparing the true values of the analyte functions with that predicted by 
the model for the patient groups, ‘residuals’ (the difference between observed 
and expected) are generated. These may be plotted and should approximate 
to a normal distribution if the model is correct. The data is presented in figure 
6.7 and fits a bell-shaped curve.  
 












Figure 6.7. ‘Residuals’ are the difference between the observed data and that 
predicted by the model generated by linear regression analysis. The plot 
should approximate to a normal distribution to confirm that the model correctly 
fits the data. As can be seen, the data fits the bell shaped curve. 
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Similarly, the P-P plot of cumulative predicted and observed probabilites 
based on the residuals should be linear (figure 6.8). The results shown for 
VAP and non-VAP groups conform to this. Overall, if a ROC curve was to be 
constructed for the ability of the panel to classify patient to VAP or non-VAP, 
the AUC would be 0.997. 
 













Figure 6.8. Probability-Probability (P-P) plot for observed versus expected 
cumulative probabilites as determined by linear regression analysis. ‘Residual’ 
refers to the difference between the observed data and that predicted by the 
model. The linearity confirms that the model has validity. 
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6.5. Discussion 
A biomarker panel was constructed and its utility in classifying patients into 
VAP, ventilated non-VAP and non-ventilated controls determined. The panel 
does not take into account the clinical state of the patient. A panel used in 
reality would be used in ventilated patients with suspected VAP. Therefore it 
would not be required to classify patients into non-ventilated control. The 
utility of the panel can thus be seen to be high, correctly classifying all of the 
non-VAP (ventilated) patients. 
Given the limited resources, the panel was not tested on new patients and 
therefore statistical methods were used to confirm the robustness of the 
panel. This could be considered to be a limitation of the study. The ‘leave one 
out’ and use of training/validation cohorts confirmed a minimal effect of 
outliers. However, the limitation was that the validation cohorts became small 
(40% of 91 patients) and therefore the results of the cross-validation showed 
some variability. A further method of assessing the panel was to remove 
analytes to leave a 6-marker and a 5-marker panel. It could be seen that the 
utility diminished as this was done and it was concluded that a 7-marker panel 
was optimal. Finally, we re-analysed the data using stepwise forward linear 
regression. This correlated with our original analysis. The linear regression 
model used stepwise forward analysis to add analytes in sequence. Each 
analyte was kept in the model if it significantly improved predictive accuracy. 
Adding the seven markers we identified with Fisher analysis in turn improved 
the model, but addition of an eighth marker onwards did not.  
The panel includes the levels of IL-1β and IL-8 in BAL. This is in accordance 
with data from Conway-Morris et al (2009), who have seen increased levels of 
these analytes in BAL in VAP [14]. 
Clinically, there is a debate as to whether it is feasible to measure a large 
number of analytes simultaneously in all patients with suspected VAP. Larger 
studies may elucidate a biomarker panel with a smaller number of markers to 
rule-in VAP, or act as a rule-out test. Furthermore, once a panel of markers 
has been identified, simpler methods of analysis may allow testing to be 
performed more cheaply. 
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6.6. Conclusions 
We have successfully developed a 7-marker bioscore that accurately 
classifies patients with VAP and non-VAP. Internal validity is strong.  
Such a panel may offer the potential to diagnose or refute patients with VAP 
in a complex clinical environment. We wish to test this biomarker in the clinical 










This study has examined a combination of soluble and surface biomarkers in 
the blood and pulmonary compartments, alone and in combination to 
discriminate patients with VAP and non-VAP. The results address a potential 
weakness of previous studies which have measured only soluble mediators, 
often in one compartment, and therefore may not appreciate the dynamic 
interaction between cell surface receptors and their soluble counterparts (e.g. 
mTREM-1 and sTREM-1 respectively), and site-specific flux between the 
alveoli and blood [48]. There is a need for reliable biomarkers in VAP in order 
to speed up diagnosis and allow increased antibiotic stewardship. In this 
regard, biomarkers such as those identified by us could provide a same-day 
result, a significant advantage to the treating clinician [148, 149].  
 
7.2. Standalone markers 
The standalone markers have been investigated for their utility in 
discriminating VAP from the other ventilated and non-ventilated groups. The 
conventional markers CRP and WCC have limited utility in this regard as does 
PCT. The blood markers did not differentiate VAP from the other groups, 
suggesting VAP to involve compartmentalization. In this regard, sTREM-1, IL-
1β and IL-8 are elevated in the BALF. The sTREM-1 data agrees with Gibot et 
al (2004) and Determann et al (2005) but differs from Song et al (2007), 
Oudhuis et al (2009), Anand et al (2008) and Conway-Morris et al (2009) in 
being elevated in VAP. Reasons for this include assay differences, patient 
selection, prior thawing/re-freezing of samples in other studies, VAP 
definitions and method of sample acquisition [14, 100-102, 104, 105]. Gibot et 
al (2004) used immunoblotting to detect sTREM-1 and BAL levels were not 
corrected for BALF dilution. Samples were acquired via mini-BAL rather than 
BAL [100]. Their cutoff level was 5 pg/ml in comparison to ours (13.6 µg/ml 
with dilutional correction). Determann et al (2005) used non-directed BAL but 
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used an ELISA technique to measure sTREM-1 as with our study. No 
correction for BALF dilution was made and microbiological culture was 
quantitative [101]. Their cutoff level was 200 pg/ml. Song et al (2007) used 
blind BAL to assess sTREM-1 (by ELISA) in patients with Pseudomonas 
Aeruginosa VAP only [102]. The studies by Horonenko et al (2007) and 
Anand et al (2008) were performed in medical ICUs only, though used 
quantitative culture of BAL [103, 104].  Huh et al (2008) examined sTREM-1 
levels in patients with bilateral lung infliltrates only, by means of non-directed 
BAL [107]. Finally, Oudhuis et al (2009) used quantitative culture of BALF, but 
corrected for urea dilution [105].  
To our knowledge, the expression of surface TREM-1 has not been assessed 
before as a diagnostic tool for VAP. Measurement of surface markers in the 
blood and BAL in VAP and other disease states is feasible and yields 
diagnostic information. The monocytic surface receptor mTREM-1 and its 
neutrophilic counterpart nTREM-1 are compartmentalized within the lung, with 
increased expression in VAP. The resuls are in agreement with increased 
mTREM-1 levels in a small cohort of patients with CAP [137]. 
The surface receptor mTREM-1 levels in the lung were surprisingly lower than 
in the blood, with BALF/blood ratios less than 1. This is likely due to increased 
shedding of up-regulated BALF mTREM-1 within the lung, as evidenced by 
the significantly greater increase in soluble sTREM-1 compared with blood. A 
potential mechanism is likely to involve the balance between bacterial induced 
metalloproteinase (MMP) mediated cleavage of cleavage of TREM-1 from 
surface of monocytes / neutrophils and action of specific MMP inhibitors [45]. 
Moreover, neutrophil derived MMP production is seen to increase markedly in 
BALF as compared to plasma from patients with hospital acquired 
pneumonia, whereas the specific tissue inhibitors of MMP (TIMP) were 
increased in plasma compared to BALF [126]. In our study, the MMP levels 
did not differ between the groups. However, the assays were only performed 
on a subset of patients from the cohort. Samples had also been stored for 2-3 
years (though had not previously been thawed), but this should not have 
affected the results [150]. A further caveat is that MMP activity levels may 
vary rendering interpretation of absolute levels difficult [126]. We did not 
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perform functional assays of MMP-8 and MMP-9 activity, but this could be 
considered in a future study. mTREM-1 and nTREM-1 levels may be affected 
by recruitment of cells from the bone marrow and by differential apoptotic 
effects between groups, neither of which have been examined in this study. In 
particular mTREM-1 activation leads to a reduction in cell apoptosis [151]. 
 
7.3. Monocytes versus neutrophils 
The BALF/blood ratios of neutrophil-based nTREM-1 and nCD11b were not 
raised in VAP, in contrast to their monocytic counterparts. Reasons for this 
were explored in the chapter on temporal changes. It appears that there are 
rises in nTREM-1, but in many patients these are of a lower magnitude than 
for mTREM-1, thus failing to show a significant difference when the data is 
pooled. The timings of the rise appeared different too. This difference is 
consistent with data from patients in septic shock, in whom blood mTREM-1 
but not nTREM-1 levels increased compared with controls [139]. Expression 
of TREM-1 on neutrophils initially falls over minutes and then increases 
following in vitro LPS stimulation. In contrast TREM-1 levels on monocytes 
steadily increase over hours. It is therefore possible that the recruitment 
timescale for the main study missed early neutrophilic changes [46]. One way 
of assessing further the dynamic interaction between surface receptor 
expression and receptor shedding may be to assay the receptors in the 
presence of protease inhibitors. Absolute sTREM-1 release from receptor 
shedding is likely to be skewed by the large differential in cell numbers 
between neutrophils and macrophages, with far greater numbers of the former 
[152]. 
 
7.4. BAL / blood ratio 
Our assays simultaneously measured blood and BAL levels of biomarkers to 
calculate a BAL / blood ratio. We believe that the BAL / blood ratio allows the 
opportunity to correct for variable levels of expression that occur naturally 
between patients and would otherwise increase inter-patient variation. This is 
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particularly demonstrated by mTREM-1, where the BAL / blood ratio resulted 
in a further improvement in diagnostic classification. Indeed, the BALF/blood 
ratio of mTREM-1, mCD11b and sTREM-1 were significantly higher in 
patients with VAP compared with those without VAP suggesting that these 
biomarkers may be useful indicators of site-specific infections. Others have 
found elevated BALF IL-1β and IL-6 levels in VAP, when using a lung to blood 
ratio like in this study [92]. The BALF/blood ratios of soluble cytokines were 
non-discriminatory in this study, perhaps due to significant 
compartmentalization by the time of sampling, producing very low blood 
levels.  
 
7.5. Site-specific diagnosis of infection 
The blood levels of the biomarkers were insufficient to discriminate between 
the patient groups; pulmonary sampling was required. The implication of this 
is that a simple blood test to diagnose VAP may be unlikely and that alveolar 
sampling is required, which is potentially not as straightforward. Our study 
identified markers such as the BALF/blood ratio of mTREM-1 which were able 
to distinguish VAP from non-pulmonary sepsis. In a complex ICU patient, the 
ability to differentiate these conditions may have significant clinical value. In 
previous studies, it has been shown that pulmonary infection may be 
distinguished from abdominal infection by combining BALF sTREM-1 and 
blood Procalcitonin measurement, although with lesser discrimination than our 
use of combined cell surface/soluble markers [82]. More recently, Ramirez et 
al reported the discriminative ability of site-sampled sTREM-1 for identifying 
pulmonary from abdominal infection as a cause for respiratory failure in a 
critically ill cohort [153]. Analysis of site-specific inflammatory markers may be 
useful in distinguishing pulmonary from non-pulmonary infection, although 
unlike cellular markers of infection, there may be greater variability in 
measurement of soluble proteins due to the need to correct for dilution 
following BALF sampling. We wish to address this aspect of the study further 
in future studies, with a larger number of patients with non-pulmonary sepsis. 
 
	   201 
7.6. Biomarker panel 
Given that VAP may be caused by a variety of micro-organisms, with the 
potential for variable activation of pulmonary immune markers, we sought to 
construct a panel of analytes that could be used to identify VAP. The study 
demonstrates that a combination of cell surface and soluble markers of 
inflammation, in particular TREM-1, sampled in blood and BALF 
simultaneously, can discriminate VAP from ventilated patients without 
evidence of pulmonary sepsis accurately. The panel was used to classify 
patients into VAP, ventilated non-VAP or non-ventilated control without prior 
knowledge of the clinical state of the patient. It correctly classified all of the 
ventilated non-VAP patients. 
Given the limited timescale, the panel was not tested on new patients. 
Statistical methods confirmed that the internal validity of the panel was strong. 
The ‘leave one out’ analysis demonstrated a minimal effect of outliers. The 
training/validation cohorts demonstrated the panel to be robust. However, the 
limitation was that the validation cohorts became small (40% of 91 patients) 
and therefore the results of the cross-validation showed some variability. 
A further method of assessing the panel was to remove analytes to leave a 6-
marker and a 5-marker panel. It could be seen that the utility diminished as 
this was done and it was concluded that a 7-marker panel was optimal. 
Finally, we re-analysed the data using stepwise forward linear regression. 
This correlated with our original analysis.  Significantly, the panel included the 
levels of IL-1β and IL-8 in BAL. This is in accordance with data from Conway-
Morris et al (2009), who have seen increased levels of these analytes in BAL 
in VAP [14].  
Clinically, there is debate as to whether it is feasible and worthwhile to 
measure a large number of analytes simultaneously in all patients with 
suspected VAP. This would depend on how accurate the panel was in terms 
of positive and negative predictive values. Larger studies may elucidate a 
biomarker panel with a smaller number of markers to rule-in VAP, or act as a 
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rule-out test. Furthermore, once a panel of markers has been identified, 
simpler methods of analysis may allow testing to be performed more cheaply.  
In summary, we have identified a panel that can differentiate VAP from non-
VAP and non-ventilated controls. We wish to investigate this further in an 
unselected cohort of patients with suspected VAP. 
 
7.7. Temporal changes in mTREM-1 and nTREM-1 
A putative biomarker ought to rise early with infection and fall with resolution 
of the illness. We identified BAL mTREM-1 and the BAL/blood ratio of 
mTREM-1 as potential diagnostic biomarkers for VAP and therefore sought to 
understand changes in their levels over time. It would also allow comparison 
of the monocyte and neutrophil receptors to understand their relevance for 
sampling at a single point of time after 48 hours of ventilation, which would be 
when clinical suspicion of VAP would occur. We sampled a cohort of patients 
prior to VAP development, during resolution of VAP, during worsening of VAP 
and a combination of all three of these in one patient. Peripheral blood WCC 
levels did not correlate well with development and resolution of infection. 
BAL mTREM-1 levels and the BAL/blood ratio generally correlated with the 
clinical status of the patient. We would like to investigate this further in future 
studies with larger numbers of patients as temporal changes have 
implications for sampling at one time point and comparing with a diagnostic 
threshold level. 
There was a difference between the data for mTREM-1 and nTREM-1. 
nTREM-1 levels may peak at an earlier timeframe than mTREM-1 following 
cell activation [42]. Both receptors levels are also a balance between 
expression and cleavage to form the soluble receptor.  
Finally, some patients (PS72, PS81, PS86 and PS87) had evidence of raised 
BAL mTREM-1 and nTREM-1 even though they had not yet got clinical 
infection. This suggests activation of these receptors prior to VAP diagnosis. 
There is controversy over VAP diagnosis in that it is diagnosed 48 hours or 
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more after intubation. This is to differentiate it from infection that is already 
present or is developing prior to intubation. The temporal analysis would be 
consistent with pulmonary immune system activation in the development of 
VAP (subclinical VAP) and prior to clinical manifestations. If the VAP process 
started before 48 hours, nTREM-1 may have risen and then started to fall 
prior to clinical suspicion and therefore biomarker sampling. In this regard, 
mTREM-1 may therefore be a more suitable biomarker, as we have seen with 
the study.  
 
7.8. The ideal biomarker 
Sackett and Haynes (2002) highlighted that a diagnostic biomarker ought to 
differentiate cases from healthy controls [62]; Increased levels should be 
associated with a higher probability of disease; levels should distinguish 
positive cases from negative ones in a cohort of suspected cases; finally, 
measurement and implementation of the biomarker should improve outcomes. 
Morrow and de Lemos (2007) suggested that an ideal biomarker should be 
easy to measure, add new information not obtained clinically or by other tests 
and aid patient management [58]. We assessed the success of our studies 
against these benchmarks. Firstly, sTREM-1 and mTREM-1 in the blood of 
patients with CAP was significantly higher than healthy controls. Considering 
VAP, several markers were raised compared with non-ventilated controls. The 
BAL mTREM-1 and BAL/blood mTREM-1 were raised in VAP. However, the 
level of expression of mTREM-1 or the ratio did not correlate with the severity 
of VAP per se. We wish to investigate the markers in a cohort of patients with 
suspected VAP. 
In terms of ease of measurement, each assay was straightforward to conduct. 
As previously described, there is debate as to the expense and ease of 
measuring multiple simultaneous markers in patients. However, our study 
suggested blood markers on their own to lack utility. It is likely that in a 
complex clinical condition such as VAP, measurement of multiple markers will 
be required. This will be justified if their clinical utility is high (for which our 
study provides encouragement). Once our biomarker panel has been tested in 
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further patients, if the markers still retain diagnostic utility, they can be 
assessed to determine their ability to improve patient management and 
antibiotic stewardship. 
 
7.9. The cellular immune response in VAP 
Our study has focused on the changes in surface expression of receptors on 
monocytes and neutrophils. However, other changes occur in VAP that we did 
not address and could be examined in future studies. Pelekanou and 
colleagues (2009) found that in VAP, there was a reduction in peripheral 
blood CD4 positive T-cells in VAP, an increase in monocyte apoptosis and a 
reduction in monocyte responsiveness to stimulation, which may be 
associated with endotoxin tolerance [154].  
 
7.10. Pathogenesis of VAP 
A number of the biomarkers were significantly raised in VAP. Perera et al 
(2001) discussed that CD11b interacted with TLR and CD14 (monocyte 
receptor) to activate the cell in response to LPS stimulation [56]. Anas et al 
(2010) highlighted the crucial role of CD14 and macrophages in the 
development of pneumonia [155]. We constructed a putative model (figure 
7.1) to link together several of these cytokines and receptors. A monocyte 
may migrate from the blood to the lung and in doing so sheds mCD62L. It 
possesses mCD11b, mTREM-1 and Toll-like receptors. Activation of the cell 
by TLR and mTREM-1 ligation allows increased mTREM-1 expression, 
increased mTREM-1 cleavage resulting in sTREM-1 secretion (which also 
appears from nTREM-1) and potentially increased mCD11b expression. 
Surface TREM-1 may act as a link in the pathway from infective organism, to 
upregulation of the inflammatory cytokines. Experimentally, mTREM-1 
activation in conjunction with lipopolysaccharride (LPS) increases IL-8 and IL-
1β release, with amplification seen in septic shock, as in our study [42, 156]. 
Differences may occur depending on whether the infection was gram-positive, 
gram-negative or fungal (or viral). mTREM-2 may modify the immune 
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response as it has effects in polymicrobial sepsis to promote bacterial 
clearance [140]. Many of these effects may occur with neutrophils too. 
Klesney-Tait et al (2013) used TREM-1 knockout mice to demonstrate that 
TREM-1 has a crucial role in allowing transepithelial migration of neutrophils 
from the blood to the lung. Mice lacking the TREM-1 gene had a significantly 
lower level of polymorph migration in response to bacterial challenge [157].  
The crucial role of TREM-1 in modulation of sepsis has been tested 
experimentally by its blockade. In studies by Gibot et al (2006) and Wang et al 
(2012) animal models of pseudomonal infection (pneumonia and sepsis 
respectively) were used to demonstrate that TREM-1 abrogation by means of 
blocking peptides or antibodies reduced the severity of infection and protected 
animals from lethality [158]. However, blockade may also increase the 
severity of pneumonia. Lagler et al (2009) blocked TREM-1 activation in mice 
with pneumococcal pneumonia. Sepsis was worsened by TREM-1 inhibition 
and the researchers cautioned against the use of TREM-1 blockade to 
modulate sepsis [159]. Two reasons may explain the discrepant results. The 
first is that there are differences between the pathogenesis of gram-positive 
and gram-negative infection, with TREM-1 blockade favouring gram-negative 
(pseudomonal) infection but worsening gram-positive (pneumococcal) sepsis. 
The second relies on the strength of the immune response. TREM-1 amplifies 
the immune response to infection. If, in the pseudomonal models, the sepsis 
and SIRS response was overwhelming then TREM-1 abrogation may have 
attenuated the inflammatory response, increasing survival. On the other hand, 
if the immune response to pneumococcus was merely adequate but not 
overwhelming, blockade of TREM-1 may have made the response insufficient 
to treat the infection and increased lethality. Overall, modulation of TREM-1 
may provide a therapeutic avenue for septic patients, such as those with VAP 
but a better understanding of its role is required.  
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Figure 7.1. Putative model for pulmonary compartment in VAP. The 
monocyte possesses CD11b and TREM-1 surface receptors. In some cases, 
activation occurs, in conjunction with ligation of a toll-like receptor. This may 
lead to increased CD11b expression and increased surface TREM-1 levels. 
Cleavage of the latter by Matrix metalloproteinases releases sTREM-1. 
Activation of the surface receptors, in particular mTREM-1 releases IL-1β and 
IL-8. TREM-2 may have a role in modification of the immune response. 
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7.11. Monocyte subsets 
mTREM-1 predominates on CD14 an CD16 positive macrophages [160, 161]. 
For the study, mTREM-1 levels were assessed on the global monocyte 
population of CD14 positive cells. However, it is possible that the effects seen 
were restricted to one or more subset populations of cells. Future studies may 
utilise further monocyte markers to differentiate these populations and allow 
measurement of mTREM-1 on each type of cell.  
 
7.12. Problems encountered during the study 
The initial phase of the study sought to develop assays to measure sTREM-1 
and surface TREM-1 (mTREM-1 and nTREM-1). Predecessors had attempted 
to use in-house ELISA kits developed with manufacturer antibodies. However, 
this was unsuccessful with failure to create reproducible standard curves. One 
reason for this may have been the quality of the purchased antibodies, which 
were recalled from supply approximately three months after the 
commencement of my study [106]. We decided against using in-house kits 
and purchased ready to use ELISA plates and reagents prior to the recall of 
the other antibodies; our kits were not affected. The flow cytometry assays 
were developed ourselves over the first 3-4 months of the study. 
A major problem encountered was an outbreak of the multi-resistant 
bacterium Acinetobacter Baumannii on the ICU at Chelsea and Westminster. 
This led to a curtailment of admissions to ICU for approximately 6 months and 
a resultant decline in the ability to recruit ICU patients into the study. The 
study was thus extended by a further period of 9 months – 1 year to allow 
sufficient recruitment. 
The final issue to discuss was that during the period of the study, only semi-
quantitative microbiological analysis was available. Quantitative analysis only 
became available after completion of the study. We believe that our results 
would have been similar if quantitative analysis had been used, as we found 
elevated levels of IL-1β and IL-8 in the BAL of patients with VAP. This was in 
accordance with a study from a group using quantitative analysis [14].  
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7.13. Limitations 
We included patients, who based on the CPIS scoring system, plus semi 
quantitative microbiological testing were highly likely to have the presence or 
absence of VAP in order to test putative biomarkers. The new CDC guidelines 
for identifying patients with VAP for surveillance control accept semi-
quantitative and quantitative cultures [28]. The diagnostic definitions used 
were also concordant when the European HELICS criteria for pneumonia 
were used [32]. Yet, in spite of utilizing standard criteria, the limits of these 
definitions for accurate diagnosis of VAP are recognised, because of such 
factors as sampling site variation, and prior antibiotic usage [162]. 
Reassuringly, from a biological perspective, the raised BAL IL-1β and IL-8 
levels in VAP from our study concur with a group utilizing different diagnostic 
methodology, implying the validity to such approaches [14].  
Second, our study did not encompass the whole range of infective aetiologies. 
For instance, no patients had Legionella pneumonia and few had bilateral 
lung infiltrates. The latter group present great diagnostic challenge and would 
benefit most from a suitable biomarker. An increased number of patients with 
acute lung injury could have influenced the results. Another practical 
consideration is that flow cytometry is a specialized technique. It requires 
samples with sufficient numbers of cells, which mandates invasive 
bronchoscopy and makes serial biomarker analysis challenging. However, 
BALF samples are the current standard of care a microbiological diagnosis of 
VAP and to our knowledge there were no adverse events associated with 
bronchoscopy [27, 163, 164].  
Another consideration is the number of patients receiving antibiotics and 
steroids, with potential immunomodulatory activity. Given the prevalence of 
these key standard interventions in critically ill patients, we believe this 
pragmatic approach enhances the applicability of the findings. Finally, the 
immune response to infecting pathogens in VAP, as in sepsis, is likely to 
involve neutrophils, monocytes and lymphocytes [165]. As such we have not 
necessarily looked at all potentially relevant phagocytic or T cell markers. That 
said, the value of biomarker panels that include sTREM-1, PCT and CD64 on 
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neutrophils has recently demonstrated the ability to predict sepsis in the 
setting of unselected critical illness, confirming the need to pursue such 
discriminatory panels in VAP, as in other disease states [165, 166]. 
7.14. Future studies 
(i) Use quantitative microbiology for sample analysis 
(ii) Measure mTREM-1, nTREM-1 and sTREM-1 in the presence of 
metalloproteinase inhibitors to determine the role of receptor shedding. 
(iii) Determine the role of TREM-2 in a larger number of patients with and 
without VAP. 
(iii) Study the role of T-cells in the pathogenesis of VAP. 
(iv) Measure mTREM-1, nTREM-1 and sTREM-1 in other body fluids to 
calculate a tissue/blood ratio and determine if this is increased in infection. 
(v) Determine the role of TREM-1 on different macrophage subsets in VAP 
(vi) Assess the biomarker panel in a new cohort of patients with suspected 
VAP. 
(vii) Measure changes in mTREM-1, nTREM-1 and sTREM-1 in cells 
stimulated ex vivo with fungal (candidal) antigens to better understand the  the 
role of TREM-1 in fungal VAP. 
(viii) Stimulate BAL macrophages and neutrophils ex vivo with LPS and LTA 
and determine the profile of mTREM-1, nTREM-1 and sTREM-1 expression 
over time to simulate VAP. 
(ix) Use luminex analysis to measure analyte levels. 
 
7.15. Summary 
In conclusion, a 7 biomarker panel compromising of soluble and cell-surface 
inflammatory markers including TREM-1 in combination with BALF/blood ratio 
differentiates VAP from non-pulmonary infection with high diagnostic 
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accuracy. Further prospective multi-center studies are needed, that 
incorporate these practically relevant and easily measurable biomarkers, to 
confirm the value of such a diagnostic bioscore in suspected VAP. 
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Appendix B 
Research and Development letter of approval from Chelsea and 
Westminster Hospital 
 
Christopher Braime – Interim Research Governance Manger 
Version 0.1 – Thursday March 26th 2009 
E: RESEARCH APPROVAL LETTERS\Anaesthetics\2009\20090819- ANA09001CN.doc  
 
 
Research and Development Support Office 
 
Contract of Research and Development Approval (Non-IMP) 
Between 
 
Dr Suveer Singh 
Chelsea and Westminster NHS Foundation Trust 




Chelsea and Westminster NHS Foundation Trust 
369 Fulham Road 
LONDON 
SW10 9NH 
The Principal Investigator The Trust 
 
in respect to the study: 
 
Protocol Reference (where applicable): NA 
Study Title: 
 
Evaluation of the expression of surface TREM-1 (Triggered Receptor Expressed on Myeloid cells and 
soluble TREM-1 in blood and bronchoalveolar lavage samples in patients admitted to intensive care, 
patients with chronic lung disease and patients with inhalational burn injuries to determine its value as a 




R&D Reference Number: ANA09001CN 
Research Ethics Number: 08/H0702/61 
Date of Issue: August 19, 2009 
 
Please quote the above reference numbers in any communications relating to this project. 
 






Although not a CTIMP trial I agree to uphold the principles of Good Clinical Practice 
throughout all conduct and documentation relating to this trial, including ensuring 
all the Study Team are trained to perform the tasks they are delegated, and that 
any delegation of PI responsibility is recorded appropriately 
 
Report all Serious Protocol Deviations to the Research and Development Support 
Office, in accordance with the Research and Development Support Office 
Standard Operating Procedure OP10 
 
Undertake project monitoring, in accordance with the monitoring plan for your 
research study 
 
To keep the Research and Development Support Office informed of all: 
 
• Amendments to study protocols 
• Amendments to financial arrangements 
• Changes to Study Team 
 
In accordance with the Human Tissue Act 2004 – I agree to destroy all tissue 
samples, as described in the Act, upon completion of the research project for 
which they were specifically approved by the Research Ethics Committee 
 
Where this study is on the UKCRN Portfolio, I agree to enter accrual data on the 
portfolio within the timeframes set by the UKCRN 
 
Christopher Braime – Interim Research Governance Manger 
Version 0.1 – Thursday March 26th 2009 
E: RESEARCH APPROVAL LETTERS\Anaesthetics\2009\20090819- ANA09001CN.doc  
 
 
To undertake R&D quarterly centralised project monitoring within the timeframes set 
by the Research and Development Support Office 
 
I agree to notify the Research and Development Support Office when the study 
closes 
 
I agree to the following responsibilities, as set out in the Research Governance 
Framework for Health and Social Care 2005: 
 
• A senior individual must be designated as PI for any research undertaken 
within the Trust.  This individual will take responsibility for the conduct of the 
Research and is accountable for this to the Trust, and if appropriate, to the 
Sponsor 
• The PI must have suitable experience and expertise in the design and 
conduct of research 
• Ensure the dignity, rights, safety and well-being of participants are given 
priority at all times 
• Ensure that research is carried out in accordance with the Research 
Governance Framework 
• Ensure that controlled trials are registered 
• Ensure that the Chief Executive, or their designate, is informed of all research 
and where appropriate indemnity is given 
• Ensure that studies comply with all legal and ethical requirements 
• Ensure that other professionals involved in the care of the research subject 
are made aware of their participation in the study 
• Ensure each member of the research team is adequately qualified 
• Ensure all students and new researchers have adequate supervision, 
support, and training 
• Ensure any protocol amendments are approved by the Research Ethics 
Committee 
• Ensure procedures are in place to guarantee the collection and 
confidentiality of high quality data 
• Ensure appropriate archiving of research data 
• Make the findings from the research open to critical review after which 
these are disseminated promptly and fed back to the participants 
• Accept a key role in the detection and prevention of scientific misconduct 
by adopting the role of guarantor on published outputs 
• Ensure all data and documentation associated with the study are available 
for audits 
• Ensure arrangements are in place for the management of financial and 
other resources provided for the study, including the managements of any 
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Research and Development Support Office, who will then activate your project on the ReDA database – 
at this point, your project is active. 
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Appendix C 
Consent form (ventilated patient) 
 
Surface TREM-1 study to detect infection                                                         Version 5    Aug 2011 
                   
 
PATIENT INFORMATION SHEET 
 
Adult volunteer  
 
INVESTIGATORS NAMES: Dr Vimal Grover, Dr. Stefan Gurney, Dr Neil Soni, Dr Suveer Singh 




Measurement of surface TREM [Triggered Receptor Expressed on Myeloid cells] levels in 
specimen collected from lung fluid and blood to detect infection. 
 
INVITATION 
 You are being invited to take part in a research study. Before you decide it is important for 
you to understand why the research is being done and what it will involve. Please take time to read 
the following information carefully and discuss it with friends, relatives and your GP if you wish. 
Ask us if there is anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part. 
Consumers for Ethics in Research (CERES) publish a leaflet entitled ‘Medical Research and You’. 
This leaflet gives more information about medical research and looks at some questions you may 
want to ask. A copy may be obtained from CERES, PO Box 1365, LONDON N16 OBW. 
 
Thank you for taking the time to read this form. 
 
EXPLANATION OF PROJECT:  
Ventilator associated Pneumonia (lung infection after being on the lung support machine) is a 
common cause of prolonged stay on the intensive care unit. It is difficult to diagnose this ventilator 
associated pneumonia and therefore a laboratory based test to help doctors detect this illness may 
lead to improvement in the management of this condition. 
We are studying patients admitted to the intensive care unit. Measurement of an immune protein 
called TREM will allow doctors to detect ventilator related pneumonia more accurately and faster 
than standard tests. We will be using the samples derived from blind bronchial sampling, 
bronchoscopic alveolar lavage (BAL) and blood taken from you. Some of these procedures are done 
routinely on patients admitted to the intensive care unit. Blind bronchial sampling and taking blood 
are done on a daily basis whereas bronchoscopic alveolar lavage (BAL) is undertaken post 
intubation, when there is a clinical indication. 
 
TREM [Triggered Receptor Expressed on Myeloid cells] is a protein produced in patients who are 
very ill (i.e. sepsis). It would not be raised in individuals without any infection. 
We will be evaluating the significance of TREM secretion in body fluids (BAL & serum) to detect 
bacterial or fungal infection. 
 
PERIOD OF STUDY 
We plan to undertake the study until January 2012. We plan to recruit 100 patients in our study. 
 
Why have I been chosen? 
You have been chosen as you are being / were admitted to the intensive care unit during which your 
breathing is supported by the ventilator (breathing machine) 




1. Fibreoptic bronchoscopy test  
This is done after intubation (after you have been put onto the lung support machine) on the 
intensive care unit depending on clinical requirements.  Samples will also be taken for research at 
those times. 
Bronchoscopy is a routine investigation that allows the doctor to examine directly the large 
air passage in the lung. You will already be under sedation, as part of your treatment on the 
Intensive care unit (ICU) and therefore will not notice the procedure. The bronchoscope, which is a 
narrow flexible instrument, is then passed through the endotracheal tube (ETT), the breathing tube 
that has already been placed on your admission to the ICU, and into the airways of your lungs. The 
airways are inspected for any signs of inflammation. Bronchial washings (flushing small quantities 
of salty water into and out of the lung) are taken. In addition, we will use a thin soft probe with a 
cotton wool-like tip to obtain a lung fluid sample. This is the end of diagnostic bronchoscopy. 
Side effects and possible risks of the procedure 
There are small risks associated with having a bronchoscopy and also small risks from 
having additional samples taken for research studies. 
Risks of Bronchoscopy 
We monitor your oxygen level throughout the procedure so you are not at risk from low 
oxygen levels. If there is a fall in oxygen levels, then the procedure is stopped, until oxygen levels 
recover. If biopsies were taken (which is not the case for this study, although may be part of the 
routine bronchoscopic investigation), then a rare complication (1:2000) of bronchoscopy is 
pneumothorax. This is a collapse of the lung, which is treated by inserting a tube through the chest 
wall, and connecting to a negative pressure bag system, that allows the lungs to expand.  
Risk of Taking Research Samples 
Bronchoscopic microsampling may cause only minor additional risk. Washing the air 
passages is also safe since the salty water is sucked out of the lungs as soon as it is put in. A BAL of 
20ml to 120ml usually causes no side effect. However in 5% of cases the washing causes a fall in 
blood oxygen levels. Since your oxygen levels are monitored we would know if you are getting 
short of oxygen and we would give you more oxygen to breath through the ventilator. We would 
stop the procedure if this did not improve oxygen levels, until improvement. Taking additional 
samples will make the bronchoscopy last about 3-5 minutes longer than it would otherwise be. 
However it is not necessary to give you more sedative or a different sedative from that we 
ordinarily use and the slightly longer procedure does not mean extra risk. 
 
2. Blind Bronchial Sampling (BBS) 
This is done daily for research purposes. 
This is done by passing a catheter through the ventilation tube and 20ml of normal saline is 
instilled. The secretions dissolve in the normal saline instilled which is suctioned out. This also 
helps in clearing the secretions. As this procedure is done not under direct vision i.e. not using a 
fibre-optic scope, it is termed blind.  
This is quicker to perform than the one assisted by the fibre-optic bronchoscope. Hence, there is 
decreased risk of complications mentioned earlier.  
  
3. Venesection: 
This is done daily for research purposes. It is done from a fresh site to avoid any bacterial 
contamination from pre-inserted lines. 
We will be collecting a 6-10mls sample of blood from a peripheral vein whenever a bronchoscopy 
procedure is undertaken. This is done under strict aseptic precautions. To minimize any discomfort 
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while performing this procedure, local anaesthetic is instilled before inserting a needle into the vein 
to draw blood. There is a slight risk of bruising at the site of venepuncture which will subside soon. 
 
4. Ventilator condensate: 
The breathing machine (ventilator) has a container attached to the tubing to collect water that 
condenses from the patient’s exhaled breath. This is normally thrown away. We will obtain 20-
40ml of this fluid (maximally on a daily basis) to measure the proteins in it. This will not affect 
your care in any way and does not require any invasive procedure. 
Confidentiality 
After obtaining the samples from you, they will be anonymised by giving them encoded reference 
number. All names and personal data which can identify you with the sample will be discarded. 
Use of samples obtained 
 
We will take samples to laboratory and we will measure levels of TREM. The results obtained will 
be without significance for you personally; i.e. they will not guide your clinical management. The 
results of the study will be submitted for publication in scientific journals, and they can be made 
available to you, if you wish to know at the end of the study. Any remaining bronchoscopy 
specimens will be analyzed for routine measurements of infection, and you will not be identifiable 
in any reports of the study.  
 
All samples will be destroyed at the end of the study. 
 
If you decide to withdraw from the study after the procedure, and before submission of data for 
publication in scientific journals, we will discard those samples and data derived from them. 
 
Participation in the study 
Finally, we would like to thank you for your interest in the study, even if you have decided 
not to take part.  There is no pressure on you to participate in the study and having agreed to 
participate you are free to withdraw at any stage without having to provide any reason. Your 
decision to participate or not will not affect in any way the treatment you may be receiving at this 
hospital.  
There will be no direct benefits to you for taking part in this study. It may allow us to 
establish the role of TREM in the early diagnosis of the source of infection, in the future. 
If you do decide to take part in the study all information relating to the study will be kept 
confidentially and you will not be identifiable in any reports of the study.  
If you need any help or advice at any time following the fibreoptic bronchoscopy procedure, 
you can contact us at any time. Please call: 
Dr Suveer Singh (Tel: 020 8746 8472), Consultant Physician in Respiratory and Intensive Care 
Medicine, Chelsea & Westminster Hospital 369 Fulham Road, London SW10 9NH. 
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Research Subject Consent Form 
 
Title of Project: Use of surface TREM-1 as a marker in detecting infection 
 





Patient/ Volunteer Declaration (please INITIAL all boxes which apply) 
 
I have been given the chance to read and understand the 
information sheet relating to the above study   
 
I have been given the opportunity to ask questions and 
discuss the study                                       
 
I have been made aware of the risks/ benefits 
 
I understand that authorized individuals may look at my 
medical notes and give permission for these individuals 
to have access 
 
I understand that I am free to withdraw from this study 
at any time without prejudice to my future care/ 
treatment 
  
Patient Hospital Number:    Patient Study Identification 
 
I agree to take part in the above study 
 
Signature ………………………………………Name ………………………………………… 
 
Date  ……………………………………………………………… 
 
Person responsible for obtaining Informed Consent: 
'To the best of my knowledge I have provided the above individual with sufficient information to 









Signature ………………………………………Name ………………………………………… 
 
Date  ………………………………………Position……………………………………… 
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Appendix D 
Consent form (non-ventilated patient) 
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PATIENT INFORMATION SHEET 
 
Adult volunteer (non ventilated) 
 
INVESTIGATORS NAMES: Dr Vimal Grover, Dr. Stefan Gurney, Dr Neil Soni, Dr Suveer Singh 
INVESTIGATIONAL SITE: Chelsea and Westminster Hospital 
 
STUDY TITLE 
Measurement of surface TREM [Triggered Receptor Expressed on Myeloid cells] levels in 
specimen collected from lung fluid and blood to detect infection. 
 
INVITATION 
 You are being invited to take part in a research study. Before you decide it is important for 
you to understand why the research is being done and what it will involve. Please take time to read 
the following information carefully and discuss it with friends, relatives and your GP if you wish. 
Ask us if there is anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part. Consumers for Ethics in Research (CERES) publish a 
leaflet entitled ‘Medical Research and You’. This leaflet gives more information about medical 
research and looks at some questions you may want to ask. A copy may be obtained from CERES, 
PO Box 1365, LONDON N16 OBW. 
 
Thank you for taking the time to read this form. 
 
EXPLANATION OF PROJECT:  
Ventilator associated Pneumonia (lung infection after being on the lung support machine) is a 
common cause of prolonged stay on the intensive care unit. 
We are studying patients admitted to the intensive care unit to evaluate the correlation of TREM 
secretion in infection. We will be using the samples derived from blind bronchial sampling, 
bronchoscopic alveolar lavage (BAL) and blood taken from you. Some of these procedures are done 
routinely on patients admitted to the intensive care unit. Blind bronchial sampling and taking blood 
are done on a daily basis whereas bronchoscopic alveolar lavage (BAL) is undertaken post 
intubation, when there is a clinical indication. 
 
You are being invited to participate, because you do NOT have a severe infection, and are 
undergoing routine bronchoscopy. Thus, we think this will be an important comparison with those 
patients with severe infections on lung support machines.  
 
TREM [Triggered Receptor Expressed on Myeloid cells] is a substance produced in patients who 
are very ill (i.e. sepsis). It is produced by the blood cells to enhance the inflammatory response to 
bacterial or fungal infection. It may not be raised as much in individuals without any infection, but 
may be increased in other lung conditions. 
We will be evaluating the significance of TREM secretion in body fluids (BAL & serum) to detect 
bacterial or fungal infection. 
 
PERIOD OF STUDY 
We plan to undertake the study until January 2012. We plan to recruit 100 patients in our study. 
 
Why have I been chosen? 
You have been chosen as you are undergoing routine bronchoscopy to investigate your lungs. 
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Procedures undertaken 
1. Fibreoptic bronchoscopy test  
This is done as clinical requirement as part of management of your lung investigations. 
Bronchoscopy is a routine diagnostic examination that allows the doctor to examine directly 
the large air passage in the lung. You will be asked not to eat or drink anything from midnight prior 
to the bronchoscopy. You will be given oxygen to breathe throughout the procedure. A local 
anaesthetic called lidocaine is then sprayed on to the back of the mouth and into the nose. This 
anaesthetic numbs the nerves so that the bronchoscope can be easily inserted into the wind passage 
without discomfort. Lidocaine is the same as the local anaesthetic used by dentists. If you are 
allergic to any local anaesthetic agents you should let us know and you will be withdrawn from the 
study. A sedative such as midazolam and/or fentanyl is injected through the vein to make you more 
relaxed and drowsy. You may be given Ventolin, which is a medicine that will prevent any 
narrowing of the airway tube, to inhale from a nebuliser, which produces a fine mist for inhalation, 
after the bronchoscopy. 
The bronchoscope, which is a flexible instrument, is then passed usually through the mouth 
and down the back of the throat. More local anaesthetic is then placed on the vocal cords and the 
bronchoscope passed through the voice box and into the lungs. Then airways are inspected for any 
signs of disease. Bronchial washings (flushing small quantities of salty water into and out of the 
lung) are taken. In addition, we will use a thin soft probe with a cotton wool-like tip to obtain a lung 
fluid sample. This is the end of diagnostic bronchoscopy.  
Bronchoscopies will only be performed by a C&WH approved bronchoscopist (Dr Suveer 
Singh, Dr Pallav Shah and colleagues under their direct supervision).   
This is done under sedation and hence, you would not be subject to any discomfort.  
Side effects and possible risks of the procedure 
There are small risks associated with having a bronchoscopy and also small risks from 
having additional samples taken for research studies. 
Risks of Bronchoscopy 
Passing a tube into the airways sometimes causes a minor nosebleed (although we usually 
use the oral route, thus avoiding this complication). After your examination, the lining of your 
mouth and throat will remain numb just in the same way as your mouth would after a dental 
procedure. You will experience a sore throat and will be coughing because of irritation in the chest. 
There may also be the possibility of coughing bloody sputum. These symptoms will wear off within 
the next 2 hours or so. You should not eat or drink for at least 2 - 3 hours. This precaution is 
necessary to keep food or liquids from accidentally entering the windpipe or lungs. Bronchoscopy is 
a standard diagnostic procedure. Fewer than one in ten people get a ‘flu’ like reaction about 6 hours 
after the test sometime with a fever. This only lasts a few hours and can be helped by taking 
paracetamol. You will have a sore throat for approximately 4 hours after the procedure. There may 
also be the possibility of coughing up a little blood. Using a mild sedative can cause your breathing 
to slow down as you become drowsy.  
We monitor your oxygen level throughout the procedure so you are not at risk from low 
oxygen levels. If there is a fall in oxygen levels, then the procedure is stopped, until  oxygen levels 
recover. If biopsies were taken (which is not the case for this study, although may be part of the 
routine bronchoscopic investigation), then a rare complication (1:2000) of bronchoscopy is 
pneumothorax. This is a collapse of the lung, which is treated by inserting a tube through the chest 
wall, and connecting to a negative pressure bag system, that allows the lungs to expand.  
Risk of Taking Research Samples 
Bronchoscopic microsampling may cause only minor additional risk. Washing the air 
passages is also safe since the salty water is sucked out of the lungs as soon as it is put in. A BAL of 
20ml to 120ml usually causes no side effect. However in 5% of cases the washing causes a fall in 
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blood oxygen levels. Since your oxygen levels are monitored we would know if you are getting 
short of oxygen and we would give you more oxygen to breath through the ventilator. We would 
stop the procedure if this did not improve oxygen levels, until improvement. Taking additional 
samples will make the bronchoscopy last about 3-5 minutes longer than it would otherwise be. 
However it is not necessary to give you more sedative or a different sedative from that we 
ordinarily use and the slightly longer procedure does not mean extra risk. 
 
2. Venesection: 
This is done for research purposes. It is done from a fresh site to avoid any bacterial contamination 
from pre-inserted lines. 
We will be collecting a 6-10mls sample of blood from a peripheral vein whenever a bronchoscopy 
procedure is undertaken. This is done under strict aseptic precautions. To minimize any discomfort 
while performing this procedure, local anaesthetic is instilled before inserting a needle into the vein 
to draw blood.  
There is a slight risk of bruising at the site of venepuncture which will subside soon. 
Confidentiality 
After obtaining the samples from you, they will be anonymised by giving them encoded reference 
number. All names and personal data which can identify you with the sample will be discarded. 
Use of samples obtained 
 
We will take samples to laboratory and we will measure levels of TREM. The results obtained will 
be without significance for you personally; i.e. they will not guide your clinical management. The 
results of the study will be submitted for publication in scientific journals, and they can be made 
available to you, if you wish to know at the end of the study. Any remaining bronchoscopy 
specimens will be analyzed for routine measurements of infection, and you will not be identifiable 
in any reports of the study.  
 
All samples will be destroyed at the end of the study. 
 
If you decide to withdraw from the study after the procedure, and before submission of data for 
publication in scientific journals, we will discard those samples and data derived from them. 
Participation in the study 
Finally, we would like to thank you for your interest in the study, even if you have decided 
not to take part.  There is no pressure on you to participate in the study and having agreed to 
participate you are free to withdraw at any stage without having to provide any reason. Your 
decision to participate or not will not affect in any way the treatment you may be receiving at this 
hospital.  
There will be no direct benefits to you for taking part in this study. It may allow us to 
establish the role of TREM in the early diagnosis of the source of infection, in the future. 
If you do decide to take part in the study all information relating to the study will be kept 
confidentially and you will not be identifiable in any reports of the study.  
If you need any help or advice at any time following the fibreoptic bronchoscopy procedure, 
you can contact us at any time. Please call: 
Dr Suveer Singh (Tel: 020 8746 8472), Consultant Physician in Respiratory and Intensive Care 
Medicine, Chelsea & Westminster Hospital 369 Fulham Road, London SW10 9NH. 
 
Thank you very much for considering this project. 
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Research Subject Consent Form 
 
Title of Project: Use of surface TREM-1 as a marker in detecting infection 
 




Patient/ Volunteer Declaration (please INITIAL all boxes which apply) 
 
I have been given the chance to read and understand the 
information sheet relating to the above study   
 
I have been given the opportunity to ask questions and 
discuss the study                                       
 
I have been made aware of the risks/ benefits 
 
I understand that authorized individuals may look at my 
medical notes and give permission for these individuals 
to have access 
 
I understand that I am free to withdraw from this study 
at any time without prejudice to my future care/ 
treatment 
  
Patient Hospital Number:    Patient Study Identification 
 
I agree to take part in the above study 
 
Signature ………………………………………Name ………………………………………… 
 
Date  ……………………………………………………………… 
 
Person responsible for obtaining Informed Consent: 
'To the best of my knowledge I have provided the above individual with sufficient information to 









Signature ………………………………………Name ………………………………………… 
 
Date  ………………………………………Position………………………………………... 
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